The Role of the Gut Microbiome In Bone and Joint by Guss, Jason Daniel
THE ROLE OF THE GUT MICROBIOME IN BONE AND JOINT  
	
	
	
A Dissertation  
Presented to the Faculty of the Graduate School 
of Cornell University  
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
	
	
	
	
	
	
	
	
	
	
 
 
 
 
 
By 
Jason Daniel Guss 
December 2018 
 
 
1	
	
 
 
 
 
© 2018 Jason Daniel Guss  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2	
	
 
THE ROLE OF THE GUT MICROBIOME IN BONE AND JOINT  
 
 
 
Jason Daniel Guss, Ph.D. 
 
Cornell University 2018 
 
 
` Osteoporosis and osteoarthritis affect millions of people worldwide every year. 
Osteoporosis related fractures totaled 8.9 million worldwide annually and osteoarthritis affects 
over 30 million people in the US alone. Recently, the gut microbiome has been identified as a 
factor that can influence chronic conditions associated with bone and joint disease such as 
obesity, diabetes, metabolic syndrome, inflammatory bowel diseases, and malnutrition. Though 
the gut microbiome is studied extensively in relation to metabolic diseases and disorders, the role 
of the gut microbiome in the development and progression of bone and joint disease is largely 
unexplored.  
 Recent evidence suggests that the gut microbiome can influence bone mass, however no 
studies have determined if the mechanical performance of the bone is influenced by the gut 
microbiome. Therefore, first, we characterize how alterations to the gut microbiome can 
influence whole bone mechanical performance at skeletal maturity. We evaluate alterations in 
the gut microbiome caused by genotypic alteration and chronic treatment with antibiotics. Our 
results demonstrate that disruption of the gut microbiome with antibiotics is associated with 
reductions in cortical bone mass and whole bone strength, as well as drastic shifts in the 
composition of the gut microbiome. Furthermore, the changes in whole bone strength are greater 
than can be explained by the associated changes in bone mass and geometry, suggesting 
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impaired bone tissue material properties in mice with an altered gut microbiome due to genotypic 
alteration and chronic antibiotic treatment.  
 Next, we evaluate the changes in bone tissue composition caused by alterations in the gut 
microbiome.  Additionally, we investigate how the functional profile of the gut microbiome can 
influence bone tissue material properties through several potential pathways: 1) regulation of 
nutrient and vitamin absorption/synthesis; 2) regulation of the immune system; 3) translocation 
of bacterial products. Our results demonstrate that disruption of the gut microbiome with 
antibiotics causes changes in bone mineral crystallinity, and that the effect is different per mouse 
genotype. Furthermore, we show that the functional capacity of the gut microbiome is 
dramatically altered in mice treated with antibiotics. A pathway involving vitamin K, a factor 
important for bone health, and associated with fracture risk, is suspected as changes in microbial 
gene pathways for vitamin K synthesis are disrupted leading to reduced vitamin K levels in 
organs.    
 Last, we evaluate how alterations in the gut microbiome may influence the development 
and severity of load-induced osteoarthritis. Here we investigate obesity and metabolic syndrome, 
two conditions associated with an altered gut microbiome and an increased risk of developing 
osteoarthritis (OA). We use a mouse model of metabolic syndrome dependent on the gut 
microbiome, a mouse model of severe obesity/diabetes, and an in vivo non-invasive loading 
model to induce osteoarthritis-like pathology. Our results demonstrate that metabolic syndrome 
in the current mouse model does not increase load-induced cartilage damage, while severe 
obesity leads to increases in cartilage damage, though only after a prolonged loading period. The 
increased cartilage damage in severely obese mice is associated with increased adiposity, 
systemic inflammation, and bacterial lipopolysaccharide. We also demonstrate that disruption of 
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the gut microbiome in the metabolic syndrome mice is associated with decreased load-induced 
cartilage damage, as well as changes in subchondral bone properties.  
 Together, the current work suggests the gut microbiome influences both the structure and 
composition of bone, and can influence the development of osteoarthritis. The current work 
helps to establish a promising foundation for future lines of investigation evaluating how the gut 
microbiome influences bone and joint and suggests that there may be a future use for 
manipulating the gut microbiome in therapies to treat and prevent bone and joint disease. 
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Chapter 1. Introduction  
 
Chapter 1.1 Introduction to the Gut Microbiome 
  
 The gut microbiome are the trillions of microorganisms and their products that inhabit the 
gastrointestinal tract. The gut microbiome is comprised of over a 1000 different species that 
coexist in a stable, but dynamic equilibrium. The gut microbiome offers unique benefits to the 
host as the gut microbiome is involved in digestion and metabolism, nutritional absorption, and 
the development and functioning of the immune system. Alterations to the gut microbiome are 
linked to various chronic conditions that include: obesity, diabetes, metabolic syndrome, 
inflammatory bowel diseases, malnutrition, cardiovascular disease, cancer, neurological 
disorders, and most recently, orthopedic bone and joint disorders. 
The following paragraph is from the paper I co-authored titled “Links Between the Microbiome 
and Bone”. The paragraph is reused with permission from Wiley. 
(Start of excerpt from Hernandez et al 2016) 
 The human microbiome is established soon after birth, usually by colonization by 
microbial flora present in the birth canal (1). The microbiota is shaped subsequently by diet and 
environmental exposure, and reaches a steady state at about three years of age (1). The great 
majority of the human microbiome is located within the gastrointestinal system. The human gut 
microbiota consists of over 1000 distinct microbial species, many of them not yet well 
characterized. Roughly two-thirds of the microbial species composition is unique to each 
individual (2). The human gut microbiota is dominated by organisms from 
the Bacteroidetes and Firmictues phyla (3). Once established in an individual, the contents of the 
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microbial community in the gut enter a dynamic equilibrium as the hundreds of different species 
compete and interact with one another and the host immune system in complex networks of 
interdependence. The relative abundance of species within the gut flora fluctuates from day to 
day based on changes in diet (3,4), but in general retains its basal constitutive state despite these 
transient disruptions. For example, after a stimulus such as a course of antibiotics or short 
gastrointestinal infection, the contents of the gut microbiota mostly return to their initial state, 
although the resulting gut microbial community may be less stable than it was prior to 
treatment (5) and small changes in content may occur (e.g. species with similar function may 
replace each other (4)). Hence, while the gut microbiome is relatively stable it can be changed by 
long periods of sustained stimuli or factors that produce large perturbations in the gut flora. (End 
of excerpt from Hernandez et al 2016). The functions of the gut microbiome are highly 
conserved and when disruptions in the microbiome occur, functions are often taken over by other 
microbiota that can fill that niche.   
 
1.1.1 Experimental Methods Used for Manipulating, Characterizing, and Understanding 
the Gut Microbiome 
 
 A number of techniques in gut microbiome research are used to manipulate the gut 
microbiome: germ-free living conditions, microbiota transplantation, cohousing, and 
administration of antibiotics. Animals raised from birth in an environment completely absent of 
any microbial life are considered “germ-free” and do not have a gut microbiome. Germ-free 
animals were first utilized in the 1950s (6).  Germ-free mice are an ideal model for understanding 
in a broad manner if the gut microbiome is involved in a mouse phenotype. For example, a 
genetic knockout mouse that displays obesity as a result of disturbances in the gut microbiome, 
no longer displays obesity when raised in germ-free conditions, thus demonstrating the 
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importance of the microbiome for the development of the phenotype (7). A major limitation in 
work with germ-free animals are the numerous physiologic changes and immune deficiencies 
present in germ-free animals that may influence study outcomes beyond the direct effect of the 
microbiota (8,9). Germ-free mice can also be used to receive a transplant of a defined gut 
microbiota to determine the specific effects of different microbiota populations. Germ-free mice 
can be colonized with a single microbial species (mono-associated),  a specific mix of  microbial 
species (defined microbiota), or an entire gut microbiome (xenografted microbiota) from another 
host  (mouse, human, etc) (10). Transplantation of gut microbiota into mice normally occurs 
through the use of a syringe and tube to directly administer the gut microbiota into the stomach 
(10). Cohousing is another technique used by the gut microbiome community to transfer the gut 
microbiome communities between mice (11). In cohousing, mice of different genotypes or 
experimental groups are placed in the same cage. Because mice are copraphagic (eat feces), the 
transfer of gut microbial content occurs between mice over time. Another technique used to 
manipulate the gut microbiome is the administration of antibiotics. Antibiotics are compounds 
able to decimate specific microbiota communities. Typically, the broad-spectrum antibiotics used 
have profound impacts on the overall composition and function of the gut microbiome 
(Antibiotics are discussed in greater detail in Section 1.2.2). Prolonged and continuous treatment 
with antibiotics for months can be used to cause a shift in the composition of the gut 
microbiome. Antibiotics allow researchers to selectively modify the gut microbiome to 
investigate the effects of specific gut microbiome populations. Additionally, antibiotic-treated 
mice are sometimes used instead of germ-free mice as the recipients of gut microbiota when 
performing a microbiota transplantation study (12).  
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Figure 1.1 Methods for manipulation of the gut microbiome 
 
 Next generation sequencing techniques are used to characterize the composition and 
functions of the gut microbiome. 16s rRNA gene sequencing analyzes a highly conserved 16S 
rRNA gene to allow for the taxonomic profiling of the gut microbiota (13,14). Common analyses 
include determining the total amount of bacteria, the relative abundance of the gut microbiota at 
each phylogenetic level (species, genus, family, phyla, etc), the overall diversity of the gut 
microbial community, and the overall phylogenetic tree to illustrate how each microbiota 
classification is related to one another. Shotgun metagenomics analyzes bacterial DNA to profile 
the gut microbiome in a similar manner to 16s rRNA sequencing, however it also allows for the 
identification and quantification of the microbial genes present in order to determine the 
functional capabilities of the gut microbiome (13-15). Shotgun metagenomics overall allows for a 
more specific taxonomic and functional classification of sequences compared to 16s rRNA gene 
sequencing, although it can be more time consuming and costly. The ability to evaluate the 
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functional capacity of the microbiome (what the microbes can do) through metagenomics can 
often be more informative than just identifying the composition (what microbes are present).  
	
1.1.2 Factors that Influence the Gut Microbiome: Emphasis on Diet and Antibiotics 
 
Many factors influence the constituents and function of the gut microbiome throughout 
life such as diet, treatment with oral antibiotics, environment, physiologic state, pathogen 
exposure, genetics, age, and probiotics. Diet and antibiotics are explained in further depth as both 
are most relevant to the thesis.  
1.1.2.1 Diet 
 
Diet can have a profound and lasting impact on both the composition and function of the 
gut microbiome. The host diet is the primary source of energy and nutrients for the gut 
microbiome. Changes in diet can have rapid effects on the gut microbiome, with detectable 
differences in the composition of the gut microbiota and the genes expressed in as little as 24 
hours (16). A consistent change in diet is able to generate permanent shifts in the composition of 
the gut microbiota, as the gut microbiota best suited to thrive with the available dietary 
components establish themselves (17). Changes in diet that last months or years are associated 
with different gut microbiome profiles (18). In addition to the composition of the diet influencing 
the gut microbiome, the total food intake, as well as fasting/feeding schedules have been shown 
to influence the composition and function of the gut microbiome (19). Changes in the gut 
microbiome resulting from diet can play a large role in the nutrients and energy the host extracts 
from a diet, as well as overall immune and metabolic function (20).  
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Our understanding of the gut microbiome and diet has focused on diets such as the 
Western diet and Mediterranean diet. Researchers use rodent chow formulas that are modeled 
after common human diets. The Western diet, with high levels of animal protein and fat, has 
been a major focus, as current diet trends are a contributor to the rising levels of obesity and 
diabetes in the United States (21). The western diet is modeled in mice by feeding mice high fat 
diets with various percentages of fat content (35%, 45%, 60%) (22). Studies in humans and mice 
have demonstrated that the Western diet reduces bacterial diversity, alters the functions of the 
gut microbiome (23,24), and leads to other serious health concerns including obesity, insulin 
resistance, and systemic inflammation that are directly or indirectly linked to the gut microbiome 
(25,26). High fat diet is also associated with an increased abundance of the phyla Firmicutes and a 
decreased abundance of the phyla Bacteroidetes (27). The Mediterranean diet is a balanced intake 
of nutrients that includes fatty acids, antioxidants, and a high intake of fiber, and is thus 
considered far healthier than the Western diet. The Mediterranean diet helps to promote 
commensal bacteria such as Lactobacillus, Bifidobacterium, and Prevotella, and has been shown 
to increase the production of short chain fatty acids, as well as decrease obesity and 
inflammation (28).  
Dietary proteins, fats, carbohydrates (starch, sugars, dietary fibers), and polyphenols 
(commonly found in fruits, seeds, vegetables), influence the composition and function of the gut 
microbiota (28). Diets high in protein and animal fat are typically dominated by Bacteroides and 
those diets high in digestible carbohydrates are dominated by Prevotella (29). High levels of 
protein in the diet have also been associated with increased microbial diversity. Digestible 
carbohydrates have different effects on the gut microbiome depending on the type of sugars. 
Non-digestible carbohydrates, or dietary fibers, are metabolized by the gut microbiota to help 
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promote the growth of certain “healthy” microbiota populations.  Prebiotics are select dietary 
fibers that can increase gut microbiome gene richness and commensal organism abundance, and 
thereby have profound impacts on other aspects of metabolism and inflammation (20,30,31). 
Polyphenols have been shown to enrich the gut microbiome with commensal bacteria such as 
Bifidobacterium and Lactobacillus.  
 
1.1.2.2 Antibiotics 
 
Antibiotics have a profound and lasting impact on the composition and functional profile 
of the gut microbiome. Antibiotics target key pathways/functions of bacteria to cause cell death 
or slow cell growth. Each class of antibiotic targets a different key pathway/function of the 
bacteria. Some of the most common pathways/functions targeted by antibiotics are inhibition of 
cell wall, protein, DNA, or RNA synthesis. The effects of antibiotic treatment are immediate, but 
can persist for months to years. Use of antibiotics during critical development windows in 
childhood can have lasting, detectable impacts into adulthood (32). Administration of antibiotics 
that last months or years will generally lead to longer, sustained changes in the gut microbiome 
than a single dose. The immediate effect of the antibiotics will be a decrease in total bacterial 
load and diversity, but gradually the gut bacteria not killed by the antibiotics will be able to 
establish their dominance and achieve the previous bacterial load level. Higher initial doses of 
antibiotics can have a more profound effect on gut microbiome populations. Additionally, the 
effect of antibiotics on the gut microbiome depend on the genetics of the host, sex of the host, 
type of antibiotic dosing (pulsed, intermittent, or continuous), previous exposure to antibiotics, 
age when administered, and other factors currently being investigated. Antibiotics will not only 
alter the composition of the gut microbiota, but also change the metagenome and transcriptome 
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of the gut microbiome (32). Antibiotics apply a selective pressure to the gut microbiome, and as a 
result the gut microbiome adapts. Bacteria that are able to resist the effects of the antibiotic are 
called antibiotic resistant. Antibiotic resistant bacteria have  resistance genes that allow them to 
survive, and to then grow in an uncontrolled manner (33). Antibiotic resistance genes can be 
transferred from one species to another. Increased antibiotic use in the United States has become 
a major concern as the number of antibiotic resistance infections grows. 
1.1.2.3 Other Factors 
 
The environment, host genetic background, host age, and probiotics taken by the host are 
other key factors that can shape the gut microbiome. Environment and geographical location has 
been shown to affect the gut microbiome (34). The differences due to geography may be a result 
of both cultural differences in lifestyle and diet, exposure to microbes specific to certain regions, 
as well as exposure to environmental pollutants (34,35). Host genetics can influence the 
composition of the gut microbiome if the genetic makeup influences any of the pathways or 
systems involved with the gut microbiome (36). For example, mice that have immune deficiencies 
respond differently to the gut microbiome, and develop a distinct microbiome (7). Aging leads to 
a great degree of change in the gut microbiome, though it is unclear what the causes for the 
associations between age and gut microbiome (37,38). Aging often comes with increased 
inflammation and it has been hypothesized that the gut microbiome plays a role in this 
phenomenon. Probiotics are another factor that influences gut microbiota composition and 
function. Probiotics are live commensal bacterial that provide a beneficial effect on the immune 
system and metabolic function. The most common bacteria used as probiotics are strains of 
lactobacillus and Bifidobacterium (39). Studies have reported promising benefits of probiotic 
administration, though the area remains controversial topic (40). For example, the transplant of a 
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probiotic Lactobacillus plantarum strain was able to prevent a malnourished phenotype from 
developing in germ-free mice with a malnourished gut microbiome (41). 
  
1.1.3 Organ Systems The Gut Microbiome Influences 
1.1.3.1 Immune System Function and Development 
	
The gut microbiome is involved in the initial development and continued function of the 
immune system. The immune system is introduced to the gut microbiome at birth. As the 
immune system develops it becomes educated as to what microbes are commensal, and what 
microbes are considered pathogenic. Early in development, the immune system has a blunted 
inflammatory response to the gut microbiota, as the body is attempting to identify microbiota 
that are symbiotic and microbiota that are pathogenic (42). The current hypothesis is that the 
immune system has evolved alongside the gut microbiome to allow specific symbiotic bacteria to 
colonize, while still being able to identify and fight off pathogenic bacteria (43). The gut 
microbiome eventually reaches a stable equilibrium with both the individual gut microbiota 
populations, as well as the host immune system. The gut microbiota is crucial for a healthy, well-
developed immune system. Rodents raised in a germ-free environment have a severely 
underdeveloped immune system and are more susceptible to infections (44). Improper education 
of the immune system to the gut microbiota has been linked to the development and severity of 
autoimmune diseases (45). 
The gut microbiome is in constant communication with both the innate and adaptive 
immune system throughout life. The host helps to maintain a homeostasis with the gut 
microbiome by producing and maintaining a mucosal layer on the gut lining. The mucosal layer 
helps to minimize any direct contact between gut microbiota and intestinal epithelial  cells (42,46). 
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Intestinal epithelial cells are the cells in closest contact with the gut microbiome on a regular 
basis. The epithelial cells that line the intestine will produce antimicrobial peptides to help limit 
direct contact between the gut microbiota and host cells. One of the main methods of 
communication between the gut microbiome and the host immune system is through the 
recognition of microbial associated molecular patterns (MAMPs). Pattern recognition receptors 
are used by host cells to detect the presence of the gut microbiome by detecting MAMPs. Toll-
like receptors (TLRs) are one of the main families of pattern recognition receptors. TLRs detect 
various MAMPs including bacterial products, components on or composing the cell surface, and 
bacterial DNA or RNA. When TLRs are triggered an intracellular inflammatory cascade begins 
to help eliminate the microbial presence. Mice deficient in TLRs or TLR downstream signaling 
have an altered gut microbiota composition and function because the mice are not able to 
appropriately detect and control the gut microbiota populations (7,47-50).  
The innate and adaptive immune system both play a key role in the regulation of a 
healthy gut microbiome (51). The antigen presenting cells help to detect for the presence of 
pathogenic bacteria or bacteria in a location they should not be (i.e. breaching of the intestinal 
barrier). Antigen presenting cells in the gut and lamina propia use TLRs to detect bacteria and 
bacterial components. Antigen presenting cells, such as dendritic cells, act as a bridge to the 
adaptive immune system so they can present the bacterial components to B and T cells. One of 
the key roles B cells play is in regulation of the gut microbiome through production of antibodies 
such as IgA. IgA antibodies produced by B cells can help to target bacteria for elimination, 
change bacterial gene expression, and maintain the integrity of the intestinal barrier (44,51). The 
various CD4+T cells secrete cytokines that help to control infections (Th17 cells), protect against 
intracellular microbiota (Th1 cells), and to even regulate/reduce the immune response when 
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appropriate (T-regulatory cells) (45). For the CD4+ T cells to properly differentiate into the major 
subtypes, the presence of the gut microbiota is required.  
 
1.1.3.2 Metabolism and Nutrition 
	
 The gut microbiome offers unique benefits to the host as the gut microbiome is involved 
in digestion, metabolism, and nutritional intake. The gut microbiome enhances the ability of the 
host to extract nutrients and energy from the diet that the host cannot extract directly. The gut 
microbiome collectively has 3.3 million non-redundant genes (~150 times larger than human 
genome). Many of the genes are devoted to processing foods (largely polysaccharides) and are 
not included in the host genome (52). Essentially, the successful operation of many metabolic 
pathways in the host rely on the combined function of the host and the microbiome (53). The main 
site for nutrient and vitamin transfer and absorption is in the intestines.  Here, the nutrients, 
vitamins, and other important metabolites are able to cross the epithelial barrier (53).  
 The gut microbiome assists with are nutrient absorption and energy extraction. 
Experiments with germ-free mice have demonstrated the clear importance of the gut microbiome 
in nutrient and energy extraction from the diet: 1) germ-free mice are underweight with less fat 
(54).; 2) germ-free mice do not develop diet induced obesity (55,56). Additionally, gut microbiota 
transplantation studies with germ-free mice have demonstrated how the gut microbiota alone can 
lead to malnutrition or obesity depending on the metabolic status of the gut microbiota donor 
(16,25). Stool from lean mice has been shown to have more calories remaining compared to stool 
from obese mice fed the same diet (57). 
The gut microbiome has other key functions that help to perform dietary choline 
metabolism, non-digested fiber fermentation, protein digestion, breakdown of dietary toxins and 
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carcinogens, absorption of electrolytes and minerals, fat digestion, and bile acid metabolism 
(57,58). The processes performed by the gut microbiome lead to the production of 
neurotransmitters, branched amino acids, short chain fatty acids (acetate, propionate, butyrate), 
triglycerides, fatty acids, vitamins (K, B group vitamins: biotin, cobalamin, folate, riboflavin, 
thiamine), and other products as well (58,59). Short-chain fatty acids have profound impacts on 
metabolism and immunity that include regulation of T-cells, improving the functioning of tight 
junction, anti-inflammatory properties, main food source for colonocytes, and even antimicrobial 
activity (60).  
 
Figure 1.2. Factors affecting the composition and function of the gut microbiome, as well as host 
functions that are affected by the gut microbiome 
 
1.1.4 Routes the Gut Microbiome Can Influence Bone and Joint  
 
The gut microbiome is capable of influencing bone and joint through three routes: 1) 
regulation of nutritional absorption; 2) regulation of the mucosal and systemic immune system; 
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and 3) translocation of bacterial products. Nutritional deficiencies in key vitamins synthesized by 
the gut microbiome such as vitamin-K, as well as overall malnutrition have been shown to be 
associated with bone fracture risk in patients (61,62). Nutrition also plays a role in osteoarthritis as 
a number of dietary factors are associated with the symptoms and progression of osteoarthritis 
(63).  
The immune system is closely intertwined with bone and joint diseases, as inflammation 
has been increasingly identified as a contributor to bone and joint disease (64,65). Interactions 
between the gut microbiome and the immune system can stimulate pro-inflammatory responses 
and are associated with systemic inflammatory diseases (66,67). The gut microbiome has also been 
implicated in metabolic conditions where chronic low-level inflammation is present such as 
diabetes, obesity, and metabolic syndrome. Patients with diabetes, obesity, and metabolic 
syndrome have increased risk of developing osteoarthritis, osteoporosis, or both. Systemic 
inflammation and overall metabolic status are thought to be a contributors to increased risk in 
patients with diabetes, obesity, and metabolic syndrome (68-73). Inflammatory cytokines and 
related mediators can directly regulate bone remodeling and can negatively impact cartilage 
health (74-80).  
Bacterial products and components able to pass through the gut endothelial barrier and 
into the systemic circulation are a potential source of inflammation (81-86). MAMPs including 
lipopolysaccharide and peptidoglycan are known to influence bone cell function and 
differentiation (87-91). TLRs that detect the presence of MAMPs have been implicated in 
chondrocyte health and osteoarthritis pathology (92-95). Additionally, the gut microbiome is able 
to synthesize short chain fatty acids that can have profound effects on inflammation, integrity of 
the gut barrier, and on health of the gut epithelial cells, thus potentially influencing nutritional 
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absorption, regulation of the immune system, and release of bacterial products to distant organs 
(96,97).  
 
Figure 1.3. Routes the gut microbiome can influence bone and joint.   
Figure is reproduced from the article “Links Between the Microbiome and Bone” and is 
included with permission from Wiley (98) 
 
Chapter 1.2. Introduction to Bone  
	
1.2.1. Osteoporosis and Related Fractures 
  
 Osteoporosis is the loss of bone mass and mechanical performance that leads to an 
increased risk of bone fracture (99) (Fig 1.4). Every year osteoporosis leads to approximately 9 
million fractures worldwide (100). The loss of bone mass begins in early adulthood and continues 
throughout life. Age is one of the most important risk factors for osteoporosis, as 90% of hip 
fractures occur in people over the age of 65 (101). Additionally, other diseases and systemic 
factors can influence the onset and progression of osteoporosis. For example, women are at 
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higher risk of osteoporotic fracture (1 in 3 women worldwide experience a fracture) because 
estrogen depletion after menopause leads to reductions in bone mass. A need for further research 
to better understand systemic factors, diseases, and other pathways that influence osteoporosis 
development.  
 
 
Figure 1.4. Representative image of a human vertebrae in healthy and osteoporotic conditions. 
Adapted from Mosekilde 1998 (99) 
 
1.2.2 Bone Composition and Architecture 
	
 Bone is a complex, heterogeneous composite material with different architectures at 
multiple scales. Bone is composed of both organic and inorganic components. Bone is composed 
of 65% mineral component and 35% organic matrix (102). The mineral component of bone is 
composed of hydroxyapatite and can have impurities such as hydrogen phosphate, sodium, 
magnesium, citrate, carbonate, and potassium (103). The organic phase of bone is composed of 
primarily type I collagen (~90%), non-collagenous proteins (~5%) such as osteopontin, 
osteocalcin, osteonectin and matrix GLA protein, lipids (~2%), and water (104).  
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 Bone is a hierarchical material with different structures across a range of length scales 
(Fig 1.5). At the macroscale, bone is divided into two main structures: cortical and cancellous 
bone. Cortical bone is the dense tissue found primarily in the shafts of long bones as well as the 
outer shells of bone. Trabecular bone is a porous, spongy structure found at the end of long 
bones and in the interior of short bones like vertebrae, and is more metabolically active (105). 
Cortical bone microstructure can be separated into osteons, composed of cylindrical layers of 
mineralized collagen (lamellae) formed around a canal (103). The osteons will typically align with 
the long axis of the bone. Cancellous bone is comprised of networks of struts called trabeculae.  
Each trabeculae is composed of lamellae that form parallel to the long axis of the trabeculae (106). 
Within each lamellae the mineralized collagen fibers are aligned. Each lamellae has a different 
orientation than the adjacent lamellae. At the sub-nanostructure level, the three main components 
of the collagen fiber are collagens, non-collagenous proteins, and apatite crystals (103). The apatite 
crystals are positioned between the ends of the aligned collagen molecules. Type I collagen is the 
primary organic component of bone and is aligned into the collagen fibers. Other, non-
collagenous proteins, on the same scale can influence size and orientation of the mineral crystals.  
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Figure 1.5. The hierarchical structure of bone shown across multiple length scales. 
Image Adapted from Rho et al 1998 (103) 
  
1.2.3. Bone Characterization 
1.2.3.1 Characterization of Bone Structure  
  
 The most common technique for imaging the structure of cortical and cancellous bone in 
animal models is x-ray microcomputed tomography (microCT) (107,108). MicroCT is a non-
invasive imaging modality with high spatial resolution that allows measurement of the 3D 
morphology of bone. A key factor in processing microCT images is determining the appropriate 
threshold to properly segment out what in the image is bone from what is not bone (108). Another 
key consideration when using microCT in an experiment is the selection of a consistent and 
appropriate region of interest. A volume of interest, rather than a single 2D image, will often be 
sampled to get measures more representative of the entire bone or region. Anatomical landmarks 
and a percentage of total bone length are often used to maintain a consistent volume of interest 
across specimens.  
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 When assessing cortical bone in mice, commonly the midshaft (diaphysis) of a long bone 
such as the femur or tibia is used. We are often interested in the midshaft because it is 
representative of the geometry of the bone during bending tests (See Whole Bone Mechanical 
Properties- Three-Point Bend Test. Characterization of the total area (Fig 1.6), the marrow area, 
the cortical bone area, average cortical thickness and the ratios amongst these area measurements 
allow for an understanding of total bone mass and relevant appositional growth patterns (See 
Bone Growth and Remodeling). The length of the whole bone used for analysis of the midshaft is 
another measure often taken to understand longitudinal growth patterns. Other geometric 
measurements include the distance from the bending axis of the bone to the periosteal surface 
(outer surface) and to the endosteal surface (inner surface). The parameters listed above are also 
often normalized by body mass and/or body length to isolate differences among study groups 
that are independent of animal body size. Cortical bone tissue mineral density can be 
approximated by measuring the x-ray attenuation coefficient, as the attenuation coefficient is 
related to the level of mineral content in the bone.   
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Figure 1.6. Measures made to quantify cortical bone at the midshaft 
 
Trabecular bone is measured with micro-CT as well, but has different measurements to 
characterize the structure and the amount of bone present. A volume of interest is first selected 
for characterization. Regions of trabecular are segmented from the rest of the whole bone. The 
ratio of the volume filled with bone to the rest of the space in the volume represents the bone 
volume fraction. Bone volume fraction is a key measure for approximating the trabecular bone 
mass and assessing overall changes in bone mass. Other measures describing the trabecular bone 
include trabecular thickness, trabecular number (average number of trabeculae per unit length), 
trabecular separation (mean distance between trabeculae), and the degree of anisotropy (if 
structure is isotropic or anisotropic) (108) . Additionally, trabeculae are classified into either rod-
like or plate-like based on the aspect ratio of the trabeculae, and new software is capable of 
determining the percentage of the structure that consists of rods and plates (109,110). 
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1.2.3.2 Characterization of Cortical Bone Mechanical Properties 
	 	
	 The mechanical properties of cortical bone can be determined on both the whole bone 
and tissue level. Due to the complex hierarchical structure of bone, large changes in the tissue 
level mechanical properties can influence overall whole bone mechanical properties. 
Understanding the interplay between the two levels can be crucial for understanding how 
diseases or other conditions that alter bone can lead to fracture.  
1.2.3.2.1 Whole Bone Mechanical Properties- Three-Point Bend Test 
  
 The two main contributors to whole bone mechanical performance are: 1) parameters 
relating to bone structure (including the amount and architecture/shape, see Characterization of 
Bone Structure), and the material composition of the bone. For example, if there are two cortical 
bone cross-sections that are identical in shape, but one bone is twice as mineralized, we would 
expect drastically different mechanical performance. Conversely, if the material characterization 
of the bone demonstrated identical material composition, but one bone had twice the cortical area 
and thickness, we would expect drastically different whole bone mechanical performance.  
 A common mechanical test to determine whole bone mechanical properties in mice is the 
three-point bending (Fig 1.7). In a three-point bend test, a long bone (usually a femur) is placed 
upon two supports. Next, an indenter located at the mid-diaphysis applies a load to the bone until 
the bone fractures. During the test, the load applied and the displacement of the femur are 
recorded (Fig 1.7). Key measurements include: maximum load (the highest load the bone can 
withstand before fracture, fracture load (the load experienced when fracture occurs), yield load 
(the load experienced when the bone begins to deform in a non-elastic manner), stiffness (how 
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much the bone will deform given an applied load), and post-yield displacement (the amount the 
bone can deform in a non-elastic manner before fracture occurs). 
 
Figure 1.7. Setup and force vs displacement curve for three-point bending test of a mouse femur 
  
A parameter that is measured using microCT and is relevant to the mechanical 
performance of bone is the moment of inertia. Moment of inertia is a calculated parameter that 
describes how well the geometry of the bone resists bending. For whole bone testing, moment of 
inertia is calculated on a region from the mid-diaphysis (same region for cortical bone 
characterization) as the mid-diaphysis is where fracture occurs. Moment of inertia is strongly 
correlated with maximum load and stiffness.  
1.2.3.2.2 Tissue-Level Mechanical Properties- Nanoindentation 
	
Tissue level properties can be approximated from three-point bending; however, such 
numerical values are not very reliable due to the heteregenous material composition of bone, and 
the nonprismatic and irregular geometry of mouse bones. The most common characterization 
22	
	
technique used for tissue-level mechanical properties is nanoindentation. Nanoindentation 
involves pressing a hard tip at a known force into the surface of the bone (Fig 1.8) (111). The tip is 
usually made of diamond. The shape of the tip can vary, but the most commonly used tip is the 
Berkovich tip (three-sided pyramidal shape) (111,112). A typical indentation test is broken up into 
three loading periods: 1) loading ramp where the applied force increases at a constant rate; 2) 
holding period at a constant load; 3) an unloading ramp (Fig 1.8) (111).  The three loading periods 
help to avoid the effects of the viscoelastic (load-rate dependent) properties of bone. During the 
indentation test the displacement (depth of the tip) and load are measured. The loading and 
unloading protocol can be repeated multiple times per area, as well as for multiple locations per 
specimen. The thickness of the indented bone specimen must be sufficiently larger than the depth 
of the indentation so that the stresses within the material are not influenced by nearby boundaries 
(111). However, a general rule is to have a sample thickness that is ten times greater than the 
indentation depth, and a sample roughness that is 10 times less than the indentation depth (112). 
Sample preparation for nanoindentation involves polishing of a sample with silicon carbide 
paper, followed by aluminum oxide slurries to create a surface roughness acceptable for 
indentation (112).  
 
Figure 1.8. Schematic of nanoindentation and an example load vs depth curve. 
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The two main outcome measures from nano-indentation are reduced modulus and 
hardness (111). Reduced modulus is calculated from the unloading curve at the maximum applied 
load, the contact area of the indenter, a pre-determined constant based on the shape of the tip, 
and constants relating to the mechanical properties of the tip (elastic modulus and Poisson’s 
ratio) (111). Hardness is calculated based on the applied force divided by the area of the imprint 
created by the applied force (111). The reduced modulus and hardness of bone differ between 
cortical and trabecular bone, skeletal site, tissue age, and testing parameters (111).  
	 	
1.2.3.3 Characterization of Material Composition- Raman Spectroscopy 
	
	 One of the most common techniques for characterizing the material composition of bone 
is Raman spectroscopy. Raman spectroscopy is a vibrational spectroscopy technique that 
involves a laser light being focused on a sample (113). The laser light induces vibrations in the 
specimen that result in the scattering of a small portion of the laser light at different wavelengths. 
The shifts in wavelength are measured and reported in terms of wavenumber units (cm-1). The 
measured shifts can be directly related to chemical composition. Bone has a common spectrum 
with well-defined band assignments for bone mineral and matrix components (Figure 1.9) (114).   
The peak at ~959 cm-1 is the phosphate (𝑣"𝑃𝑂%&') band and is a measure of the mineral content 
of the bone and is the strongest peak identified in bone (113,114). The Amide I peak, with 
characteristic bands at ~1660 cm-1 and ~1690 cm-1 is the most commonly reported band with 
regard to  collagen content (113,114). Other peaks used to evaluate collagen content are the Amide 
III peak with characteristic bands at ~1242 cm-1 and ~1272 cm-1, and the proline and 
hydroxyproline bands at ~853 cm-1 and ~876 cm-1. Important considerations when choosing a 
peak to evaluate collagen and organic matrix components are: 1) Amide peaks can be 
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polarization dependent; 2) Amide peaks are not collagen specific (114). The peak at ~1070 cm-1 is 
the most intense carbonate (𝑣"𝐶𝑂&*') band, and can be used to measure the extent of B-type 
carbonate substitution for phosphate ions in the bone.  
 The three measures most commonly derived from the characteristic Raman spectra of 
bone. The mineral:matrix ratio is the ratio of the mineral component of bone to the organic 
component, and is calculated as the ratio of the 𝑣"𝑃𝑂%&'peak to one of the peaks used to report 
collagen content (Amide I, Amide III, Proline+Hydroxyproline). Mineral:matrix is useful to 
detect changes in mineral content that can occur due to vitamin deficiency, disease, and/or 
genetic background. Mineral:matrix has been correlated with stiffness and strength on the whole 
bone level, and with modulus and hardness on the tissue level (114). The carbonate:phosphate ratio 
describes the degree to which carbonate ions have been substituted for phosphate ions in the 
mineral apatite, and is calculated as the ratio of the 𝑣"𝑃𝑂%&'peak to the 𝑣"𝐶𝑂&*' peak.  Carbonate 
to phosphate can vary with bone architecture, age, and mineral crystallinity (113). The carbonate 
to phosphate ratio has been associated with tissue and whole bone mechanical performance (114). 
Crystallinity is related to the size, shape, and perfection of the bone mineral crystals, and is 
calculated as the inverse of the full-width-half-max of the 𝑣"𝑃𝑂%&'peak (115).  Crystallinity has 
been correlated with stiffness, bending modulus, and yield stress on the whole-bone level (116,117), 
and strength, stiffness, modulus, and yield stress on the tissue-level (115). Mineral:Matrix, 
carbonate:phosphate, and crystallinity increase with tissue age (113). Recently, the ratio between 
the 1660 cm-1 and 1690 cm-1 bands in the Amide I peak has been shown to be indicative of the 
maturity of the collagen cross-links (118). Raman spectra are expressed as ratios between peaks to 
avoid variation associated with spectra acquisition settings. Tissue heterogeneity is a measure 
used to characterize the variability of a parameter (mineral:matrix, carbonate:phosphate, 
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crystallinity, etc) over a specified area. Tissue heterogeneity is calculated by determining the 
full-width-half-max of the Gaussian distribution of all the measured spectra parameter values. 
Tissue heterogeneity is thought to play a role in the mechanical performance of bone, 
specifically influencing crack propagation and stress concentrations (119).  
 
Figure 1.9. Example spectra of bone with important peaks highlighted.  
Adapted from Mandair et al 2015 (114) 
  
Multiple processing steps are required to obtain relevant measures from the acquired 
spectra. The following processing steps are required in the following order for a sample of bone 
embedded in PMMA: 1) normalization of sample spectra and PMMA spectra to the PMMA peak 
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at ~813 cm-1. This step helps to eliminate any effects of inter-test variability of the Raman 
systems; 2) subtraction of the PMMA contribution from the measured sample spectra to 
eliminate any potential contributions of the PMMA to the measured spectra; 3) baselining of 
each peak to ensure only contributions from each specific peak are used for the calculation of 
Raman outcome parameters and to eliminate any effects of background flourescence. 
	
1.2.3.4 Bone Growth, Modeling, and Remodeling 
  
 Three main types of bone cells are involved in the development and functioning of the 
skeleton (Figure 1.10). Osteoblasts are the cells that help to form new bone by first depositing 
osteoid (mixture of collagen and other proteins). Osteoblasts then deposit calcium and other 
minerals into the osteoid to make bone. Osteoclasts are the cells that resorb bone. Osteoblasts 
and osteoclasts are found on the surfaces of bones. Osteocytes are former osteoblasts that have 
become embedded inside the bone tissue. Osteocytes help to maintain mineral balance, 
communicate with osteoblasts and osteoclasts to trigger resorption and formation, and play a key 
role in sensing mechanical stimuli in bone. 
 The two types of bone growth are appositional and endochondral. Appositional bone 
growth occurs when bone tissue is added to the outer circumference (periosteum) by osteoblasts 
to increase the size and modify the shape of the bone. Endochondral bone growth occurs at 
regions called growth plates to extend the length of bones. Bone cannot directly be added to the 
end of bones, as the end regions are in direct contact with each other and are moving at the 
joints. Instead, bone is added at the growth plate in the epiphysis. Chondrocytes at the growth 
plate will first produce cartilage, and then over time the osteoblasts will deposit bone matrix and 
mineral to eventually form hard mineralized bone.   
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 Bone modeling occurs to adapt the bone structure to mechanical loading, increase bone 
size, and to maintain overall mechanical performance of the bone (120). Bone modeling primarily 
occurs during growth but continues throughout life (121). During bone modeling, the processes of 
bone formation or bone resorption are not coupled. The action of osteoblasts to deposit new bone 
and osteoclasts to resorb bone are independent of one another. An example of bone modeling is 
bone formation on the periosteal surface to increase bone size and shape. 
 In contrast, in bone remodeling, the action of the osteoblasts and osteoclasts are 
coordinated (120). As bone becomes old or damaged, repair of the old and damaged bone in 
necessary to maintain the integrity of the skeleton. This process is called bone remodeling. 
Osteoclasts first initiate the process by resorbing the old or damaged bone. Osteoblasts then 
move into the area to fill the resorbed area with new bone. Osteocytes are thought to direct the 
initiation of bone remodeling. Bone remodeling at a healthy rate is beneficial for the skeleton and 
helps to maintain its mechanical performance. However, in pathological conditions, an 
imbalance between osteoclastic resorption and osteoblastic formation leads to a deteriorated 
skeleton and increased fracture risk.  
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Figure 1.10. The three key cells involved in bone growth, modeling, and remodeling. 
 
Chapter 1.3. Introduction to Cartilage and Osteoarthritis 
Chapter 1.3.1 The Burden of Osteoarthritis 
 
Osteoarthritis is the most common cause of joint disability for adults in the world. 
Osteoarthritis is a joint disorder that involves mechanical wear and tear of the joint leading to 
degeneration of both bone and cartilage.  Common symptoms of osteoarthritis include pain, 
swelling, and loss of joint function/range of motion. The total number of people with 
osteoarthritis is expected to increase drastically in the coming years as life expectancy increases. 
Currently, there are no preventive treatments for osteoarthritis and there are only limited 
treatments that work to slow the progression of osteoarthritis or reduce symptoms such as pain. 
Knees are the most common joint to experience osteoarthritis due to the large load-bearing 
responsibility during activities of daily living. The most common outcome for severe knee 
osteoarthritis is complete joint replacement, where the diseased joint is surgically removed and 
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an implant inserted. Joint replacements have lengthy recovery times, risk of infection, and are 
costly. There is an urgent need to better understand both the pathogenesis of osteoarthritis so that 
improved therapies can be created and the burden of osteoarthritis reduced.	
Chapter 1.3.2 Changes to an Osteoarthritic Joint 
	
A joint is the location where two bones intersect and motion can occur. The two main 
components of a joint are the articular cartilage (on the surface of the bone to allow for 
articulation of the joint, and the subchondral bone (bone directly underneath the cartilage) (Fig 
1.11). Cartilage is responsible for lubrication between two bones and to allow for smooth 
movement. The subchondral bone helps to provide overall structural stability for the joint. The 
knee joint also includes the synovial membrane that contains synovial fluid that acts a source of 
nutrients and lubrication, the meniscus to provide additional lubrication and load-bearing ability, 
and ligaments to stabilize the joint and prevent excessive movement in certain planes of motion. 
In an osteoarthritic joint, severe pathophysiologic changes are observed that include cartilage 
loss, changes to subchondral bone morphology, osteophyte formation, and inflammation (Fig 
1.11). Clinically, osteoarthritis is detected using radiographic evidence, as well as swelling and 
reports of pain and limited mobility.  
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Figure 1.11. Changes in a healthy joint and an osteoarthritic joint. 
 
Chapter 1.3.2.1 Articular Cartilage in Healthy and Osteoarthritis Conditions 
	
 Cartilage is composed of chondrocytes as well as the surrounding extracellular matrix. 
The extracellular matrix is composed of water, collagen, proteoglycans, and non-collagenous 
proteins. Cartilage is avascular in nature, and as a result, has a very limited ability to repair itself. 
Articular cartilage can be divided into three zonal layers each with specific morphological 
characteristics (Fig 1.12): superficial, middle, and deep zones. The structure of the superficial 
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zone is tightly packed collagen fibers that are aligned with the articular surface. Chondrocytes in 
this zone are flatter in shape (122). As the superficial layer becomes damaged, the deeper zones 
become more susceptible to damage. The middle zone consists of thicker collagen fibrils 
arranged in an oblique orientation. Chondrocytes in the middle zone are more spherical in shape 
(122). The deep zone has the thickest collagen fibrils aligned perpendicular to the articular surface.  
Chondrocytes in the deep zone are aligned in a column-like orientation (122). The tidemark 
separates the deep zone from the calcified cartilage zone. The calcified cartilage zone secures the 
collagen fibrils to the subchondral bone beneath to ensure the cartilage remains in place.  
 
Figure 1.12. The three different zones of cartilage and the related structures.  
Adapted from Fox et al 2009 (122) 
 
Under osteoarthritic conditions, erosion of the cartilage surface is common. During the early 
stages of osteoarthritis development chondrocytes that were previously inactive will become 
active and begin cloning themselves to form clusters. The superficial zone is the first region to 
experience any erosion. Typically, small fibrillations in the cartilage surface occur first (Fig 
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1.13) (122). Increased cartilage calcification with also occur in the earlier stages of osteoarthritis 
development. Cartilage calcification can be detected by the progression of the tidemark towards 
the articular surface. During early osteoarthritis there is an up-regulation of proteinases that 
degrade cartilage. Matrix metalloproteinases (MMP’s) degrade the surrounding extracellular 
matrix and are thought to be a potential therapeutic target for osteoarthritis (122). Reductions in 
the health and integrity of cartilage can be detected by observing the overall loss of 
proteoglycans in the cartilage observed in histology slides. The more substantial the loss of stain 
and the deeper into the cartilage the loss of proteoglycans, the more severe the cartilage health. 
Once the cartilage matrix has been degraded it is not possible for the cartilage matrix to be 
repaired to its original state.  In the most severe osteoarthritis conditions, the entire articular 
cartilage has worn away, and in the joint there is bone on bone contact, resulting in severe pain, 
swelling, and further degeneration of the joint. 
 
Figure 1.13. Signs of osteoarthritis in articular cartilage.  
Adapted from Goldring 2012 (123) 
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Chapter 1.3.2.2 Subchondral Bone in Healthy and Osteoarthritis Conditions 
	
The subchondral bone provides stability to the joint as it is the tissue that can withstand the 
highest loads in the joint. The subchondral bone can be divided into the subchondral cortical 
bone plate, and the distal epiphyseal cancellous bone region (Fig 1.14.) As osteoarthritis 
progresses, we see changes that occur to both the cortical and cancellous subchondral bone (Fig 
1.14) (124).  During early stages of osteoarthritis, both the subchondral cortical bone and the 
cancellous bone plate experience thinning due to an increased bone remodeling rate (125). As the 
subchondral bone plate thins, there is an expansion of the calcified cartilage region, leaving 
multiple tidemarks. In later stages of osteoarthritis, the rate of bone resorption slows and the 
bone formation rate remains unchanged, leading to subchondral bone plate thickening. 
Clinically, subchondral bone thickening is a radiographic hallmark of osteoarthritis.  
	
 
Figure 1.14. Changes to subchondral bone in early and late stages of osteoarthritis.  
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Chapter 1.3.2.3 Osteophyte Formation 
	
	 Osteophytes are another hallmark of osteoarthritis. An osteophyte is a bony outgrowth 
that develops from the periosteum at the junction between cartilage and bone in the joint (Fig 
1.15) (126). Osteophytes are thought to develop during OA to help stabilize the joint and to 
redistribute mechanical loads appropriately. Osteophytes can form in early stages of 
osteoarthritis and are not always detectable clinically. Osteophytes first begin to form when cells 
in the synovial lining begin to proliferate. Cells begin to deposit additional matrix, and then in 
later stages endochondral ossification occurs. The final osteophyte is integrated with the 
subchondral bone.  
	
Figure 1.15. Changes to subchondral bone in early and late stages of osteoarthritis.  
Adapted from van der Kraan 2007 (126) 
	
Chapter 1.3.3 In-Vivo Rodent Models of Osteoarthritis 
	
To better understand osteoarthritis, several models have been developed that create 
osteoarthritis-like pathology in rodents. The models fall into four different categories (127): 1) 
Mechanical- a noninvasive mechanical load is applied to the joint of the animal to induce the 
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development of osteoarthritis like changes in the joint; 2) Surgical: a destabilization of the joint 
is created by surgically removing ligaments. The altered joint mechanics leads to cartilage 
damage and advanced signs of osteoarthritis; 3) Spontaneous and genetic: Mice develop 
osteoarthritis pathology due to age. Different strains of mice, as well as specific knock-out, 
knock-in, and transgenic mice are more susceptible to the development of osteoarthritis with age; 
4) Chemical: chemicals are injected into the joint to induce inflammation, and to degrade 
chondrocyte health and extracellular matrix components leading to osteoarthritis development.  
The two main types of mechanical load-induced models are cyclic compression and a 
traumatic injury (128). In the traumatic injury models, a single large force is applied to the joint 
that results in an acute traumatic injury such as a fracture (129) or a rupture of a ligament (130). The 
in-vivo cyclic tibial compression models apply a load through the ankle and knee joint. After a 
sustained period of loading (1-6 week depending on the model) both cartilage damage and 
changes to the subchondral bone occur. The thesis will focus on the cyclic compressive in-vivo 
loading model developed by the van der Meulen lab (131). In the van der Meulen model, cyclic 
compression leads to changes in articular cartilage that include decreased cartilage thickness, 
loss of proteoglycans, surface fibrillations, vertical clefts past the superficial zone, and erosion of 
the cartilage surface. Cyclic compression leads to changes in bone that include subchondral bone 
plate thickening, subchondral trabecular bone loss in the epiphysis, and osteophyte formation. 
Longer durations of loading (1, 2, or 6 weeks), as well as the higher load magnitudes (4.5N or 
9N), lead to an increased amount of cartilage damage and subchondral bone changes.  
Chapter 1.4 Thesis Aims 
	
	 Osteoporosis and osteoarthritis affect millions of people worldwide every year. 
Osteoporosis related fractures totaled 8.9 million worldwide annually (132) and osteoarthritis 
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affects over 30 million people in the US alone. Recently, the gut microbiome has been identified 
as a factor that can influence chronic conditions associated with bone and joint disease such as 
obesity, diabetes, metabolic syndrome, inflammatory bowel diseases, and malnutrition. 
Therefore, the aims of this dissertation are: 1)	 Determine the effects of altering the gut 
microbiome on bone phenotype and bone mechanical performance; 2) Determine the effects of 
altering the gut microbiome on the chemical composition of cortical bone; 3) Determine the 
effects of the gut microbiome on the development and severity of in-vivo non-invasive load 
induced osteoarthritis. 
Chapter 1.4.1 Aim 1- Determine the effects of altering the gut microbiome on bone phenotype 
and bone mechanical performance.  
	
The gut microbiome is associated with chronic conditions that are associated with 
increased fracture risk. Recent evidence suggests that the gut microbiome can influence bone 
mass, however no studies have determined if the mechanical performance of the bone is 
influenced by the gut microbiome. Additionally, previous studies have not evaluated mice at 
skeletal maturity. In this aim, alterations to the gut microbiome are caused by genotypic 
alteration and chronic treatment with antibiotics. Cortical and trabecular bone morphology is 
analyzed by micro-computed tomography (microCT). Three-point bending is performed on the 
femur to investigate the mechanical performance of cortical bone in mice with an altered gut 
microbiome. The composition of the gut microbiome is characterized using 16S rRNA 
sequencing. The results of this aim were presented at American Society for Bone and Mineral 
Research annual meeting and published in the Journal of Bone and Mineral Research (133). 
Chapter 1.4.2 Aim 2- Determine the effects of altering the gut microbiome on the chemical 
composition of cortical bone 
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	 In Aim 1 we found that modifications to the gut microbiome led to alterations in the the 
mechanical performance, suggesting impaired bone tissue material properties. Raman 
spectroscopy is used to determine the chemical composition of cortical bone sections from the 
tibial metaphysis. To further understand how the gut microbiome can influence bone tissue 
material properties we perform shotgun metagenomics to evaluate the functional capacity of the 
microbiome. The results from shotgun metagenomics are used to explore the three potential 
routes the gut microbiome can influence bone: regulation of nutritional absorption, translocation 
of bacterial products, and regulation of the immune system (98). The results of this aim were 
presented at the 2018 World Congress of Biomechanics Conference, the 2018 American Society 
for Bone and Mineral Research meeting and are prepared for submission to the Journal of Bone 
and Mineral Research.  
Chapter 1.4.3 Aim 3- Determine the effects of the gut microbiome on the development and 
severity of in vivo non-invasive load induced osteoarthritis 
 
Metabolic syndrome is characterized by obesity, hyperglycemia, and insulin resistance, 
and recently a close relationship to the gut microbiome has been established. Metabolic 
syndrome is also associated with increased risk of developing osteoarthritis (OA), but it is 
unclear if the association is attributable to increased mechanical loading on joints caused by 
obesity or other aspects of the metabolic syndrome. Here we examined the effects of metabolic 
syndrome, obesity, and the gut microbiome on osteoarthritis by using an in vivo non-invasive 
loading model to induce osteoarthritis in mice. We use a mouse model of metabolic syndrome 
dependent on the gut microbiome for the phenotype to develop, as well as a mouse model of 
severe obesity/diabetes induced by feeding of a high fat diet. 16S rRNA gene sequencing was 
performed to evaluate the compositional differences in the gut microbiome. The results of this 
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aim have been presented at the Orthopedic Research Society Upstate NY and Northeast Regional 
Meeting, the Orthopedic Research Society annual meeting, the Cartilage Repair Symposium, and 
has been accepted for publication in Osteoarthritis and Cartilage.  
Chapter 2- Alterations to the Gut Microbiome and Bone Phenotype 
	
This chapter was published in the Journal of Bone and Mineral Research in 2017 in Volume 32, 
Issue 6. The article is titled “Alterations to the Gut Microbiome Impair Bone Strength and Tissue 
Material Properties” and is reprinted here with permission of Wiley (133).  
Chapter 2.1 Abstract 
	
Alterations in the gut microbiome have been associated with changes in bone mass and 
microstructure, but the effects of the microbiome on bone biomechanical properties are not 
known. Here we examined bone strength under two conditions of altered microbiota: 1) an 
inbred mouse strain known to develop an altered gut microbiome due to deficits in the immune 
system (the toll-like receptor 5 deficient mouse, TLR5KO); and 2) disruption of the gut 
microbiota (∆Microbiota) through chronic treatment with selected antibiotics (ampicillin and 
neomycin). The bone phenotypes of TLR5KO and WT (C57Bl/6) mice were examined following 
disruption of the microbiota from 4 weeks to 16 weeks of age as well as without treatment (n = 
7-16/group, 39 animals total). Femur bending strength was less in ∆Microbiota mice than in 
untreated animals and the reduction in strength was not fully explained by differences in bone 
cross-sectional geometry, implicating impaired bone tissue material properties. Small differences 
in whole bone bending strength were observed between WT and TLR5KO mice after accounting 
for differences in bone morphology. No differences in trabecular bone volume fraction were 
associated with genotype or disruption of gut microbiota. Treatment altered the gut microbiota 
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by depleting organisms from the phyla Bacteroidetes and enriching for Proteobacteria, as 
determined from sequencing of fecal 16S rRNA genes. Differences in splenic immune cell 
populations were also observed; B and T cell populations were depleted in TLR5KO mice and in 
∆Microbiota mice (p <0.001), suggesting an association between alterations in bone tissue 
material properties and immune cell populations. We conclude that alterations in the gut 
microbiota for extended periods during growth may lead to impaired whole bone mechanical 
properties in ways that are not explained by bone geometry. 
	
 Chapter 2.2 Introduction 
 
The microbes that inhabit the gastrointestinal tract are known collectively as the gut 
microbiota. Alterations in the gut microbiota are associated with a number of conditions that 
cause bone loss or increase fracture risk including malnutrition (134,135), inflammatory bowel 
disease (136-138), obesity (71,139), and metabolic disease (140-142). The gut microbiota, therefore, have 
the potential to influence bone and contribute to differences in fracture risk among patient 
populations.  
The gut microbiome is initially obtained at birth (143) and subsequently shaped by factors 
such as environment (144) and diet (4,23). Exposure to the gut microbiome is necessary for the 
proper education and development of the innate and adaptive immune systems (145). Dendritic 
cells, macrophages, granulocytes, T and B cells, and intestinal epithelial cells directly interact 
with the gut microbiome (145). Toll-like receptors are one set of receptors on immune cells that 
recognize the components of the gut microbiome and facilitate communication between the gut 
microbiome and the immune system (146). Alterations in the gut microbiota or improper 
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communication between the immune system and gut microbiota can lead to chronic immune 
responses and disease (147).  
The effects of the microbiome on bone structure and density have been studied in mice 
using two standard tools for manipulating the microbiome: germ-free animals and oral antibiotic 
treatments (10,12).  The changes in bone following these manipulations of the gut flora differ 
considerably among studies. Germ-free mice (raised in the absence of live microbes) have been 
reported to display reduced bone mass(41), as well as increased bone mass (148) as compared to 
mice raised in conventional environments. Alterations in the gut microbiota through treatment 
with oral antibiotics have been  reported to affect bone density in mice, but the findings have 
been mixed, possibly due to differences in animal age, sex, antibiotic used, dosing schedule and 
mouse genotype (149-152).  
Genetic models are another tool for studying the effects of the microbiome on animal 
physiology. The Toll-like receptor 5 deficient mouse (TLR5KO) is a congenic mouse strain that 
has been used to study the effects of the gut microbiome on animal physiology and disease. Toll-
like receptor 5 (TLR5) is the innate immune receptor for flagellin and does not have an 
endogenous ligand (153). Hence, phenotypic traits of the TLR5KO mouse are primarily due to 
alterations in host-microbe interactions (47). Failure of the TLR5KO mouse to respond to flagellin 
is associated with changes in the gut microbiome that lead to increases in intestinal and systemic 
inflammation and a metabolic syndrome-like phenotype characterized by mild obesity, insulin 
resistance, increased blood pressure and increased blood glucose (7,47). The metabolic syndrome-
like phenotype of the TLR5KO mouse does not develop in mice raised in a germ-free 
environment and can be transferred to wild-type mice through transplantation of the gut 
microbiota, demonstrating that the phenotype depends on the gut flora (7).   
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While prior work has shown that the disruption or absence of the microbiome can 
influence bone, interpreting conflicting findings among studies is challenging because many 
prior studies use young animals of different ages (less than 12 weeks of age) or low resolution 
imaging techniques (mouse DXA). Comparing bone phenotypes in such young animals is not 
recommended because bone is changing rapidly during growth (154). Additionally, none of the 
previous studies have examined the effect of alterations in the gut microbiota on bone 
mechanical performance. In the present study, we tested the hypothesis that alterations in the gut 
microbiota can have an effect on whole bone biomechanical performance. Specifically, we 
determined changes in bone structure and strength associated with alterations in the gut 
microbiota caused by 1) genotypic alterations (the TLR5KO mouse) and 2) chronic treatment 
with antibiotics that target the gut microbiota. 
	
Chapter 2.3 Materials and Methods 
Chapter 2.3.1 Study Design 
	
Animal procedures were approved by Cornell University’s Institutional Animal Care and 
Use Committee. Mice from the C57BL/6J inbred strain and the B6.129S1-Tlr5tm1Flv/J 
(TLR5KO) congenic strain were acquired from the Jackson Laboratory (Bar Harbor, ME) and 
each bred separately in conventional housing in our animal facility. C57BL/6J is the 
recommended control strain for TLR5KO (7,155). Animals were housed in plastic cages filled with 
1/4-inch corn cob bedding (The Andersons’ Lab Bedding, Ohio), fed with standard laboratory 
chow (Teklad LM-485 Mouse/Rat Sterilizable Diet) and water ad libitum, and provided a 
cardboard refuge environmental enrichment hut (Ketchum Manufacturing; Brockville, Ontario). 
Male mice were divided into four groups: two groups treated to disrupt the gut microbiota 
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(C57BL/6J: n=7, TLR5KO: n=8) and two untreated groups (C57BL/6J: n=12, TLR5KO: n=16). 
Mice with disrupted microbiota are referred to as “∆Microbiota.”  Mice were housed in cages 
with other animals from the same genetic background/treatment group. Treated groups received 
broad-spectrum antibiotics (1.0 g/L ampicillin, 0.5 g/L neomycin) in their drinking water from 
weaning at 4 weeks of age until skeletal maturity (16 weeks of age) (7). Chronic antibiotics used 
in this manner causes consistent disruptions to the gut microbiota over a prolonged time period 
(11). Ampicillin and neomycin have poor bioavailability, thereby limiting extra-intestinal effects 
of treatment (7,156). Additionally, neomycin and ampicillin have never been associated with 
impaired bone growth. Animals were euthanized at 16 weeks of age. Femora, tibiae, epididymal 
fat pads, and spleen were collected immediately after euthanasia. Fecal pellets were collected 
one day prior to euthanasia to allow analysis of the microbiota. 
	
Chapter 2.3.2 Cortical Bone Mechanical Testing 
	
The right femora were harvested, wrapped in PBS-soaked gauze, and stored at -20°C 
prior to analysis. Femur length was measured from the greater trochanter to the lateral condyle 
using digital calipers. Images of the femoral diaphyseal cross-section were obtained by micro-CT 
with a voxel size of 25 µm (GE eXplore CT 120; 80 kVp, 32 µA, 100 ms integration time). 
Images were processed using a Gaussian filter to remove noise and a global threshold for each 
group was used to segment mineralized tissue from surrounding non-mineralized tissue. Femoral 
cross-sectional geometry was determined using a volume of interest extending 2.5% of total bone 
length and centered midway between the greater trochanter and lateral condyle (BoneJ, 
bonej.org, version 1.3.3) (157). Measurements included total area, cortical cross-sectional area, 
cortical thickness, marrow area, and moment of inertia about the medial-lateral axis.  
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 Femora were thawed to room temperature and maintained hydrated during mechanical 
testing. Right femora were loaded to failure in three-point bending in the anterior-posterior 
direction at a rate of 0.1 mm/s using a span length of 6 mm between outer loading pins (858 Mini 
Bionix; MTS, Eden Prairie, MN, USA).  Force and displacement were measured using a 10 lb. 
load cell (Transducer Techniques, SSM-100, Temecula, CA) and a linear variable differential 
transducer at a 100 Hz sampling rate. Bending stiffness was calculated as the slope of the linear 
portion of the force-displacement curve (154). Peak bending moment was calculated as half the 
peak load multiplied by half the span length (154). The peak bending moment is related to bone 
tissue material properties and bone midshaft geometry by the following equation (158): 
𝑀 = 𝜎/ ∙ 𝐼𝑐 
where M is peak bending moment, 𝜎/ is bone tissue material strength, I is the moment of inertia, 
and c is the distance from the neutral axis to bone surface.  The term 
34 incorporates all 
geometrical properties that can influence peak bending moment. Differences in peak bending 
moment that are not explained by  
34 are caused by alterations in tissue material properties. Due 
to irregularities in force versus displacement data associated with motion some specimens were 
excluded from the biomechanical analysis (4 WT, 1 WT ∆Microbiota, 3 TLR5KO). 
Chapter 2.3.3 Trabecular Bone Morphology 
	
Images of the tibiae were collected using micro-computed tomography with 6 µm voxels 
(µCT35; Scanco Medical AG, Switzerland; 55 kVp, 145 µA, 600 ms integration time). The 
trabecular bone microarchitecture of the proximal tibial metaphysis was examined in a region 
extending from the growth plate to 10% of total bone length. Measurements included bone 
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volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and 
cortical tissue mineral density (ct. TMD). A global threshold for each group was used to segment 
mineralized tissue from surrounding non-mineralized tissue. A randomized subset (n=8) was 
selected for analysis of trabecular bone morphology for the TLR5KO mice. 
	
Chapter 2.3.4 Gut Microbiome Analysis 
Chapter 2.3.4.1 DNA Extraction 
	
Gut microbiota analysis was performed on six samples per group. Isolation of DNA from 
feces was performed by using PowerSoil DNA Isolation Kit (MO BIO Laboratory Inc., Carlsbad, 
CA) according to manufacturers’ instructions. DNA concentration and purity were then 
evaluated using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Rockland, 
DE) at wavelengths of 230, 260, and 280 nm. 
	
Chapter 2.3.4.2 Quantitative PCR 
	
The total bacterial load of fecal samples was determined using quantitative PCR (qPCR) 
as previously described (159).  The total bacterial load was defined as the total number of 16S 
rRNA gene copies. Briefly, quantification of the 16S rRNA target DNA was achieved by using 
the forward: 5’-TGG AGC ATG TGG TTT AAT TCG A-3’, and reverse: 5’-TGC GGG ACT 
TAA CCC AAC A-3’) (160,161) Unibac primers, and 10-fold serial dilutions ranging from 100 to 
107 plasmid copies of a plasmid DNA standard which was cloned in-house(159). Plasmid 
standards and feces samples were run in duplicates. The average of the cycle threshold value was 
used for calculation of the total bacterial load. 
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Chapter 2.3.4.3 Next-Generation Sequencing and Bioinformatics 
	
Amplification of the 16S rRNA gene, library construction and bioinformatics were 
executed according to previously described methods (159). Briefly, for amplification of the V4 
hypervariable region of the bacterial/archaeal 16S rRNA gene, primers 515F and 806R were 
used (162). The 5'-barcoded amplicons were generated in triplicate using 12-300 ng of template 
DNA, 2 X EconoTaq® Plus Green Master Mix (Lucigen®, Middleton, WI) and 10 µM of each 
primer. Replicate amplicons were pooled and purified using the Gel PCR DNA Fragment 
Extraction kit (IBI Scientific, Peosta, IA) and visualized by electrophoresis through 1.2% 
(weight/volume) agarose gel stained with 0.5 mg/ml ethidium bromide. Blank controls in which 
no DNA was added to the reaction were performed. Purified amplicon DNA was quantified 
using fluorometry (Quant-iT™ PicoGreen® from Life Technologies Corporation, Carlsbad, CA, 
USA). 
Standardization of feces amplicon sample aliquots was performed to the same 
concentration and then pooled into one run according to individual barcode primers for the 16S 
rRNA gene. Final equimolar libraries were sequenced using the MiSeq reagent kit v2 (300 
cycles) on the MiSeq platform (Illumina, Inc., San Diego, CA, USA).  
Raw 16S rRNA gene sequences generated were demultiplexed using the open source 
software pipeline Quantitative Insights Into Microbial Ecology (QIIME, version 1.7.0-dev) (163). 
Sequences were filtered for quality using established guidelines (164). Taxonomy was assigned 
using UCLUST (www.drive5.com) consensus taxonomy assigner, against the Greengenes 
reference database(165). Low-abundance clusters were filtered, and chimeric sequences were 
removed using USEARCH (166). Additionally, we generated a species-level OTU table using the 
MiSeq Reporter Metagenomics Workflow. The MiSeq Reporter classification is based on the 
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Greengenes database (http://greengenes.lbl.gov/), and the output of this workflow is a 
classification of reads at multiple taxonomic levels: kingdom, phylum, class, order, family, genus 
and species. 
Shannon diversity index was performed (QIIME, version 1.7.0-dev). Before estimating 
the Shannon diversity index, all sample libraries were rarefied to an equal depth of 10,000 
sequences (QIIME, version 1.7.0-dev). 
	
Chapter 2.3.5 Colon Histology 
	
To evaluate gut inflammation, colons were collected at euthanasia and fixed in 10% 
neutral buffered formalin for 48 hours. Colons were embedded in paraffin, sectioned, and scored 
by the Cornell Animal Health Diagnostic Center. Each sample was scored based on 4 assays: 
lymphoid aggregate size, lymphoid aggregate density, apoptotic cells per high powered field, and 
presence of inflammation.	
Chapter 2.3.6 Flow Cytometry 
	
Splenocytes were harvested from the spleen of three mice from each group immediately 
after euthanasia as described previously (167,168). The splenocytes were subsequently stained by 
incubation in 50 µL of FACS containing antibodies (1:500 dilution) for an hour. For analyzing B 
cells, Anti-CD20 antibody conjugated to Phycoerythrin (PE) (BD Pharmagen) was used and for 
T cells Anti-CD3 antibody conjugated to PE (BD Pharmagen) was used. The stained cells were 
rinsed twice with FACS buffer and re-suspended in 50 µL FACS buffer to be analyzed by BD 
Accuri C6 flow cytometer. The flow cytometer results were analyzed using FlowJo software 
(FlowJo LLC, Ashland, Oregon).  Gut microbiota interact with and can be regulated by B and T 
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cell populations (145,169). Therefore, we examined the relative percentages of B and T cells in 
spleens of these mice.   
	
Chapter 2.3.7 Statistical Analyses 
	
Measures of bone were adjusted for body mass (unadjusted values are provided in 
Supplemental Table b) (154). Homogenous variance was tested using Levene’s test and normality 
tested using the Shapiro-Wilk Test. If parametric assumptions were met, a one-way ANOVA 
followed by post-hoc Holm correction for multiple comparisons was performed to test for 
differences between groups. If parametric assumptions were violated, either data was submitted 
to a log transform to achieve homogenous variance and normality or a non-parametric ranked 
Dunn’s test followed by post-hoc Bonferroni adjustment for multiple comparisons was used.  
To determine if genotype or treatment influenced whole bone strength in ways that were 
not explained by cross-sectional geometry, we performed an ANCOVA, implemented with a 
GLM model using 
34 as the covariate with genotype and treatment as fixed effects. Statistical 
tests were conducted using JMP Pro (v.9, 2013, SAS Institute Inc., Cary, NC, USA). 
	
Chapter 2.4 Results 
Chapter 2.4.1 Body Mass and TLR5KO Phenotypes 
	
The TLR5KO mice showed a mild obesity phenotype with an average body mass 10.4% 
greater than WT (p <0.05; Fig 2.1A) and an average epididymal fat pad mass 52.0% greater than 
WT (p <0.05; Fig 2.1B). Body mass and fat pad mass in TLR5KO mice with disrupted 
microbiota and WT mice with disrupted microbiota were similar, as demonstrated in prior work 
(7). No differences in colon histological scoring were observed among groups. One TLR5KO 
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mouse had elevated colon histological scores suggesting mild colitis, but did not display gross 
differences in bone morphology or body mass and was not excluded from the study (155). 
 
Figure 2.1. Metabolic and bone phenotype of mice with an altered gut microbiome. 
	
TLR5KO mice had greater body and fat pad mass. Disruption of the gut microbiota in TLR5KO 
mice prevented the development of increased body and fat pad mass. Disruption of the gut 
microbiota in WT mice had no effect on (A) body mass or (B) epididymal fat pad mass. (C) 
TLR5KO mice femur length was less than WT in both untreated and treated groups (D) Total 
area was increased in untreated TLR5KO mice compared to untreated WT mice. Disruption of 
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gut microbiota led to a reduced total area in TLR5KO ∆Microbiota mice. (E) Disruption of the 
gut microbiota in both genotypes was associated with a reduced tibial metaphysis cortical TMD. 
(F) No differences in tibial metaphysis BV/TV were observed between any groups. Solid colored 
lines on dot plots represent mean. Measures in Fig 2.1C, 2.1D, 2.1E, 2.1F are adjusted for body 
mass.     *  p < 0.05. 
	
Chapter 2.4.2 Femoral Whole-Bone Bending Strength and Geometry in TLR5KO Mice 
	
 
Bone morphology in TLR5KO mice differed from WT mice. Total cross-sectional area 
was larger in TLR5KO mice compared to WT mice (p < 0.05, Fig 2.1D). Marrow area, cortical 
area, and cortical thickness (Table a) in TLR5KO mice were similar to that in WT mice. 
TLR5KO mice had a larger moment of inertia compared to WT mice (p < 0.05, Fig 2.2A). 
Femoral bone length was 1.5% smaller in TLR5KO mice compared to WT mice (p < 0.05, Fig 
2.1C, Table a).  
 The peak bending moment in untreated TLR5KO mice was similar to that in WT mice 
(Fig 2.2B), but the moment of inertia in TLR5KO mice was larger than in WT mice. Whole bone 
strength in TLR5KO mice was less than that in WT mice after accounting for differences in 
cross-sectional femoral geometry (ANCOVA, effect of genotype, p<0.0001, Fig 2.2C). No 
differences in post yield displacement (Table a) or bending stiffness (Fig 2.2D) were observed 
between WT and TLR5KO mice. 
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Table a  Micro-computed tomography measures of cancellous and cortical bone and whole bone 
mechanical testing measures after adjustments for body mass are shown. 
    Wild Type                                        TLR5KO 
 Body Mass 
Adjusted 
Measure 
Untreated  ∆Microbiota  Untreated  ∆Microbiota  
 Bone Volume 
Fraction 
0.15 ± 0.02 0.15 ± 0.03 0.14 ± 0.01 0.14 ± 0.01 
Trabecular  
Thickness (µm) 
0.045 ± 0.002 0.043 ± 0.005 0.041 ± 0.003 a 0.038 ± 0.002$ 
Proximal 
Tibia 
Trabecular 
Separation (µm) 
0.197 ± 0.014 0.192 ± 0.008 0.187 ± 0.007 0.178 ± 0.007$ 
Cortical TMD 
(mg HA/cm3) 
999 ± 10 979 ± 8* 999 ± 13 980 ± 7# 
 Growth Plate 
Thickness (µm) 
558 ± 46 562 ± 41 550 ± 54 528 ± 21 
 Cortical Area 
(mm2) 
0.87 ± 0.07 0.81 ± 0.09* 0.94 ± 0.07 0.69 ± 0.04# 
Femoral 
Diaphysis 
Marrow Area 
(mm2) 
1.05 ± 0.06 1.17 ± 0.10* 1.17 ± 0.15 1.00 ± 0.08# 
Total Area 
(mm2) 
1.93 ± 0.12 1.98 ± 0.17 2.12 ± 0.17 a 1.68 ± 0.08#,$ 
Cortical 
Thickness (µm) 
210 ± 10 189 ± 15* 216 ± 13 172 ± 12#,$ 
Moment of 
Inertia (mm4) 
0.15 ± 0.02 0.14 ± 0.02 0.17 ± 0.03 a 0.10 ± 0.01#,$ 
Moment of 
Inertia/ c (mm3) 
0.22 ± 0.03  0.22 ± 0.03 0.25 ± 0.03  0.17 ± 0.01#,$ 
 
Whole 
Femur 
Length (mm) 16.04 ± 0.18 16.13 ± 0.12 15.80 ± 0.24a 15.71 ± 0.12$ 
Peak Bending 
Moment 
(N∗mm) 
40.79 ± 2.71 37.18 ± 2.35* 38.75 ± 2.37 30.22 ± 1.76#,$ 
Bending 
Stiffness 
(N/mm) 
193 ± 26  177 ± 21 175 ± 33 152 ± 7 
Post Yield 
Displacement 
(mm) 
0.20 ± 0.17 0.35 ± 0.09 0.29 ± 0.11 0.42 ± 0.07 
Values are mean  ± SD. TMD=Tissue mineral density 
*WT-∆Microbiota v. WT-untreated, p<0.05  
#TLR5KO-∆Microbiota v. TLR5KO-untreated, p<0.05  
aTL5KO-untreated v. WT-untreated, p<0.05  
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$TLR5KO-∆Microbiota v. WT-∆Microbiota, p<0.05  
Chapter 2.4.3 Femoral Whole-Bone Bending Strength and Geometry in Mice With a 
Disrupted Microbiota  
	
Disruption of the gut microbiota resulted in differences in geometry in TLR5KO mice 
and in WT mice. Disruption of the gut microbiota in WT mice resulted in increased marrow area, 
decreased cortical area, and decreased cortical thickness compared to untreated WT mice (p < 
0.05, Table a). Disruption of the gut microbiota did not result in changes in total area, moment of 
inertia, or femoral length in WT mice (Fig 2.1C, Fig 2.1D, 2.2A, Table a). Disruption of the gut 
microbiota in TLR5KO mice resulted in decreased total area, marrow area, cortical area, cortical 
thickness, and moment of inertia as compared to untreated TLR5KO mice (p < 0.05, Fig 5.1D, 
Fig 2.2A, Table a). Disruption of the gut microbiota did not influence femoral length in 
TLR5KO mice (Fig 2.1C, Table a). Femoral length was 2.6% smaller in TLR5KO ∆Microbiota 
mice compared to WT ∆Microbiota mice (p < 0.05, Fig 2.1C, Table a). 
Disruption of the gut microbiota was associated with reduced peak bending moment. 
Disruption of the gut microbiota in WT mice resulted in an average peak bending moment 9% 
less than in untreated WT mice (p < 0.05, Fig 2.2B). Disruption of the gut microbiota in 
TLR5KO mice led to a peak bending moment 22% less than in untreated TLR5KO mice (p < 
0.05, Fig 2.2B). After accounting for differences in cross-sectional geometry, peak bending 
moment in mice with a disrupted microbiota was less than that in untreated mice (ANCOVA, 
effect of ΔMicrobiota, p < 0.0001, Fig 2.2C). The effect of disruption of the gut microbiota on 
bone tissue material properties appeared to differ between WT and TLR5KO mice (ANCOVA, 
ΔMicrobiota x genotype, p=0.09, Fig 2.2C).  Disruption of the gut microbiota in both WT and 
TLR5KO mice showed a trend suggesting reduced whole bone femoral bending stiffness (p < 
0.15, Fig 2.2D, Table a). Disruption of the gut microbiota was not associated with differences in 
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post yield displacement (Table a).  
 
	
 
Figure 2.2. The effects of altering the gut microbiome on moment of inertia and whole bone 
strength. 
Whole bone bending strength in mice with altered microbiota was less than would be expected 
from differences in cross-sectional geometry.(A) The moment of inertia was larger in TLR5KO 
mice. (B) Whole bone bending strength (peak bending moment) was less in ∆Microbiota mice 
than in untreated animals. The peak bending moment in TLR5KO mice did not differ from that 
of WT mice. (C) Whole bone bending strength in TLR5KO mice was less than in WT mice after 
accounting for I/c (difference between solid red and blue lines). Bending strength in ∆Microbiota 
mice was less than that in untreated animals (difference between dotted and solid lines indicates 
results of ANCOVA). (D). Disruption of the gut microbiota in both WT and TLR5KO mice 
showed a trend suggesting reduced whole bone femoral bending stiffness. Solid colored lines on 
dot plots represent mean. Measures in Fig 2.2A, 2.2B, and 2.2D are adjusted for body mass. *  p 
< 0.05 
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Chapter 2.4.4 Tibial Trabecular Microarchitecture and tissue mineral density 
	
Cancellous bone volume fraction in the proximal tibia did not differ among groups (Fig 
2.1F). No differences in tibial cortical bone tissue mineral density were observed between 
untreated WT and TLR5KO mice. Disruption of the gut microbiota was associated with 
reductions in cortical bone tissue mineral density in both strains of mice (p < 0.05, Fig 2.1F). The 
thickness of the growth plate in the proximal tibia did not differ among groups (Table a).  	
Chapter 2.4.5 Microbiome Analysis 
	
Sequences from feces microbiome assays were filtered for size, quality, and for the 
presence of chimeras and the total post-quality control number of sequences used in this study 
were 2,465,448.  The average coverage was 102,727 ± 32,103 (mean ± SD) reads per sample. No 
differences in the mean number of reads for each group were observed (WT: 112,309 ± 11,935; 
WT ∆Microbiota: 88,325 ± 18,501; TLR5KO: 101,706 ± 39,625, and TLR5KO ∆Microbiota: 
108,568  ± 47,800) (p = 0.612). 
Although the total bacterial load did not differ among the four groups (Fig 2.3D), 
profound changes in the gut microbiota were observed. The gut microbiota composition at the 
phyla level differed among groups (Fig 2.3A). The gut microbiota in WT and TLR5KO mice 
was dominated by the Bacteroidetes phylum (Fig 2.3A, 2.3C). The gut microbiota in 
∆Microbiota mice was dominated by the Proteobacteria phylum (Fig 2.3A, 2.3B). Proteobacteria 
abundance was greater in TLR5KO ∆Microbiota mice compared to WT ∆Microbiota mice (p < 
0.05, Fig 2.3B). The diversity of the gut microbiota, as measured by the Shannon Diversity 
Index, was reduced in groups with a disrupted gut microbiota (TLR5KO: 4.8 ± 0.5; TLR5KO 
∆Microbiota: 1.7 ± 0.2; WT: 4.7 ± 0.4; WT ∆Microbiota: 2.5 ± 0.3) (p < 0.05, Fig 2.3E). 
Compared to untreated animals from the same genetic background, reductions in gut microbiota 
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diversity in TLR5KO ∆Microbiota mice were greater than those in WT ∆Microbiota mice (p < 
0.05, Fig 2.3E). One sample from the WT ∆Microbiota mice was determined to be an outlier and 
removed (Fig 2.3E). 
	
Chapter 2.4.6 Splenocyte Populations 
	
The total percentage of CD20+ B cell splenocytes was reduced in TLR5KO mice and WT 
∆Microbiota mice compared to untreated WT mice (p < 0.05, Fig 2.3F). The percentage of CD3+ 
T cells in the spleen was reduced in TLR5KO and WT ∆Microbiota mice compared to untreated 
WT mice (p < 0.05, Fig 2.3G). Splenocytes from TLR5KO ∆Microbiota mice were not obtained 
due to user error.  
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Figure 2.3. Gut microbiota composition and  immune system profile in TLR5KO mice and 
∆Microbiota mice. 
	
Disruption of the gut microbiota with antibiotics did not alter total bacterial load, but had 
dramatic effects on gut microbiota composition and bacterial diversity, and immune cell 
count.(A) The relative composition of bacterial phyla shifted from a Bacteroidetes dominated 
phyla in untreated mice to one dominated by Proteobacteria in ∆Microbiota mice (n=6/group). 
(B) Proteobacteria is enriched in ∆Microbiota mice, especially in TLR5KO ∆Microbiota mice 
(Bonferroni correction). (C) Bacteroidetes dominates gut microbiota composition in untreated 
WT and TLR5KO. (D) Total bacterial load was unaffected by antibiotic treatment. (E) Bacterial 
diversity was dramatically reduced in ∆Microbiota mice. (F) The percentage of splenic CD20+ B 
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cells was reduced in ∆Microbiota mice and untreated TLR5KO mice (n=3/group). (G) The 
percentage of splenic CD3+ T cells in the spleen was reduced in ∆Microbiota mice and untreated 
TLR5KO mice (n=3/group). Solid colored lines on dot plots represent mean. *  p < 0.05 after 
adjusting for multiple comparisons. 
 
Chapter 2.5 Discussion  
	
Here we report the effects of an altered gut microbiota on bone mechanical properties in 
WT and TLR5KO mice. Disruption of the gut microbiota through long-term exposure to 
antibiotics led to reductions in whole bone bending strength that exceeded what could be 
explained by the associated changes in cross-sectional geometry, suggesting impairment of bone 
tissue material properties.  Small differences in whole bone bending strength were observed 
between WT and TLR5KO mice after accounting for differences in bone morphology. 
Together the differences in whole bone strength, cross-sectional geometry and tissue 
mineral density suggest that alterations in the gut microbiota changed the mechanical properties 
of the bone tissue itself. Whole bone strength in bending is determined by both cross-sectional 
geometry and tissue material properties. In bending, the ratio 34 is the geometric measure that 
describes the entire effect of cross-sectional geometry on bending strength and is directly 
proportional to the maximum load an object can sustain in bending. Consistent with this 
relationship, the ratio 
34 was the single best predictor of whole bone strength, accounting for 71% 
of the variation in peak bending moment across groups. However, differences in the regression 
lines (Fig 2.2C) indicated that the ratio 
34 did not completely explain differences in strength 
among the four groups, a situation that implies alteration in bone tissue mechanical properties. 
Tissue mineral density (TMD) is a material property that can influence bone strength (170). TMD 
in the tibial metaphysis of mice with a disrupted microbiota was less than that of untreated mice. 
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Although we did not measure TMD at the femoral midshaft directly, our findings in the tibia 
suggest that TMD may partially explain the reductions in femoral bone strength. Other factors 
such as collagen quality and non-collagenous proteins may also explain the reductions in femoral 
bone strength.  
TLR5KO mice had larger total area than WT mice, but similar marrow area and cortical 
area. Increased total area without differences in marrow or cortical area at skeletal maturity has 
been associated with more rapid periosteal expansion during growth (154). The increased 
periosteal expansion in TLR5KO mice may be a mechanism employed by the skeleton to 
maintain whole bone strength despite impaired bone tissue material properties (171).  
Disruption of the gut microbiota resulted in decreased cortical bone at the femoral 
diaphysis in both WT mice and TLR5KO mice. Disruption of the gut microbiota in WT mice 
was not associated with alterations in total area, but was associated with decreased cortical area 
and cortical thickness. Disruption of the gut microbiota in TLR5KO mice prevented the more 
rapid periosteal expansion that occurred in untreated TLR5KO mice, and resulted in smaller 
cortical area, marrow area, and cortical thickness. Though marrow area was smaller in TLR5KO 
ΔMicrobiota mice, marrow area was larger than would be expected from the associated changes 
in total area. Decreased cortical area and cortical thickness is often attributed to decreased 
accumulation of bone mass during growth (154). 
Treatment with antibiotics had a larger effect on bone morphology and whole bone 
strength in TLR5KO mice than in WT mice. This observation has many potential explanations: 
First, disruption of the gut microbiota prevented the development of the mild obesity phenotype 
in TLR5KO mice. Obesity is associated with differences in bone morphology and mechanical 
performance(172) . The bones in treated TLR5KO mice, therefore, not only have the effect of an 
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impaired microbiota, but also reduced adiposity.  Second, disruption of the gut microbiota in 
TLR5KO mice had a larger effect on the relative abundance of Proteobacteria and microbial 
diversity (the Shannon diversity index) than in WT mice, which could help explain the larger 
effect on the bone phenotype. Third, the immune system and immune responses are impaired in 
TLR5KO mice, leading to altered gene expression and activity by the gut microbiota (47).  
The composition of gut microbiota in untreated and treated mice was consistent with 
prior work. The total bacterial load in fecal samples did not differ between antibiotic treated and 
untreated groups, consistent with previous reports that oral antibiotic treatment can cause a large 
initial reduction in a bacterial population that recovers over time to a newly stabilized population 
(150,173,174). The dominant phylum in untreated mice was Bacteroidetes, consistent with reports 
that Bacteroidetes are the predominant phylum throughout a healthy mouse’s lifespan (175). 
Disruption of the gut microbiota by chronic antibiotic treatment led to a gut microbiota 
population enriched by the phylum Proteobacteria (a minor component of the untreated mouse 
gut microbiota). The high relative abundance of Proteobacteria observed in mice with a disrupted 
microbiota at 16 weeks of age was similar to the immature and unstable gut microbiota typical of 
newborn mice (169). As a mouse matures, its immune system begins to regulate gut microbiota 
composition via B cell production of IgA antibodies that target Proteobacteria (169). The antibiotic 
treatment in the current study may have prevented the shift from Proteobacteria to Bacteroidetes 
that normally occurs in mice after weaning. Furthermore, the reduced splenic B cell count in 
mice with a disrupted microbiota is also consistent with the increased presence of Proteobacteria. 
The prevalence of members of the Proteobacteria phylum has been associated with increased 
incidence of microbial dysbiosis, metabolic disease, and inflammation, all factors known to 
influence host physiology and the immune system (146,176).   
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To understand the mechanisms linking changes in the microbiota to impaired bone tissue 
material properties it is useful to consider the three primary mechanisms through which the 
microbiome can influence organs distant from the gut: regulation of the immune system, 
regulation of nutrient absorption, and translocation of bacterial products across the epithelial 
barrier (98).  
 We consider the effects of the microbiota on the immune system to be a likely 
explanation for the differences in bone tissue material properties in the current study. Disruption 
of the gut microbiota with antibiotics reduced CD20+ B and CD3+ T cell populations and was 
correlated with reduced whole bone strength. Similarly, untreated TLR5KO mice also had 
reduced CD20+ B and CD3+ T cell populations. B and T cell populations have the potential to 
cause profound changes in bone remodeling and bone turnover (177-181). However, it is not yet 
clear how alterations in B and T cell populations would lead to changes in bone tissue material 
properties.  
While we cannot ignore the possibility that alterations in nutritional absorption influenced 
our findings, we consider this explanation unlikely for several reasons: First, body mass and fat 
pad mass in the mice were all similar or greater than that in untreated wild type animals, 
suggesting an acceptable caloric intake. Second, trabecular bone volume fraction was not 
different among the groups, and femoral length only had small differences. Trabecular bone 
volume fraction and whole bone length are typically severely reduced in situations of nutritional 
deficiency (41,182). Trabecular bone is extremely responsive to impaired nutrition; animals 
submitted to short-term severe calcium and vitamin D deficiencies showed reductions in 
trabecular bone volume fraction of 24-58% (183,184), yet we did not observe reductions in 
trabecular bone volume fraction. Third, the reduction in peak bending moment seen in mice with 
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a disrupted microbiota is not fully explained by changes in bone geometry or bone mass, whereas 
in animal models of reduced dietary calcium and vitamin D, reductions in whole bone strength 
are usually well described by changes in bone geometry, mass, and tissue mineral density (183,184). 
Lastly, examination of colon histology did not indicate intestinal inflammation in any of our 
groups, suggesting that treatment with antibiotics to disrupt the gut microbiota did not lead to 
increased gut inflammation that can impair nutritional absorption (185,186).   Animal models with 
extensive intestinal inflammation commonly develop reduced body mass and dramatic trabecular 
bone loss, which, again, was not present in any of our treatment groups (187,188). 
Translocation of bacterial products (or even live bacteria) across the gut endothelial barrier is 
another potential mechanism for gut microbiota to influence bone. Microbial products such as 
lipopolysaccharide and flagellin are capable of traveling through the bloodstream to distant 
organs and causing localized inflammation (189). Translocation of bacteria across the endothelial 
barrier is one of the mechanisms that explains the TLR5KO metabolic syndrome phenotype, so 
translocation may be involved in the observed differences in bone (47). While bone cells can 
respond to lipopolysaccharide and flagellin (98), how such a response would lead to changes in 
bone tissue mechanical properties is not clear. 
A number of strengths of the current study are worth noting. First, the study is unique in 
examining the effect of alterations in the gut microbiome on whole bone mechanical 
performance. Previous studies in which the microbiota was modified focused solely on bone 
structure or bone mass and did not examine mechanical performance. Second, the current study 
examined the effects of prolonged disruption of the gut microbiota during growth on the bone 
phenotype achieved at skeletal maturity. Most of the prior studies of bone in mice under 
conditions of altered gut microbiota examined bone from young, rapidly growing animals (7-9 
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weeks of age)(98), and did not evaluate the bone phenotype at skeletally maturity. Differences in 
bone phenotype in growing animals sometimes indicate differences in growth rate and do not 
always imply changes in bone phenotype at skeletal maturity (154,190,191). As we only looked at 
skeletally mature mice, we could not assess differences in bone growth and acquisition, although 
differences in cross-sectional geometry such as total area suggest differences in rates of 
periosteal expansion (see above). Third, the current study provided both a detailed analysis of 
bone along with a full analysis of the constituents of the gut microbiome as determined using 
16S rRNA sequencing and therefore provides differences in phyla, bacterial diversity, and total 
bacterial load along with a detailed bone morphological and biomechanical analysis. We are 
aware of only one prior study that provides both a detailed analysis of bone morphology and a 
detailed analysis of the microbiome (192). 
Despite the novelty of the current study, some limitations must be considered when 
interpreting the results. The contents of the gut microbiota are dynamic and robust to external 
stimuli; short-term treatments (~1-2 weeks) with antibiotics generate a transient change in the 
gut microbiota that mostly returns to baseline when treatment was suspended (173). To examine a 
condition of sustained alterations in the gut microbiota during growth we treated mice with 
chronic antibiotics from the age of weaning until skeletal maturity. Although chronic antibiotic 
treatment is rarely applied to humans throughout growth and development, less drastic changes 
in the human gut microbiota do occur for prolonged periods of time as a result of diet or 
metabolic status (173). The study is further limited by not directly performing a compositional 
assessment of bone tissue. Direct measures of bone tissue material properties can help explain 
the mechanical phenotypes but more direct assays of mouse bone tissue mechanical properties 
than those performed here have additional limitations, especially in determination of tissue 
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strength (see Supplementary Material from Jespen et al 2015 (154)). The current study does not 
include assessment of bone turnover.  Recent findings, however, suggest that the relationship 
between the microbiota and bone remodeling is complex and dynamic. For example, mice 
treated with an antibiotic cocktail of ampicillin, vancomycin, metronidazole, and neomycin show 
changes to serum turnover markers after one week of treatment, but no detectable differences 
from untreated animals after one month of treatment (149). Understanding the effects of 
manipulation of the microbiome on bone remodeling would therefore require examination at 
many points during growth/treatment. Lastly, the current study uses the C57BL/6J as a control 
strain for the TLR5KO strain, despite the TLR5KO mice containing minor remnants of 
B6.129S1 genetics. However, the TLR5KO congenic strain is backcrossed for 11 generations to 
the C57BL/6J background to ensure the two strains are over 99.9% genetically identical, thus 
limiting potential effects of B6.129S1 genetics.  
Despite the limitations of our study, our observations regarding changes in bone tissue 
mechanical properties suggest a new explanation to a long-standing clinical question. Fracture 
risk in some patient populations is much greater than expected from bone mineral density, a 
situation commonly attributed to impaired “bone quality”(193). Although the term bone quality 
encompasses many different characteristics of bone (194), impaired bone tissue mechanical 
properties are a well-recognized component. Changes in bone tissue mechanical properties are 
often cited as a contributor to fracture risk that exceeds what is explained by BMD in patients 
with obesity, diabetes, and inflammatory bowel disease – three chronic clinical conditions that 
are also associated with drastic changes in the gut microbiome. Our findings in mice suggest an 
intriguing possibility that alterations in gut microbiota may contribute to alterations in clinical 
fracture risk by regulating bone tissue mechanical properties, although further studies are 
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required to confirm this hypothesis. 
	
Chapter 2.6 Conclusion 
	
We conclude that alterations in the gut microbiota throughout growth can lead to changes in 
whole bone strength that are greater than expected from whole bone size or shape. These 
findings suggest that alterations in the gut microbiota can influence bone tissue mechanical 
properties.  
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Chapter 2.8 Supplementary Material  
 
Table b Micro-computed tomography measures of cancellous and cortical bone and whole bone 
mechanical testing measures are shown. 
    Wild Type                                        TLR5KO 
 Measure Untreated ∆Microbiota  Untreated ∆Microbiota  
 Bone Volume 
Fraction 
0.15 ± 0.02 0.15 ± 0.03 0.15 ± 0.01 0.13 ± 0.01 
Trabecular  
Thickness (µm) 
44.70 ± 1.98 43.30 ± 5.63 41.30 ± 2.66 36.40 ± 2.13#,$ 
Proximal 
Tibia 
Trabecular 
Separation (µm) 
197 ± 14 191 ± 11 187 ± 7 176 ± 7$ 
Cortical TMD (mg 
HA/cm3) 
999 ± 10 979 ± 8* 997 ± 13 981 ± 7# 
 Growth Plate 
Thickness (µm) 
558 ± 46 562 ± 41 550 ± 54 526 ± 21 
 Cortical Area 
(mm2) 
0.87 ± 0.07 0.82 ± 0.10 0.96 ±  0.07 a 0.67 ± 0.05#,$ 
Femoral 
Diaphysis 
Marrow Area 
(mm2) 
1.06 ± 0.07 1.17 ± 0.10 1.17 ± 0.15 0.99 ± 0.08#,$ 
Total Area (mm2) 1.93 ± 0.13 1.98 ± 0.18 2.13 ± 0.17 a 1.66 ± 0.08#,$ 
Cortical Thickness 
(µm) 
210 ± 10 189 ± 17* 220 ± 14 a 170 ± 12#,$ 
Moment of Inertia 
(mm4) 
0.15 ± 0.02 0.15 ± 0.03 0.18 ± 0.03a 0.10 ± 0.01#,$ 
Minimum Moment 
of Inertia/ c (mm3) 
0.22 ± 0.03 0.22 ± 0.03  0.25 ± 0.03 a 0.16 ± 0.01 #,$ 
 
Whole 
Femur 
Length (mm) 16.05 ± 0.21 16.15 ± 0.24 15.88 ± 0.26  15.61 ± 0.14 #,$ 
Peak Bending 
Moment (N∗mm) 
41.09 ± 2.84 37.32 ± 2.86* 40.47 ± 3.00 29.43 ± 1.87 #,$ 
Bending Stiffness 
(N/mm) 
194 ± 18 177 ± 21 195 ± 38 143 ± 10 # 
Post Yield 
Displacement 
(mm) 
0.31 ± 0.12 0.32 ± 0.08 0.27 ± 0.11 0.34 ± 0.10 
Values are mean  ± SD. TMD=Tissue mineral density 
*WT-∆Microbiota v. WT-untreated, p<0.05  
#TLR5KO-∆Microbiota v. TLR5KO-untreated, p<0.05  
aTL5KO-untreated v. WT-untreated, p<0.05  
$TLR5KO-∆Microbiota v. WT-∆Microbiota, p<0.05  
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Chapter 3- Alterations to the Gut Microbiome and Bone Tissue Composition 
	
This chapter is in preparation for submission to the Journal of Bone and Mineral Research. The 
manuscript is titled “Alterations in the gut microbiome change bone tissue composition” 
 
Chapter 3.1 Abstract 
	
	 The gut microbiome has been shown to alter whole bone strength by modifying bone 
tissue material properties. Here we report a metagenomic analysis of the fecal microbiome to 
identify changes in the functional capacity of the gut microbiome in situations where bone 
quality is impaired. Male C57Bl/6 mice (WT) and Toll-like receptor 5 deficient mice (TLR5KO, 
a strain with altered gut microbial function) were subjected to disruption of the gut microbiota 
(ΔMicrobiome) using oral antibiotics (starting at 4 weeks of age) or remained untreated (n=7-
8/group). Prior work has indicated that ∆Microbiome impaired bone tissue strength in WT mice 
but did not modify tissue strength in TLR5KO mice. Disruption of the gut microbiome in the two 
mouse strains led to differential modifications to the abundance of microbial genes responsible 
for the synthesis of vitamins (K and B); bacterial cell wall and capsule; and carbohydrate 
production. Raman spectroscopy of bone from these mice indicated that in WT mice, disruption 
of the gut microbiome resulted in reduced bone mineral crystallinity while in TLR5KO mice, 
∆Microbiome was associated with increased bone mineral crystallinity (p<0.05). Supplementary 
biochemical analysis focused on vitamin K, a factor secreted by gut microbes that has previously 
been associated with bone health. Vitamin K content in the cecum, liver and kidneys was 
dominated by microbe-derived forms and differences among groups mirrored changes in 
crystallinity (decreased by ∆Microbiome in WT mice, increased in TLR5KO mice) and bone 
matrix osteocalcin content. Together these findings suggest that disruption of the gut microbiome 
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may impair bone tissue strength in WT mice by causing deficiencies in bone matrix composition 
while in TLR5KO mice, disruption of the gut flora led to adequate (or even increased) amounts 
of components of bone matrix and hence no modifications in bone tissue material properties. 
This study illustrates the use of metagenomic analysis to link the microbiome to bone phenotypes 
and implicates microbially synthesized vitamin-K as a regulator of bone matrix quality. 
Chapter 3.2 Introduction 
	
	 Bone mineral density is the primary clinical measure used to estimate the risk of 
osteoporosis-related fracture. However, in many clinical studies bone mineral density does not 
fully explain fracture risk, suggesting that aspects of bone other than density/mass influence 
fracture risk (195,196). The term “bone quality” is used to refer to characteristics of bone other than 
bone mineral density that influence bone strength and fracture risk (197). Recently, the gut 
microbiome has been identified as a factor that can influence bone quality by modifying bone 
tissue composition and material properties (133). 
The gut microbiome consists of the genomic components, products, and microorganisms 
in the gastrointestinal tract. Changes in the constituents of the microbiome have been associated 
with a number of chronic diseases including arthritis and cardiovascular disease. Recent studies 
have indicated that the gut microbiome can influence bone mass: mice raised from birth in an 
environment completely absent of microbial life (germ-free) have altered long bone length and 
trabecular and cortical bone mass (41,148,149). Disruption of the gut microbiome using oral 
antibiotics can lead to changes in trabecular and cortical bone mass and femoral geometry in 
mice (133,150-152,198). We recently demonstrated that disruption of the gut microbiome with oral 
antibiotics led to reductions in femoral whole bone strength that could not be explained by 
changes in bone mass and geometry, implicating impaired bone tissue quality (Fig 3.1) (133). 
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Specifically, we examined C57Bl/6 mice (WT) as well as a mouse strain known to develop an 
altered gut microbiota (the Toll-like receptor 5 deficient mouse, TLR5KO). We found that 
disruption of the gut microbiome alters bone tissue strength in WT (C57Bl/6) mice (shift in 
regression line in Fig. 1) but did not alter bone tissue strength in the Toll-like receptor 5 deficient 
mouse (single shared regression line in Fig 3.1).   
 
Figure 3.1. Disruption of the gut microbiome leads to changes in whole bone mechanical 
performance 
	
Disruption of the gut microbiome in WT mice is associated with reductions in whole bone 
strength greater than can be explained by differences in femoral geometry (differences in 
regression lines), while in TLR5KO mice, disruption of the gut microbiota did not modify the 
relationship between bone geometry and whole bone strength (adapted from Guss et al. 2017) 
(133). 
 
 Studies demonstrating an effect of the microbiome on bone have included analysis of the 
composition of the gut flora using sequencing of the bacterial 16S rRNA gene to determine the 
relative abundance of microbial taxa based on phylogeny (phylum, class, order, etc.) (41,133,192,198). 
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While bacterial phylogeny is useful for understanding the microbial community, more detailed 
sequencing often is required to identify molecular pathways that link the microbiome to host 
phenotype. Metagenomic analysis sequences the entire microbial genome, and provides 
information on the functional capacity of the gut microbiome (i.e. which genes are present) 
(15,199). Metagenomic analysis is useful because many interactions between the microbiota and the 
host are a result of microbial function rather than microbial taxonomy. To our knowledge, 
metagenomic analysis of the microbiome has not yet been used to understand the effects of the 
microbiome on bone.  
The gut microbiome may influence bone tissue through three general mechanisms: 1) 
regulation of nutrient absorption and microbe-derived vitamins; 2) regulation of the immune 
system; and 3) translocation of inflammatory bacterial products across the gut barrier (98). While 
regulation of the immune system and inflammatory molecules released by bacteria can lead to 
changes in bone resorption, bone formation and bone mass (200), these mechanisms only regulate 
bone matrix quality by modifying tissue age, a factor that does not vary much in mice. In 
contrast, vitamins produced by the gut microbiota can influence bone tissue. In particular, 
vitamin K is produced by the gut microbiota and has long been associated with bone health 
(201,202). 
 Changes in the composition and structure of the organic or mineral composition of bone 
can lead to changes in both tissue-scale and whole bone mechanical performance (114,203,204). 
Bone tissue chemical composition can be assessed using Raman spectroscopy to determine: 
crystallinity (the size and stochiometrric perfection of the hydroxyapatite crystal lattice), 
mineral-to-matrix ratio (the extent of collagen mineralization and mineral content), and the 
carbonate-to-phosphate ratio (the extent of carbonate substitution into hydroxyapatite crystals). 
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Additionally, nanoindentation can characterize the mechanical properties (hardness and reduced 
modulus) at the tissue-scale (203). Although multiple studies report modifications in bone 
composition and nanomechanical properties in the context of bone quality and fracture risk 
(114,203,205-207), no previous studies have evaluated changes in bone tissue composition associated 
with changes in the gut microbiome. 
The goal of this line of investigation is to determine how modifications to the gut 
microbiome can influence bone tissue quality. Using samples from a previously reported study 
including microbiome-induced changes in bone strength (Fig. 3.1), we performed metagenomic 
analysis of fecal microbiota as well as microscale chemical analysis of bone tissue. Specifically, 
we determined the changes in the fecal metagenome and bone tissue chemical composition and 
nanomechanical properties following alterations to the gut microbiome caused by (1) genotypic 
alterations (Toll-like receptor 5 deficient mouse) and (2) chronic treatment with antibiotics to 
disrupt the gut microbiome.  
Chapter 3.3 Materials and Methods 
 
Chapter 3.3.1 Study Design 
	
Animal procedures were approved by Cornell University’s Institutional Animal Care and 
Use Committee. Mice from the C57BL/6J inbred strain and the B6.129S1-Tlr5tm1Flv/J 
(TLR5KO) congenic strain were acquired (Jackson Laboratory, Bar Harbor, ME), and each 
strain bred separately in conventional housing in our animal facility. C57BL/6J is the 
recommended control strain for TLR5KO (7,15,155,199). Animals were housed in plastic cages filled 
with 1/4-inch corn cob bedding (The Andersons’ Lab Bedding, Maumee, Ohio), fed with 
standard laboratory chow (Teklad LM-485 Mouse/Rat Sterilizable Diet) and water ad libitum, 
and provided a cardboard refuge environmental enrichment hut (Ketchum Manufacturing, 
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Brockville, Ontario). The study examined male C57BL6/J (WT) and Toll-like receptor 5 
deficient (TLR5KO) male mice either treated to modify the gut microbiome or untreated. Treated 
groups received broad-spectrum antibiotics (1.0 g/L ampicillin, 0.5 g/L neomycin) in their 
drinking water from weaning at 4 weeks of age until skeletal maturity (16 weeks of age) (7). 
Chronic antibiotics cause disruptions to the gut microbiome that are maintained over a prolonged 
time period (11). Ampicillin and neomycin have poor oral bioavailability, thereby limiting extra-
intestinal effects of treatment (7,156). Additionally, neomycin and ampicillin have never been 
associated with impaired bone growth, do not influence bone length, body mass or gut 
inflammation (133) and do not cause noticeable changes in serum calcium or vitamin D 
(Supplemental Fig 3.7).  Mice treated to disrupt the microbiome are referred to as 
“∆Microbiome.”  Mice were housed in cages with other animals from the same genetic 
background/treatment group. Animals were euthanized at 16 weeks of age.  The right tibia, 
cecum, liver, kidney, and fecal samples were collected. Kidney and liver were stored at -20°C 
freezer and cecum and fecal samples were stored at -80°C freezer. 
The study was performed using two cohorts of animals. One cohort of animals, described in a 
prior study (Fig. 3.1 (133)), was used for metagenomic analysis and tissue chemical, 
nanomechanics and biochemistry (∆Microbiome C57BL/6J: n=7, TLR5KO: n=8; untreated WT, 
C57BL/6J: n=11, TLR5KO: n=8). A second cohort of animals was used for follow-up 
biochemical analysis of tissue biochemistry (∆Microbiome TLR5KO: n=6; untreated WT, 
C57BL/6J: n=6, TLR5KO: n=6). 
	
Chapter 3.3.2 Metagenomic Analysis 
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	 Fecal samples collected one day prior to euthanasia were used for metagenomics 
analysis. Metagenomic analysis was performed on six samples per group (2 animals per cage). 
DNA was extracted (DNeasy PowerSoil DNA Isolation Kit, MO BIO Laboratories Inc., 
Carlsbad, CA) following manufacturer’s recommendations. The fecal pellet was added to the 
PowerBead tubes (Qiagen, Germantown, MD) and followed by a 10-minute vortex step. 
Following addition of Solution C1, to enhance cell lysis, samples were incubated at 70 C for 10 
minutes and then subjected to a vortex step for 15 minutes using the MO BIO Vortex Adapter 
tube holder. Isolated DNA was quantified (Qubit dsDNA Broad Range Assay Kit, Life 
Technologies, Carlsbad, CA). Aliquots of DNA were normalized to the same concentration of 
0.2 ng/ul of DNA per sample. A sequence library was prepared (Nextera XT DNA Library 
Preparation Kit, Illumina, San Diego, CA) to yield an average library size of 500 bp. Final 
equimolar libraries were sequenced (MiSeq reagent kit v3 on the MiSeq platform, Illumina, San 
Diego, CA) to generate 300 bp paired-end reads (159). 
 Metagenomic analyses were performed using MG-RAST (Metagenome Rapid 
Annotation using Subsystem Technology version 4.0.3). In the MG-RAST analysis, the 
fragments of DNA in a sample are compared to protein, RNA, and subsystem databases. 
Functional annotation of sequences in the current study used the SEED subsystem (208). The 
functional abundance analysis was performed using a “Representative Hit Classification” 
approach with a maximum e-value of 1 x 10-5, minimum identity of 60%, and a minimum 
alignment length of 15 measured in amino acids for proteins and base pairs for RNA databases. 
The subsystems are grouped into hierarchical classifications ranging from the broadest functional 
category at “Level 1”, to more specific functional roles at “Level 2” and “Level 3”, and then to 
the most detailed category of “Function”.  The data underwent a normalization and 
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standardization process (within MG-RAST) to reduce inter-sample variability and to allow data 
to be more easily comparable. The normalized counts were calculated as: 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑? =𝑙𝑜𝑔2(𝑟𝑎𝑤4CDEFGH + 1). The standardized counts were calculated as: 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑖𝑧𝑒𝑑? =(𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑? − 𝑚𝑒𝑎𝑛 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑? )/𝑠𝑡𝑑𝑒𝑣 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑? . Normalized counts are used as 
a measure of the abundance of genes that match a functional category.  
 Principal coordinate analysis (PCoA) of the functional hierarchy based on the Bray-
Curtis distance was performed to investigate overall functional diversity amongst samples. 
Principal coordinate analysis reduces the dimensionality of a complex dataset with thousands of 
variables to a smaller number so the diversity between samples can be easily visualized in a two- 
or three-dimensional scatterplot (209). Each principal coordinate explains a percentage of the 
variation in the data set, with the first two principal components accounting for the most 
variation. PCoA was performed at subsystem Level 1, Level 2, and Level 3 hierarchies.  
Chapter 3.3.3 Raman Spectroscopy and Nanoindentation 
	
	 The right tibiae were harvested and fixed in 10% neutral buffered formalin for 48 hours. 
Tibiae were then embedded undecalcified in methyl methacrylate and a single 2-mm-thick 
transverse section from the proximal metaphysis was collected using a diamond wafering saw 
(Buehler, Lake Bluff, Illinois). All sections were polished anhydrously on a Multiprep automatic 
polishing system (Allied High Tech, Rancho Dominguez, CA) at 30 RPM with a 200g sample 
load. Samples were polished with increasing grit silicon carbide polishing paper (800, 1200 grit) 
using ethylene glycol as a lubricant, and followed by a series of slurries of aluminum oxide 
powder (particle size of 3 µm, 1µm, and 0.1 µm) in ethylene glycol (210). The final root mean 
square (RMS) roughness of the surface was determined to be ~35nm by measurement of ten 5 
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x5-µm2 scans per sample with a surface profilometer (VKX Laser-Scanning Microscope; 
Keyence, Inc.).  
 A Raman imaging system (InVia Confocal Raman Microscope; Reinshaw Inc.) was used 
to collect spectra of the tibial cross sections using two different sampling strategies: 1) Analysis 
of regions throughout the cross section (n=4/group); and 2) High-density spatially-resolved 
mapping analysis of one quadrant (n=7-10/group). For analysis throughout the cross section, 20 
individual point spectra were collected across four quadrants of the cross section corresponding 
to 25%, and 75% of the cortical thickness with an additional three points collected 50 microns 
away from the midline of the cortex (forming a ‘+’ sign). The five spectra were averaged to 
determine a single representative measure per quadrant per sample. Spectra were collected over 
the range 720-1,820 cm-1 with a 785nm laser and a 50x long-working-distance objective 
(N.A.=0.55) collecting for 30s at 50% power with cosmic ray correction. Spectra first were 
normalized to the absorbance of PMMA at 813 cm-1 (MATLAB, MathWorks). Last, spectra 
were baseline-corrected to account for background fluorescence.  The following Raman bands 
were evaluated: phosphate (PO	%&') v1PO4 (integration area ~930-980 cm-1) (211), amide III 
(integration area ~1215-1300 cm-1) (211), and carbonate (CO	&*') CO3 (integration area ~1050-1100 
cm-1) (211). From each spectrum the following measures were calculated: mineral-to-matrix ratio 
(determined as the area ratio of phosphate v1PO4 and amide III); carbonate substitution 
(measured as the area ratio of carbonate to phosphate v1PO4); and mineral crystallinity (measured 
as the inverse of the full-width-half-max of a Gaussian fit of the phosphate v1PO4 peak) (212). For 
the high-density spatially-resolved mapping, spectra were acquired every 4 µm over a 40 µm x 
40 µm area in the posterior region, centered between the periosteum and endosteum to avoid 
recently formed bone tissue, for 121 total spectra (213). The center of the cortex was selected to 
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characterize mature bone. The high data density (121 spectra) was used to determine mean 
values as well as compositional heterogeneity,  measured by the full width at half maximum of a 
Gaussian function fit of the distribution of each Raman measure.  
 Nanoindentation was performed on the same sections and regions analyzed by Raman 
spectroscopy. Nanoindentation arrays were performed using a Berkovich indenter tip (TI-900 
Triboindenter, Bruker, Eden Prairie, MN) calibrated to a silica glass standard. Each array 
consisted of a 4 x 4 grid of indentations with a 30 second ramp load to Pmax = 2500 µN, a 30 
second hold to reach equilibrium, and a five-second elastic unloading. Indents were placed 15 
µm away from each other to avoid mechanical interactions among indentations.  
Hardness (H) and reduced modulus (Er) were determined from the force vs. displacement curves 
of each indentation (214) using the following relations: 𝐻 =	TUVWXY      ,   𝐸[ = \ ]* XY , 
for which S is the contact stiffness (the slope of the load-displacement curve upon initial 
unloading) and Ac is the projected contact area of the indentation. The nominal contact depth of 
the indents in the bone samples was 260 nm.  
	
Chapter 3.3.4 Biochemical Analysis 
	
	 Biochemical analyses of tissues were performed after receiving the results of the 
metagenomics analysis as a means of testing the functional significance of modifications to the 
microbial metagenome (n=6/group). Based on the metagenomics findings, the biochemical 
analysis focused on vitamin K. Vitamin K is a class of fat-soluble vitamers consisting of 
phylloquinone (vitamin K1 in older literature) and the menaquinones (vitamin K2 in older 
literature).  Menaquinones exist in 10 known forms, identified by the length of the isoprenoid 
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side chain of the molecule (MK4-MK13) (215). Phylloquinone and MK-4 are derived from the 
diet. The remaining nine known forms of menaquinone are synthesized primarily by bacteria in 
the gut, although some bacterially-derived forms of vitamin K are found in fermented or cured 
food products (215). The cecum is an important site for microbial production of vitamin K (216). 
The liver and kidney are distant organs where vitamin K accumulates (217). Phylloquinone (PK) 
and menaquinones (MK-4-13) concentrations in the cecum, liver and kidney were measured by 
liquid chromatography/mass spectroscopy (LC/MS) (218). Procedures for vitamin K extraction 
and sample purification are described elsewhere (218). The LC/MS system consists of an Agilent 
6130 Quadrupole MSD with an atmospheric pressure chemical ionization (APCI) source 
connected to an Agilent series 1260 HPLC instrument (Agilent Technologies, Santa Clara, 
CA).  Separations were completed using a reversed-phase C18 analytical column (Kinetex 2.6 
µm, 150 mm x 3.0 mm; Phenomenex, Inc., Torrance, CA). 
A major function of vitamin K in bone is carboxylation of Gla-containing proteins during bone 
formation. Osteocalcin is a Gla-containing protein and the most abundant non-collagenous 
protein in bone. Mouse humeri were dissected and wrapped in PBS soaked gauze. The tested 
mouse humeri were homogenized in 600 µl of extraction buffer containing 0.05M EDTA, 4M 
guanidine chloride and 30mM Tris-HCl (Omni BeadRuptor 24, Omni International, Atlanta, 
GA). After homogenization, the solution was centrifuged at 13000 rpm for 15 minutes to 
eliminate remaining mineral debris from the supernatant. The supernatant was dialyzed against 
1x PBS and 5mM EDTA for two days to eliminate denaturant. Extracted bone protein 
concentrations of the dialyzed solutions were assessed using a Pierce™ Coomassie Plus 
(Bradford) Assay Kit. The extracts then were serially diluted 1000-fold in PBS for use with the 
LSBio Mouse OC ELISA kit, which has a working range of 0.156-10 ng/mL. The OC 
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quantification ELISA was performed as per manufacturer protocol. Osteocalcin content was 
assessed in 4-6 animals per group. 
Chapter 3.3.5 Statistical Treatment 
	
	 Group differences between Raman mapping measures, nanoindentation measures, 
metagenome sequence abundances, vitamin K levels, and osteocalcin content were determined 
using a one-way ANOVA with group as the factor followed by the Holm correction for multiple 
comparisons with a=0.05 (JMP Pro 9.0.0).  The effect of genotype, treatment, genotype x 
treatment, and quadrant on Raman measures was detected using a 2-factor repeated measures 
ANOVA and included individual as a random effect to account for repeated measures within 
each animal (JMP Pro 9.0.0). Post-hoc comparisons using least squared mean student t-tests with 
Holm correction for multiple comparisons were performed when interaction effects were 
significant.  
Chapter 3.4 Results 
 
Chapter 3.4.1 Metagenomic Functional Analysis 
 
	 The functional capacities of the gut microbiome differed among groups (Fig 3.2A). 
Principal coordinate analysis based on Bray-Curtis dissimilarity showed that the overall 
functional capacity of untreated WT and TLR5KO mice were similar (two groups clustered 
together, Fig 3.2B). Disruption of the gut microbiome caused drastic changes in the functional 
capacity of the gut microbiome that differed between the two genotypes, as indicated by distinct 
clusters in the principal coordinate analysis (Fig 3.2B).  
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Figure 3.2. Disruption of the gut microbiome leads to large changes in the functional capacity of 
the gut flora  
 
Disruption of the gut microbiota led to large changes in the functional capacity of the gut flora. 
(A) The abundance of genes from multiple functional categories were differentially modified in 
the gut flora of ΔMicrobiome mice. (B) Principal coordinate analysis showed that the overall 
functional capacity of ΔMicrobiome mice was distinct from that of untreated WT and TLR5KO 
mice. Furthermore, the functional capacity of WTΔMicrobiome and TLR5KOΔMicrobiome 
were distinct from one another. 
 
The metagenomics findings identified differences in vitamin biosynthesis in 
ΔMicrobiome mice. Pathways related to the synthesis of vitamin B and vitamin K were altered 
by disruption of the gut microbiome. Mice with a disrupted gut microbiome had lower 
normalized counts for genes associated with the synthesis of vitamin B2, B6, and B7 compared 
to untreated mice (Fig 3.3A), but had greater normalized counts for genes involved in the 
synthesis of vitamin B9 and K. Principal coordinate analysis at SEED subsystems level 2 
hierarchy revealed that the overall functional capacity of genes for vitamin B and K biosynthesis 
was dramatically different between untreated mice and mice with disrupted gut microbiota 
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(Supplemental Figure 3.8A). Further investigation identified differential presence of multiple 
genes involved in menaquinone biosynthesis (Fig 3.3B, Supplemental Fig 3.8B): normalized 
counts for MenH, MenF, and MenE genes are greater in ΔMicrobiome mice (Fig 3.3B) and the 
abundance of MenB genes was less in ΔMicrobiome mice than in untreated WT and TLR5KO 
mice.  
The overall functional capacity and the abundance of genes for six of eight carbohydrate 
functional categories were altered by ΔMicrobiome in both WT and TLR5KO mice (Fig 3.3C, 
Supplemental Fig 3.8C). The functional capacity of genes for carbohydrates in WTΔMicrobiome 
and TLR5KOΔMicrobiome were distinct from each other (Supplemental Fig 3.8C). No 
differences in the overall abundance of fermentation genes were detected. However, principal 
coordinate analysis at SEED subsystems level 3 hierarchy revealed that the overall functional 
capacity of genes for fermentation were dramatically different following disruption of the gut 
microbiome (Supplemental Fig 3.8D).  
The abundance of genes related to the cell wall and cell capsule differed among groups 
(Fig 3.3D). Normalized counts for genes for capsular and extracellular polysaccharides were less 
abundant in mice with a disrupted gut microbiome than in untreated mice. Disruption of the gut 
microbiome led to increased abundance of genes associated with Gram-negative cell wall 
components, particularly in the TLR5KOΔMicrobiome. Normalized counts for genes for Gram-
positive cell wall components were less abundant in untreated TLR5KO mice compared to WT 
mice. Genes for Gram-positive cell wall components were less abundant in 
TLR5KOΔMicrobiome mice compared to untreated TLR5KO mice and compared to 
WTΔMicrobiome mice. Principal coordinate analysis at SEED subsystems level 2 hierarchy 
revealed that the overall functional capacity of genes for cell wall and cell capsule were 
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drastically changed due to disruption of the gut microbiome (Supplemental Fig 2E). The 
functional capacity of genes relating to Gram negative cell wall components differed between 
ΔMicrobiome mice and untreated mice (Supplemental Fig 3.8F).		
	
Figure 3.3. Key pathways for vitamin synthesis, carbohydrates, and bacterial cell wall and 
capsule components are disrupted in ΔMicrobiome mice.  
 
Key pathways are disrupted in ΔMicrobiome mice. (A) The abundance of genes involved in 
Vitamin B and K synthesis were altered. (B) Several gene pathways for menaquinone 
biosynthesis were disrupted in ΔMicrobiome mice, while some were similar compared to 
untreated controls. (C) Carbohydrate pathways were affected by disruption of the gut 
microbiome. The abundance of genes for six of eight carbohydrate functional categories were 
altered by ΔMicrobiome in both WT and TLR5KO mice. (D) Pathways relevant for bacterial cell 
wall and capsule components were altered in mice with a disrupted gut microbiome. Disruption 
of the gut microbiome led to increased abundance of genes associated with Gram-negative cell 
wall components, particularly in the TLR5KOΔMicrobiome mice. Normalized counts for genes 
for Gram-positive cell wall components were less abundant in untreated TLR5KO mice 
compared to WT mice. Genes for gram-positive cell wall components were less abundant in 
TLR5KOΔMicrobiome mice compared to untreated TLR5KO mice and compared to 
WTΔMicrobiome mice. 
Chapter 3.4.2 Raman Spectroscopy and Nanoindentation 
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	 In the analysis across the tibial cross-section (Fig 3.4A), disruption of the gut microbiome 
resulted in changes in bone tissue crystallinity and carbonate substitution. In WT mice, 
disruption of the gut microbiome led to decreased crystallinity, increased carbonate substitution 
and no detectable differences in mineral:matrix (two-way ANOVA, Fig. 3.4A-D). However, in 
TLR5KO mice, disruption of the gut microbiome led to increased crystallinity without detectable 
changes in carbonate substitution or mineral:matrix (two-way ANOVA, Fig. 3.4A-D). Among 
untreated animals, crystallinity was, on average lower in TLR5KO mice than in WT mice and 
there were no detectable differences between carbonate substitution and mineral:matrix. 
Carbonate substitution was less in TLR5KOΔMicrobiome mice compared to untreated TLR5KO 
mice. 
 High density mapping of the posterior tibia revealed changes in Raman parameters 
consistent with those found in the cross sectional analysis (Fig 3.4E). Disruption of the gut 
microbiome resulted in differences in crystallinity among groups (p<0.001, ANOVA). Post-hoc 
analysis showed increased crystallinity in the TLR5KO mice following disruption of the gut 
flora and trends suggesting decreased crystallinity in the WTΔMicrobiome mice (Fig 3.4F). No 
differences in crystallinity were observed among WT and TLR5KO mice with unmodified gut 
flora. No differences in mineral:matrix or carbonate substitution were observed among the 
groups (Fig. 3.4E-H). No differences in tissue heterogeneity (distribution width) in 
mineral:matrix, carbonate substitution, or crystallinity were detected among groups 
(Supplemental Fig 3.9A-C).  
Reduced modulus measured using nanoindentation was similar among groups 
(Supplemental Fig 3.10A; WT: 30.8 GPa ± 1.06; WTΔMicrobiome: 30.4 GPa ± 1.20; TLR5KO: 
31.0 GPa ± 1.62, and TLR5KOΔMicrobiome: 31.4 GPa ± 1.41, mean ± SD). Hardness was 
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similar among groups (Supplemental Fig 3.10B; WT: 1.08 GPa ± 0.07; WTΔMicrobiome: 1.09 
GPa ± 0.04; TLR5KO: 1.08 GPa ± 0.06, and TLR5KOΔMicrobiome: 1.11 GPa ± 0.03).  
	
 
Figure 3.4. Disruption of the gut microbiome leads to changes in bone tissue composition. 
 
Disruption of the gut microbiome led to changes in bone mineral crystallinity. (A) Five Raman 
point spectra were collected in each of the four anatomical quadrants of a tibial diaphysis cross 
section (n=4/group). (B) Crystallinity was decreased in WTΔMicrobiome mice compared to 
untreated WT, whereas crystallinity was increased in TLR5KOΔMicrobiome compared to 
untreated TLR5KO. (C) Mineral:matrix ratio was not affected by genotype or ΔMicrobiome. (D) 
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Carbonate substitution was increased in WTΔMicrobiome mice compared to untreated WT, but 
decreased in TLR5KOΔMicrobiome mice compared to untreated TLR5KO. (E) High density 
spatially-resolved mapping analysis was also performed with Raman spectroscopy on the 
posterior region of a tibial diaphysis cross section (n=7-10/group). The mapping results were 
consistent with the cross sectional analysis. (F) Bone mineral crystallinity was greater in 
TLR5KOΔMicrobiome mice compared to TLR5KO. A trend toward decreased crystallinity in 
WTΔMicrobiome mice was observed.  (G) Mineral:matrix ratio was similar among groups. (H) 
Mean carbonate:phosphate was similar among groups. Lines indicate p < 0.05 in pairwise 
comparisons. 
 
Chapter 3.4.3 Biochemical Analysis 
 
 Vitamin K content in the cecum, liver, and kidney primarily consisted of microbe-
derived menaquinones; on average, the microbe-derived menaquinones (MK5-13) accounted for 
83.3% to 99.9% of the total vitamin K content (Fig 3.5A-C). Total cecal vitamin K content was 
lower in WTΔMicrobiome mice compared to untreated WT mice (Fig 3.5A). Cecal vitamin K 
content was greater in TLR5KOΔMicrobiome compared to untreated TLR5KO mice. TLR5KO 
mice had greater cecal vitamin K content compared to WT mice. Total liver vitamin K content 
was lower in WTΔMicrobiome compared to untreated WT mice (Fig 3.5B). 
TLR5KOΔMicrobiome mice had greater liver vitamin K content compared to WTΔMicrobiome 
mice. Kidney vitamin K content demonstrated similar trends of decreased content in 
WTΔMicrobiome and increased content in TLR5KOΔMicrobiome (Fig 3.5C). Mean matrix-
bound osteocalcin concentration did not differ significantly among groups in this cohort (p = 
0.13, ANOVA, Fig. 3.6) although trends demonstrated a decrease in matrix-bound osteocalcin 
content level in WT mice with a disrupted gut microbiome, and an increase in TLR5KO mice 
with a disrupted gut microbiome.  
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Figure 3.5. Vitamin K content is altered by disruption of the gut microbiome. 
	
Vitamin K content was altered by disruption of the gut microbiome. (A) Cecal vitamin K content 
was decreased in the WTΔMicrobiome mice compared to untreated WT mice. However, vitamin 
K content was increased in TLR5KOΔMicrobiome mice. Similar patterns were seen in (B) liver 
vitamin K content and (C) kidney. * indicates p < 0.05 using the Holm posthoc test. 
	
 
 
Figure 3.6. Osteocalcin content in the humerus of mice. 
	
Osteocalcin content in the humerus of mice displayed trends similar to those seen in Raman 
spectra (Fig. 3.4) and tissue vitamin K concentrations (Fig. 3.5).  p = 0.13 with ANOVA. 
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Chapter 3.5 Discussion 
 
 We demonstrate for the first use of a metagenomic analysis of the fecal microbiota to 
identify causes for modifications in bone tissue material properties. We found that the functional 
capacity of the gut microbiome was differentially regulated by oral antibiotics in WT and 
TLR5KO mice, and that the abundance of genes associated with vitamin-K production in the gut 
microbiota were altered. Differences in the metagenome were associated with changes in bone 
tissue crystallinity and the concentrations of vitamin K in the cecum and internal organs. We 
interpret these findings to suggest that modifications to the functional capacity of the gut 
microbiome in WT mice can lead to modifications in vitamin K secreted by the gut flora that are 
associated with insufficiencies in bone tissue matrix composition and quality.  
The changes in bone tissue chemistry observed here are consistent with modifications in 
whole bone mechanical performance reported previously for this cohort (Fig. 3.1). Crystallinity 
has previously been correlated with bone tissue strength and/or stiffness in humans and animals 
(115,116,219). The reduction in matrix crystallinity in WTΔMicrobiome mice is consistent with the 
reductions in whole bone strength that are not explained by geometry in WT mice (Fig. 3.1, blue 
lines). In contrast, in the TLR5KO mice, disruption of the gut microbiome is associated with 
increased matrix crystallinity, yet there was no noticeable change in the relationship between 
whole bone strength and geometry (Fig. 3.1, red line). We interpret these findings as suggesting 
that ΔMicrobiome led to a deficiency in matrix quality in WT mice but did not cause such 
deficiencies in TLR5KO mice. In contrast, nanoindentation measures did not differ among 
groups, a fact we attribute to the fact that mechanical failure under three-point bending is due to 
excessive tensile stresses, while nanoindentation assesses the matrix mechanical performance 
under compressive stresses.  
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Although the metagenomic analysis identified differences among groups in the overall 
functional capacity of the gut microbiome, and specifically the abundance of genes related to 
vitamin synthesis, cell wall and capsule synthesis, and carbohydrate synthesis, the current study 
focused on vitamin synthesis as the factor most likely to influence bone tissue quality (as 
opposed to bone quantity). While components of the cell wall and capsule can migrate to the 
bone and influence bone remodeling and likely bone volume or density (98), no mechanism 
linking microbial cell wall/capsule components to altered bone tissue constituents has been 
proposed. Additionally, our prior taxonomic analysis of the gut flora this cohort (133) suggests that 
the differences in functional capacity of the bacterial cell wall and capsule in the current study 
may simply reflect differences in taxonomy. Specifically, ΔMicrobiome was associated with 
increases in the abundance of genes associated with production of Gram negative cell capsule 
components and our prior 16S rRNA analysis indicated increases in the abundance of organisms 
from the Gram negative phyla Proteobacteria. Similarly, ΔMicrobiome was associated with 
reductions in abundance of genes associated with Gram positive cell capsule components while 
our prior report showed reductions in the abundance of organisms from the Gram positive phyla 
Firmicutes. Second, although carbohydrate synthesis can influence the production of molecules 
such as short chain fatty acids that have been associated with changes in bone formation and 
remodeling (149), a mechanism through which short chain fatty acids lead to altered bone tissue 
quality has not yet been proposed.  
The observed differences in the abundance of genes associated with vitamin synthesis led 
to follow up biochemical analyses focused on vitamin K. Vitamin K has long been associated 
with bone health (201,202). Concentrations of vitamin K in the cecum and kidney varied among 
groups in patterns mimicking variation in matrix crystallinity, supporting the idea that reductions 
86	
	
in microbe-derived vitamin K is correlated with impaired bone tissue mechanical performance. 
Microbe-derived forms of vitamin K (menaquinones 5-13) dominated the total amount of 
vitamin K and differences among groups, further suggesting a microbiome-based modulation of 
vitamin K as a potential factor that can influence whole bone strength.  
Although vitamin K may influence bone tissue quality in multiple ways, the best 
understood mechanism is γ carboxylation of gamma-carboxyglutamic (Gla-) containing proteins 
(220). The body contains many vitamin K-dependent proteins, however, the vitamin K-dependent 
protein osteocalcin is the most abundant non-collagenous protein in bone tissue and is known to 
influence bone tissue mechanical properties (221,222). Vitamin K-dependent γ carboxylation of 
osteocalcin is required for proper binding of osteocalcin to bone tissue (220,223). Interestingly, our 
preliminary biochemical analysis of bone tissue shows trends suggesting variation in matrix-
bound osteocalcin among groups that are similar to those seen in matrix crystallinity and cecal 
and kidney vitamin K concentrations (decreased in WTΔMicrobiome and increased in 
TLR5KOΔMicrobiome, Fig. 3.6). Furthermore, the variation in crystallinity measured by Raman 
spectroscopy in the study is also consistent with modifications to the concentration of non-
collagenous proteins such as osteocalcin. Crystallinity is descriptive of the size, perfection, and 
maturity of hydroxyapatite crystals (115). Non-collagenous proteins such as osteocalcin, matrix 
Gla protein, and osteopontin can regulate and direct the formation and size of collagen fibrils, as 
well as mineralization and crystal nucleation, leading to changes in crystallinity (224-229). Indeed, 
osteocalcin-deficient mice have altered bone mineral crystal size and decreased crystallinity, 
similar to the response to WTΔMicrobiome mice (230). Although limited samples were used for 
the biochemical analysis of osteocalcin, when viewed in the context of biomechanical findings in 
this cohort (Fig. 3.1), the metagenomics findings, Raman spectroscopy, cecal and tissue vitamin 
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K concentrations, the current study provides preliminary evidence that the microbiota may 
regulate bone tissue quality through the synthesis of vitamin K (Supplemental Fig 3.11). These 
findings illustrate how metagenomics analysis of the microbiota can be used to generate 
hypotheses regarding the underlying mechanisms of altered bone strength.  
We previously measured a small but significance difference in bone tissue quality 
between untreated WT and TLR5KO mice (Fig 3.1). Differences in mechanical function of 
bones between the two mouse strains may be a result of other differences in the composition and 
functional capacity of the gut microbiome between the two mouse strains (Fig 3.2A-B, Fig 3.3A-
D, Supplemental Fig 3.8A-D) or potentially due to systemic inflammation and metabolic 
syndrome seen in untreated TLR5KO mice. Previous studies have found obesity and the 
metabolic syndrome to impair bone mass and bone strength in mice, although the findings are 
mixed and depend on methods of inducing inflammation/obesity (231-234). Lastly, it is possible 
that the impaired immune system and/or effects of microbial products such as short chain fatty 
acids or microbe associate molecular patterns are influencing bone quality, although a 
mechanism for these factors to influence bone tissue quality (as opposed to quantity) has not yet 
been proposed.  
Several strengths in the study are worth noting. To our knowledge the current study is the 
first to associate changes in the gut flora metagenomic profiles with bone phenotypes. Previous 
studies have reported changes in phylogenetic profile using 16S rRNA sequencing (41,133,149,192). 
Because many different microbes have the same functional capacity, a shift in the phylogenetic 
population in the gut microbiota may not represent differences in the functions of the microbiota 
that influence the host. Metagenomic analysis, therefore, provides more information about 
potential links between the microbiome and bone. Second, to our knowledge, the current study is 
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the first to evaluate how alterations to the gut microbiome can influence bone tissue composition 
and material properties. Most previous studies have focused on how the gut microbiome can 
influence bone microstructure and bone remodeling, but have not reported bone mechanical 
performance, a trait that is more directly related to fracture risk. Lastly, the vitamin K assays 
allowed for the differentiation between dietary and microbe-derived forms of vitamin K. 
Previous studies evaluating vitamin K and bone phenotype in rodents have been restricted to 
phylloquinone or only one menquinone (235-237). 
Despite the strengths of the current study, a few limitations must be considered when 
interpreting the findings.  First, as with many metagenomic analyses, the current study was 
hypothesis-generating and, as molecules of interest were not known a priori, it was not possible 
to design the study with statistical power for all follow up biochemical assays (matrix osteocalcin 
in particular, Fig 3.6). Despite this limitation, the trends in osteocalcin, cecal and kidney vitamin 
K and bone tissue crystallinity were all consistent with one another, supporting a potential 
microbiome – vitamin K - matrix osteocalcin mechanism. However, the effects of vitamin K may 
be a result of other vitamin K-dependent molecules in bone tissue (matrix Gla protein, etc.) or 
other ligands of vitamin K in the body (the pregnane X receptor, for example (238)). Additionally, 
although Raman spectroscopy is useful for examining chemical composition, other modifications 
in tissue composition may not be detectable through Raman spectroscopy, especially because the 
technique examines only a small region of each specimen. However, the current study provided 
more spectra per bone sample than many studies investigating bone tissue composition in mice 
using Raman spectroscopy (219,239-241). Third, the biochemical analysis focused only on vitamin K 
in the cecum, liver, and kidney. Future studies will require a more comprehensive testing of other 
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key potential factors such as vitamin B, circulating MAMPs such as LPS, and intestinal short-
chain fatty acids.  
 In conclusion, we find that disruption of the gut microbiome leads to drastic shifts in the 
overall functional capacity of the gut microbiome that can differ among mouse strains. We 
observed shifts in functional capacity of the gut microbiota that were associated with changes in 
bone mineral crystallinity, the degree of carbonate substitution, and concentrations of 
microbially-derived forms of vitamin K in the body. Together our findings support the use of 
metagenomics for a microbiome analysis, and provide preliminary evidence for a mechanism in 
which production of vitamin K by the gut flora may influence downstream pathways responsible 
for bone tissue composition and structure.  
 
 
Chapter 3.6 Acknowledgements 
	
This publication was supported in part by the National Institute of Arthritis and 
Musculoskeletal and Skin Diseases of the National Institutes of Health (U.S) under Award 
Number AR068061 and by the Department of Defense Congressionally Directed Medical 
Research Programs under Award Number W81XWH-15-1-0239. The content of the work is 
solely the responsibility of the authors and does not necessarily represent the official views of the 
National Institutes of Health or the Department of Defense. Additional funding was obtained 
from the USDA ARS Cooperative Agreement 58 -1950 - 7 -707. Any opinions, findings, or 
conclusion expressed in this publication are those of the authors and do not necessarily reflect 
the view of the US Department of Agriculture. 
Authors’ roles: Conceived and designed the experiments: JDG, CJH, RCB, SLB, MKS, 
DV, SPB, ED. Performed the experiments: JDG, SR, ZR, CHH, CJT, MKS. Analyzed data: 
90	
	
JDG, CJH, ET. Wrote and Revised Manuscript:  JDG, CJH. Critical revision and final approval 
of the manuscript: All authors.  
Chapter 3.7 Supplemental Material 
	
	
	
 
Figure 3.7. Serum calcium and serum 25-hydroxyvitamin D are similar in a small subset of 
animals 
	
Serum calcium and serum 25-hydroxyvitamin D in a small subset of animals. Serum measures 
were taken from a small subset of animals. (A) Serum calcium and (B) serum 25-hydroxyvitamin 
D were similar among groups. Serum total 25(OH)D was measured using LC/MS/MS (Waters 
Acquity UPLC with TQD triple quadrupole mass spectrometer) and NIST standards for assay 
calibration. Serum calcium was measured on an automated clinical chemistry analyzer (Olympus 
AU400; Olympus America Inc., Melville, NY, USA).	
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Figure 3.8. Principle coordinate analysis of key pathways demonstrate the effects of disruption 
of the gut microbiome 
	
Principal coordinate analysis of key pathways demonstrated the effects of disruption of the gut 
microbiome. Disruption of the gut microbiome led to drastic changes in the overall functional 
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capacity of genes for (A) Vitamin synthesis, (B) Menaquinone (Vitamin K-2) synthesis, (C) 
carbohydrate pathways, (D) fermentation, (E) bacterial cell wall and capsule components, (F) 
Gram negative cell wall components (such as LPS). 
 
 
 
 
 
Figure 3.9. Heterogeneity in Raman measurements were similar among groups.  
 
 
High density spatially resolved maps of 121 spectra were taken with Raman spectroscopy on the 
posterior region of a tibial diaphysis cross section (n=7-10/group). The heterogeneity per sample 
was calculated from the full-width-half-max of a Gaussian fit of the distribution of each Raman 
measure.  The heterogeneity of (A) crystallinity, (B) mineral:matrix, and (C) 
carbonate:phosphate were similar among groups. 
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Figure 3.10. Bone tissue material properties were similar among groups. 
 
 
Bone tissue material properties in the tibial diaphysis were assessed with nanoindentation. (A) 
Modulus and (B) hardness were similar among groups. 
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Figure 3.11. Proposed vitamin K and microbiome dependent pathway for modifying bone tissue 
material properties 
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Chapter 4- Alterations to the Gut Microbiome and Osteoarthritis 
 
This chapter has been accepted into the journal Osteoarthritis and Cartilage. The article is titled 
“The effects of metabolic syndrome, obesity, and the gut microbiome on load-induced 
osteoarthritis”.	
Chapter 4.1 Abstract 
 
  Metabolic syndrome is characterized by obesity, hyperglycemia, hypertension, insulin 
resistance, and dyslipidemia. Metabolic syndrome is associated with osteoarthritis (OA), but it is  
unclear if the association is attributable to increased mechanical loading on joints caused by  
obesity or other aspects of metabolic syndrome. Here we examined the effects of metabolic  
syndrome, obesity, and the gut microbiome on load-induced OA. Cartilage damage was induced 
through cyclic compressive loading in four groups of  adult male mice: Toll-like receptor-5 
deficient (TLR5KO) mice that develop metabolic syndrome due to alterations in the gut 
microbiome, TLR5KO mice submitted to chronic antibiotics to prevent metabolic syndrome 
(TLR5KOΔMicrobiota), C57BL/6J mice fed a high  fat diet to cause obesity (HFD), and 
untreated C57BL/6J mice (WT). Loading was applied for 2 weeks (n=10-11/group) or 6 weeks 
(n=10-11/group).After 2 weeks of loading, cartilage damage (OARSI score) was not different 
among groups. After 6 weeks of loading, HFD mice had increased load-induced cartilage 
damage, while TLR5KO mice had cartilage damage comparable to WT mice. 
TLR5KOΔMicrobiota mice had less cartilage damage than other groups. HFD mice had elevated 
serum inflammatory markers. Each group had a distinct gut microbiome composition. 
Conclusions: Severe obesity increased load-induced cartilage damage, while milder changes in 
adiposity/metabolic syndrome seen in TLR5KO mice did not. Furthermore, the effects of 
systemic inflammation/obesity on cartilage damage depend on the duration of mechanical 
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loading. Lastly, reduced cartilage damage in the TLR5KOΔMicrobiota mice suggests that the gut 
microbiome may influence cartilage pathology. 
Chapter 4.2 Introduction 
 
 Metabolic syndrome is a cluster of conditions including abdominal obesity, 
hyperglycemia, hypertension, insulin resistance, and dyslipidemia that put an individual at 
increased risk of developing type 2 diabetes. Recent evidence suggests that abnormalities related 
to metabolic syndrome may exacerbate osteoarthritis (OA) pathology (242,243). Understanding the 
mechanisms relating metabolic diseases and OA has the potential to improve prevention and 
treatment of joint disease.  
 Obesity is a well-recognized clinical risk factor for OA. The association between obesity 
and OA is commonly attributed to increases in joint loading associated with increased body 
mass. However, rates of OA in non-load bearing joints are greater in patients with obesity 
(244,245), a finding that suggests that systemic factors contribute to the risk of OA (242,246-248). 
Further supporting the idea that systemic factors influences OA, patients with type 2 diabetes and 
metabolic syndrome have increased risk of OA (70,246,248-251), although it is unclear if the 
association with OA is due to increases in body mass or systemic factors.  
 Animal models are useful for studying the relationship between OA and metabolic 
syndrome. Mice fed a high fat diet (HFD) to induce an obese, diabetic state display accelerated 
progression of OA in both aging and surgical destabilization models of OA, and develop more 
severe OA after intra-articular fracture (252-254). Leptin receptor-deficient mice (db/db) display 
severe obesity and develop more intense degradation of the joint following surgically-induced 
OA (255,256). A limitation of these mouse models of obesity (leptin (ob/ob) or leptin-receptor 
deficient mice (db/db) and mice fed a HFD), is that they display severe obesity and 
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hyperglycemia that is more representative of a diabetic state (22,257) than that of metabolic 
syndrome (Table c). Furthermore, leptin is involved in mechanisms that affect chondrocyte 
metabolism and cartilage health (258,259), making it difficult to separate the effects of obesity from 
those of leptin dependent pathways in the db/db and ob/ob mice.  To date the relationship 
between obesity, metabolic syndrome, and OA has only been studied in animals using post-
traumatic, surgically-induced, or aging OA models. Little is known about the effect of in-vivo 
loading models that produce more modest OA pathology. 
Table c		Metabolic characteristics of mouse models used to study the effect of obesity, systemic 
inflammation and/or type 2 diabetes on OA compared to TLR5KO mouse	
 
Metabolic 
Measure (Reported 
% Increase 
Compared to WT 
Control) 
C57BL/6J 
Fed High Fat 
Diet- 60% 
Calories from fat 
Leptin Receptor 
Deficient 
(db/db) 
Leptin 
Deficient 
(ob/ob) 
Toll-like 
receptor 5 
Deficient 
(TLR5KO) 
Blood glucose  149%(254) 159%(255) Not reported in 
OA studies 
16%(7) 
Body mass 73%(253); 
54%(254) 
47%(255); 
210%(256) 
252%(256) 23%(7) 
Adiposity  251%(253) 229%(256) 219%(256) 173%(7) 
 
 
  Obesity and the metabolic syndrome are also associated with changes in the gut 
microbiome (260). The gut microbiome is the collection of trillions of micro-organisms that 
inhabit the gastrointestinal tract and play a key role in host metabolism, immune function, and 
nutrition (261). The Toll-like receptor 5 deficient mouse (TLR5KO) spontaneously develops a 
metabolic syndrome phenotype due to alterations in functions of the gut microbiome. TLR5 is 
the receptor for bacterial flagellin, and does not have an endogenous ligand. TLR5KO mice 
exhibit mild hyperglycemia, mild insulin resistance, and a mild obesity (7). TLR5KO mice do not 
develop metabolic syndrome when raised germ-free (never exposed to microbes) or when 
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submitted to chronic oral antibiotics that disrupt the gut microbiome. Therefore, the TLR5KO 
mouse provides a model of metabolic syndrome that can be averted by manipulating the gut 
microbiome. 
 Although prior work has indicated that metabolic abnormalities in severe obesity can 
influence OA development and severity, no studies have examined a mouse model of metabolic 
syndrome without severe obesity. Additionally, few studies have attempted to understand how 
manipulation of the gut microbiome may influence OA. In the present study, we tested the 
hypothesis that metabolic syndrome without severe obesity exacerbates the development of OA. 
Specifically, we used a non-surgical, load-induced model of OA and a gut-microbiome 
dependent model of metabolic syndrome to determine: 1) how the metabolic syndrome affects 
the development of load-induced OA pathology; and 2) how modification of the gut microbiota 
to prevent the metabolic syndrome phenotype affects the development of OA pathology.  
 
Chapter 4.3 Materials and Methods 
 
Chapter 4.3.1 Study Design 
 
Animal procedures were approved by the Cornell Institutional Animal Care and Use Committee. 
C57BL/6J and TLR5KO (congenic strain B6.129S1-Tlr5tm1Flv/J) were acquired (Jackson 
Laboratory, Bar Harbor, ME) and bred via homozygous mating in a conventional animal facility. 
Animals were housed in plastic cages filled with ¼-inch corn cob bedding (The Andersons’ Lab 
Bedding, Ohio), provided standard laboratory chow (Teklad LM-485 Mouse/Rat Sterilizable 
Diet) and water ad libitum, and provided a cardboard refuge environmental enrichment hut 
(Ketchum Manufacturing; Brockville, Ontario). Male mice were divided into four groups): 1) 
control C57BL/6J mice (WT); 2) TLR5KO mice that develop metabolic syndrome; 3) TLR5KO 
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mice receiving broad-spectrum antibiotics in their drinking water (1.0 g/L ampicillin, 0.5 g/L 
neomycin) to prevent the development of the metabolic syndrome phenotype 
(TLR5KOΔMicrobiota) (7); and 4) C57BL/6J mice fed a HFD (60% energy from fat, Test Diet 
58Y1) to induce severe obesity and a diabetic-like state (HFD) (22). Antibiotic use and HFD 
began at 4 weeks of age and continued until euthanasia. The antibiotics used are poorly absorbed 
in the gut and therefore target the gut microbiota without influencing other regions of the body. 
Animals were housed 3-4 to a cage with others from the same treatment group.  
Chapter 4.3.2 In-Vivo Cyclic Compression 
	 	
	 At 20 weeks of age animals began daily, non-surgical, in vivo loading of the left tibia to 
induce cartilage damage. The procedure has been shown to induce cartilage damage as soon as 
two weeks after loading begins (262).  Compressive cyclic loading was applied to the left tibia 
with a 4.5N peak load for 1,200 cycles at 4 Hz for 5 days per week. The right hindlimb served as 
a non-loaded contralateral control. The mice were placed under general anesthesia (2% 
isoflurane, 1L/min) while loading was applied. Animals were exposed to loading for either 2 
weeks (n=10-11/group) or 6 weeks (n=10-11/group). The sample size was determined through a 
priori power analysis. 
Animals were euthanized after loading was completed (at 22 or 26 weeks of age). Upon 
euthanasia, right and left limbs and epididymal fat pads were harvested. Blood was collected 
through cardiac puncture at euthanasia. The knee joints from both limbs were dissected and fixed 
in 4% paraformaldehyde for 24 hours. Fecal pellets were collected on the day prior to euthanasia 
and stored at -80°C prior to analysis. 
Chapter 4.3.3 Subchondral Bone and Trabecular Microarchitecture 
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 Knee joints from animals loaded for 6 weeks were suspended in 70% ethanol and 
scanned by microcomputed tomography (µCT35; Scanco Medical AG, Switzerland; 55 kVp, 145 
µA, 600 ms integration time, 10 µm voxel size). Images were collected at the subchondral bone 
plate and proximal epiphysis. An average global threshold for all samples was determined to 
segment mineralized and non-mineralized tissue (108) . Measures of the subchondral bone plate 
included thickness and tissue mineral density (TMD). Trabecular bone microarchitecture of the 
proximal epiphysis was examined in a region extending from the end of the subchondral bone 
plate to the start of the growth plate. Measurements of trabecular microarchitecture included 
bone volume fraction (BV/TV), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp).  
Chapter 4.3.4 Assessment of Osteoarthritis in Histology Sections 
 
	 Knee joints were decalcified in EDTA for 2 weeks, dehydrated in increasing ethanol 
gradients, and embedded in paraffin. Serial coronal sections, 6 µm thick, were taken. Sections 
spaced at 90 µm intervals were stained with Safranin O/Fast green for histological scoring and 
assessment of cartilage morphology. The OARSI scoring system was used to assess degenerative 
changes resulting from loading (263). Baseline cartilage composition and cellularity in control 
limbs was assessed by a modified Mankin scoring system (264). Localized thickness of cartilage 
was measured on sections used for histological scoring (Osteomeasure, OsteoMetrics, USA).  
Chapter 4.3.5 Metabolic and Inflammatory Blood Serum Measurements 
 
	 Serum was stored at -80°C and sent to the Duke Molecular Physiology Institute 
Biomarkers Shared Resource for analysis. Serum from 26 week old animals (n=6-10/group) was 
measured using a custom Proinflammatory Panel (Meso Scale Diagnostics; Rockville, Maryland) 
measuring IL-1β, IL-6, IL-12p70, KC, IL-10, and TNF-α, a Mouse Metabolic Kit (Meso Scale 
Diagnostics; Rockville, Maryland) to assess leptin and insulin, and an EndoZyme kit (Hyglos; 
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Bernried, Germany) to measure serum lipopolysaccharide (LPS, a bacterial molecular product). 
Values for IL-12p70 were below the limits of detection and were excluded (Supplementary 
Table f).  
Chapter 4.3.6 Gut Microbiota Analysis 
 
	 DNA was isolated from fecal pellets using the Mo Bio PowerSoil DNA Isolation 
Magnetic kit with the recommended proteinase K step to assist in cell lysis. 16S rRNA libraries 
were prepared using the Earth Microbiome Project protocol (162) with primers as described 
previously (265). Paired-end 150x150 reads were imported into QIIME2 (https://qiime2.org) (163) 
and demultiplexed. The samples were analyzed using DADA2, which removes chimeric 
sequences, and retains unique de novo sequence variants (266). Taxonomies were assigned using 
QIIME’s machine learning classifier trained on Greengenes sequences. 
Chapter 4.3.7 Statistics 
 
 The effect of load and group on OARSI score, micro-CT measures, and cartilage 
thickness were detected using a 2-factor repeated measures ANOVA with interactions that 
included individual as a random effect (JMP Pro 9.0.0). Group differences between histological 
scores, micro-CT measures, serum measures, body mass, and fat pad mass were determined 
using a one-way ANOVA with group as the factor followed by the Holm correction for multiple 
comparisons with α=0.05.  A multivariate analysis was used to create a matrix of Pearson’s 
product-moment correlation coefficients to identify linear relationships between OARSI and 
Mankin scores and indicators of systemic inflammation and metabolic syndrome (body mass, fat 
pad mass, serum markers) within the 6 week groups. An analysis of covariance was performed to 
determine if any correlations were explained by group. A Pearson’s product-moment correlation 
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analysis was used to identify relationships between loaded limb OARSI scores and control limb 
subchondral bone measures.  
Chapter 4.4 Results 
 
Chapter 4.4.1 Body Mass, Fat Pad Mass, and Metabolic Profile 
 
 Body mass and serum markers of metabolism exhibited the following patterns: severe 
obesity in HFD mice, mild obesity in TLR5KO mice, and normal body mass in WT and 
TLR5KOΔMicrobiota mice. Body mass and fat pad mass were greatest in HFD mice (Fig 4.1A-
1B). Body mass and fat pad mass were greater in TLR5KO mice than in WT mice or 
TLR5KOΔMicrobiota mice. HFD mice had the greatest serum levels of insulin (Fig 4.1C) and 
leptin (Fig 4.1D).  TLR5KO mice had greater serum levels of insulin and leptin compared to WT 
mice. Mean body mass, serum insulin and serum leptin were similar between the 
TLR5KOΔMicrobiota and WT mice.  
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Figure 4.1. Metabolic phenotype of mice with an altered gut microbiome and fed a high fat diet. 
	
TLR5KO mice displayed hallmarks of metabolic syndrome including increased (A) body mass, 
(B) epididymal fat pad mass, (C) serum insulin levels, and (D) serum leptin levels compared to 
WT mice. High fat diet mice had increased levels of adiposity, insulin, and leptin. Body mass 
and epididymal fat pad mass are pooled from 22 week and 26 week old animals. Serum is from 
26-week old mice. Solid colored lines on dot plots represent the mean value. Groups sharing the 
same letter are not significantly different from each other (p < 0.05) 
 
Chapter 4.4.2 Histology and Osteoarthritis Cartilage Pathology 
 
	 Mechanical loading caused cartilage damage as measured by OARSI score following 
either 2 weeks (95% confidence interval of difference between groups: [0.05, 0.18]) or 6 weeks 
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of loading (Fig 4.2A-B, [0.10, 0.32]). At 2 weeks of loading, mean OARSI scores were similar 
among the loaded limbs of the four groups (Fig 4.2A). After 6 weeks of loading, HFD mice had 
greater OARSI scores with more surface fibrillations and vertical clefts in the loaded limbs than 
other groups (Fig 4.2A-B) and TLR5KOΔMicrobiota mice had lower OARSI scores in loaded 
limbs compared to the other groups. Control limb OARSI scores were similar among groups at 2 
weeks of loading. Control limb OARSI scores at 6 weeks of loading were greater in HFD mice 
compared to TLR5KOΔMicrobiota mice. Control limb Mankin scores of HFD mice and 
TLR5KOΔMicrobiota mice were greater than those in WT mice at 6 weeks (Fig 4.2C), but were 
similar in animals that received loading for 2 weeks (Supplemental Fig 4.6). Cartilage thickness 
did not differ among groups (Supplemental Fig 4.7).  No effect of mechanical loading on 
cartilage thickness was detected.  
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Figure 4.2. The effects of altering the gut microbiome and obesity on load-induced cartilage 
damage 
	
Twenty-week old male mice were subjected to either 2 or 6 weeks of cyclic mechanical loading 
to induce OA pathology. (A) After both 2 weeks and 6 weeks of mechanical loading there was an 
effect of load on OA pathology as measured by OARSI score. No differences the effect of 
loading were observed among groups at 2 weeks, however, after 6 weeks of loading, HFD mice 
had elevated loaded limb OARSI scores compared to other groups, and TLR5KOΔMicrobiota 
mice had lower loaded limb OARSI scores (upper case letters used to denote group differences 
of loaded limb OARSI scores). Control limb OARSI scores were greater in HFD mice compared 
to TLR5KOΔMicrobiota mice after 6 weeks of loading (lower case letters used to denote group 
differences of control limb OARSI scores). (B) Example histology of control and loaded limbs is 
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shown with surface fibrillations and vertical clefts identified. (C) Modified Mankin scores were 
greater in HFD and TLR5KOΔMicrobiota mice compared to WT. Solid colored bars on plots 
represent mean. Groups sharing the same letter are not significantly different from each other (p 
< 0.05). 
 
Chapter 4.4.3 Subchondral Bone Plate and Cancellous Bone Morphology 
 
 Subchondral bone TMD (Fig 4.3A) was lower in TLR5KOΔMicrobiota mice than in 
other groups.  Subchondral bone plate thickness in TLR5KOΔMicrobiota mice (Fig 4.3C) was 
lower than that in WT and HFD mice. Subchondral bone plate thickness was greater in HFD 
mice compared to TLR5KO mice (Fig. 4.3A). Loaded limb OARSI scores were correlated with 
control limb subchondral bone TMD (r=0.69, [0.40, 0.86], Fig 4.3B) and control limb 
subchondral bone thickness (r=0.66, [0.35, 0.84], Supplemental Fig 4.8). Epiphyseal bone 
volume fraction was less in HFD mice than in WT mice (Fig 4.3D). Trabecular thickness and 
trabecular separation were less in TLR5KOΔMicrobiota mice than in other groups 
(Supplemental Fig. 4.9). Mechanical loading was not associated with alterations in any other 
measures of bone (Fig 4.3A-B, 4.3D). 
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Figure 4.3. The effects of an altered gut microbiome and in-vivo cyclic compression on 
subchondral bone plate and cancellous bone morphology 
 
Measures of subchondral and epiphyseal bone after 6 weeks of loading are shown. (A) 
TLR5KOΔMicrobiota mice showed lower levels of subchondral tissue mineral density (TMD). 
(B) Control limb subchondral bone TMD was correlated with loaded limb OARSI scores 
(r=0.69, 95% confidence interval of correlation coefficient: [0.40, 0.86]). A Pearson’s product 
moment correlation analysis was used to identify relationships between loaded limb OARSI 
scores and control limb subchondral bone TMD. (C) TLR5KOΔMicrobiota mice showed lower  
levels of subchondral bone thickness as compared to other groups. (D) Epiphyseal bone volume  
fraction was less in HFD mice compared to other groups. Solid colored lines on dot plots 
represent mean. Groups sharing the same letter are not significantly different from each other    
(p < 0.05). 
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Chapter 4.4.4 Serum Inflammatory Markers From 6 Week-Loaded Animals 
 
 Serum levels of LPS, KC, and IL-10 were greatest in HFD mice (Fig 4.4A, 4.4C, 4.4D, 
Table d). Serum levels of TNF-α were greater in HFD mice than in TLR5KOΔMicrobiota mice. 
Serum levels of IL-6 were lower in TLR5KOΔMicrobiota mice compared to WT mice. Serum 
IL-1 levels did not differ among groups.  
 
 
 
Figure 4.4. Serum inflammatory markers from 6 week-loaded animals. 
 
Serum markers after six weeks of loading are shown. Mice fed a high fat diet had elevated (A) 
serum lipopolysaccharide (LPS). (B) Serum LPS was correlated with loaded limb OARSI scores 
in untreated animals. Among the WT, HFD, and TLR5KO groups, LPS explained 44% of the 
variation in OARSI score across groups (R2 =0.44, p=0.0003). High fat diet mice also had 
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elevated serum levels of (C) KC and (D) IL-10. Solid colored lines on dot plots represent mean. 
Groups sharing the same letter are not significantly different from each other (p < 0.05). 
 
 
Table d Serum markers of cytokines and lipopolysaccharide (LPS) 
Serum 
Measure 
WT TLR5KO TLR5KOΔMicrobiota HFD 
KC (pg/mL) 139±37.0 159±54.8 149±9.26 269±48.8a,*,$ 
IL-10 
(pg/mL) 
12.6±3.75 12.4±2.03 11.5±2.23 19.8±7.94a,*,$ 
TNF-
α(pg/mL) 
7.66±1.31 7.43±1.23 5.94±1.31 9.40±2.32$ 
IL-6 (pg/mL) 30.2±15.9 21.3±11.5 11.4±2.50# 18.7±10.6 
IL-1β 
(pg/mL) 
0.534±0.192 0.350±0.172 0.447±0.198 0.512±0.158 
LPS (EU/mL) 1410±909 1140±484 1870±663 2990±779 a,*,$ 
Values are mean ± SD. 
#TLR5KOΔMicrobiota vs.WT  
aHFD vs. WT  
*TLR5KO v HFD 
$HFD v. TLR5KOΔMicrobiota 
 
 
Chapter 4.4.5 Correlations Among Histological Score and Metabolic and Inflammatory 
Measures 
 
 Loaded limb OARSI scores were correlated with body mass (r=0.31, [0.01, 0.56], Table 
e, Supplemental Fig. 4.10), fat pad mass (r=0.43, [0.15, 0.65], Supplemental Fig. 4.11), KC 
(r=0.39, [0.00, 0.68]), IL-10 (r=0.41 [0.03, 0.69]), and LPS (r=0.54, [0.24, 0.74]). Of the 
parameters correlated with loaded limb OARSI scores, LPS was the only parameter that had a 
significant effect on loaded limb OARSI score when group was included in the regression model. 
Among the WT, HFD, and TLR5KO groups, LPS explained 44% of the variation in OARSI 
score across groups (R2=0.44, p=0.0003, Fig 4.4B). Within the TLR5KOΔMicrobiota mice, LPS 
was not correlated with OARSI score. Leptin and insulin were not correlated with loaded limb 
OARSI score. Control limb Mankin scores were correlated with body mass (r=0.48,[0.21, 0.68]), 
fat pad mass (r=0.47, [0.20, 0.68]), LPS (r=0.48,[0.16, 0.71]), IL-6 (r=-0.41,[-0.69, -0.03]), 
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insulin (r=0.51,[0.15, 0.75]), leptin (r=0.55, [0.21, 0.77]). Control limb Mankin scores were not 
correlated with loaded limb OARSI scores.   
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Table e	A correlations matrix of histological scores and metabolic and inflammatory measures 
after 6 weeks of loading is shown.	
 
Bold numbers represent a significant correlation (p<0.05). Bottom left half of table are pairwise 
correlation value (r). Top left half of table are confidence interval of correlation.  
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Chapter 4.4.6 Gut Microbiota Analysis 
 
 Gut microbiota composition varied dramatically among groups at both the phyla and 
class level (Fig 4.5A, Supplemental Fig. 4.12). Gut microbiota composition at the phyla level 
was dominated by Bacteroidetes and Firmicutes (Fig 4.5B, 4.5C). The relative abundance of 
Bacteroidetes was greater in WT and TLR5KO mice compared to TLR5KOΔMicrobiota mice. 
HFD mice had the greatest abundance of Firmicutes. TLR5KOΔMicrobiota mice had the greatest 
abundance of Proteobacteria (Fig 4.5D). Principal coordinate analysis based on Bray-Curtis 
dissimilarity indicated that each group uniquely clustered together and had a distinct microbial 
community structure (Fig 4.5E, Supplemental Fig. 4.13). The diversity of the gut microbiota, as 
measured by the Shannon Diversity index, was reduced in the TLR5KOΔMicrobiota mice 
compared to other groups (Fig 4.5F). 
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Figure 4.5. Gut microbiome analysis of 6 week-loaded animals  
 
The taxonomic profile of the gut microbiota from animals after six weeks of loading is shown. 
(A) There are large differences in the relative abundance of organisms at the phyla level. (B) The 
relative abundance of Bacteroidetes was greatest in TLR5KO and WT mice. (C) The relative 
abundance of Firmicutes was greatest in HFD mice and (D) the relative abundance of 
Proteobacteria was greatest in TLR5KOΔMicrobiota mice. (E) Principal coordinate analysis  
based on the Bray-Curtis dissimilarity shows that each group forms its own distinct clusters from 
each other. Bacterial diversity was dramatically reduced in TLR5KOΔMicrobiota mice (F). Solid 
colored lines on dot plots represent mean. * p < 0.05 
 
Chapter 4.5 Discussion 
 
 In the current study, we examined the role of obesity, a metabolic syndrome-like 
phenotype, and the composition of the gut microbiome in the development of OA using an in-
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vivo tibial loading model. We demonstrate that alterations in obesity, the gut microbiome, and 
elevated levels of systemic inflammatory mediators can influence the development of load-
induced cartilage damage, although the effects require time to manifest.  Additionally, we 
demonstrate that the metabolic syndrome-like phenotype characteristic of the TLR5KO mouse is 
not sufficient to increase load-induced cartilage damage. 
We attribute a portion of the increased load-induced cartilage damage in HFD mice to 
increased systemic inflammation. We see elevated levels of serum KC in the HFD mice, 
consistent with previous reports in HFD mice submitted to post-traumatic OA (253), and in 
patients with OA that have increased serum IL-8 (the human analog of KC) (267).  The elevated 
serum levels of IL-10 in HFD mice in the current study may reflect an active anti-inflammatory 
response to the OA pathology, consistent with findings of elevated levels of IL-10 in the synovial 
fluid of patients with OA (268). Serum LPS was elevated in HFD mice, and was the only systemic 
factor examined in this study that explained differences in OARSI score across groups. Serum 
LPS has been associated with low-grade inflammation and is thought to play a role in the 
development of OA in individuals with obesity and metabolic syndrome (269). Others have shown 
that mice fed a high fat diet develop an altered gut microbiome and a more permeable intestinal 
barrier, leading to elevated LPS levels and systemic inflammation (270). LPS can also initiate local 
inflammatory responses within the joint that may enhance the effects of mechanical loads (269). 
Consistent with our results, serum and synovial fluid LPS levels are associated with signs of OA 
in patients (271), supporting a possible role of LPS in the pathogenesis of OA cartilage pathology.  
 Adiposity is thought to influence OA pathology (242,272). In our study HFD mice had the 
greatest levels of adiposity and the greatest loaded limb OARSI scores. However, several 
TLR5KO mice displayed fat pad mass within the range seen in HFD mice, yet did not have 
115	
	
increased OARSI scores in loaded limbs like that seen in HFD mice (Supplemental Fig. 4.11). 
Additionally, serum factors associated with increased adiposity, such as leptin and insulin, were 
not associated with loaded limb OARSI score. Hence, our findings suggest that adiposity does 
not fully explain the increased cartilage damage in the current study. 
Our findings suggest that the effects of systemic inflammation, adiposity, and the gut 
microbiome on load-induced cartilage damage are time dependent. After 2 weeks of loading, 
loaded limb OARSI scores were similar among groups, but after 6 weeks of loading HFD mice 
had greater loaded limb OARSI scores. Hence, the additional four weeks of loading may be 
required for systemic inflammation and adiposity to have an effect on OA cartilage pathology. 
Similarly, TLR5KOΔMicrobiota mice display less cartilage damage after 6 weeks of loading but 
not after 2 weeks, suggesting that the effect of the gut microbiome is time dependent as well. The 
effect of time is not surprising as joint degeneration in humans occurs over decades  (273).  Our 
findings may have implications for clinical treatment for patients with obesity or metabolic 
syndrome. For example, if a patient has a recent load-induced injury subsequent treatments that 
correct metabolic abnormalities may slow subsequent development and progression of OA.  
High fat diet and TLR5KO mice both exhibited clear signs of metabolic abnormalities 
and excess adiposity, but only HFD mice exhibited signs of more severe OA with prolonged 
loading. Compared to WT, The HFD mice showed severely elevated insulin levels (530% 
increase) and severe obesity (261% increase in fat pad mass). The TLR5KO mice had mild 
increases in insulin levels (175% increase) and mild obesity (149% increase in fat pad mass) 
compared to WT. We attribute the different degrees of cartilage pathology in the HFD and 
TLR5KO mice to one of three possibilities: First, the severity of metabolic abnormalities in 
TLR5KO mice may have been insufficient to worsen cartilage pathology. Larger changes in 
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systemic inflammation and/or adiposity may be required to increase load-induced cartilage 
damage. Second, metabolic syndrome and the related systemic environment in the TLR5KO 
mice may require more time to become evident in cartilage pathology (just as HFD mice 
required more than 2 weeks). Last, we must consider the possibility that TLR5 signaling within 
the joint may contribute to OA; TLR5 is expressed at higher levels in synovial tissue of OA 
patients compared to healthy individuals (274).  
 The TLR5KOΔMicrobiota mice display less cartilage damage after 6 weeks of loading 
compared to other groups and little difference between the loaded and control limbs. The 
reduced cartilage damage is likely not explained by adiposity or systemic inflammation, two 
factors that were comparable in TLR5KOΔMicrobiota and WT mice. The antibiotics used here to 
disrupt the gut microbiota are poorly absorbed at the gut lining, thus making it unlikely that 
antibiotics have a direct effect on joint tissues. Others have shown that oral antibiotic treatment 
can lead to reduced OA joint pathology in humans (275) and animals (276). We consider the most 
likely explanation for the reduced cartilage damage in the TLR5KOΔMicrobiota mice is 
alterations in the gut microbiome. We see large differences in the composition of the gut 
microbiota between TLR5KOΔMicrobiota and WT mice. The gut microbiome may influence 
distant organs through three different mechanisms: regulation of nutrient/vitamin absorption, 
interactions with the immune system at the gut lining, and translocation of microbe-associated 
molecular patterns (MAMPs) from the gut to the circulation (98). The TLR5KOΔMicrobiota did 
not display overt signs of impaired nutrient absorption; TLR5KOΔMicrobiota mice had 
comparable body mass to WT mice. However, we cannot ignore the possibility that vitamins 
derived from the gut microbiota may influence cartilage damage mechanisms. Immune 
regulation at the gut lining may contribute to the reduced OARSI scores, as modification of the 
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constituents of the gut microbiota are known to influence inflammation and/or immune 
activation at the gut lining and circulating immune cells and cytokines. Additionally, 
modification of the gut microbiota could have altered the translocation of MAMPs across the gut 
endothelium and into the systemic circulation. LPS is one example of a MAMP commonly 
observed in the blood (277). A larger study with more stringent controls of the microbiome 
constituents, and that included WT mice treated with antibiotics is required to better understand 
the specific mechanisms behind the reduced OARSI scores in the TLR5KOΔMicrobiota group. 
The distinct gut microbial communities may also help to explain the opposite trends in OA 
cartilage pathology between the TLR5KOΔMicrobiota and HFD mice.   
 Additionally, it remains possible that the reduced OARSI scores and increased Mankin 
scores in the TLR5KOΔMicrobiota mice may be secondary to changes in bone tissue and 
cartilage. Alterations in bone tissue have recently been shown to influence OA cartilage 
pathology (278,279). The TLR5KOΔMicrobiota mice had reduced subchondral bone plate TMD 
and thickness, which may help explain the reduced effect of mechanical loading, since 
subchondral bone TMD and bone thickness were both correlated with loaded limb OARSI score 
(280). We also recently showed that the same modifications to the gut microbiome in the current 
study were associated with reductions in whole bone strength caused by changes in bone tissue 
material properties (133). The relationship between subchondral bone properties and load-induced 
cartilage damage is complex and warrants further investigation (281). With regard to cartilage 
properties, TLR5KOΔMicrobiota mice had increased control limb Mankin scores. It is possible 
that the alterations to the gut microbiome had a direct effect on cartilage health, although it does 
not appear that the increased Mankin scores influenced load-induced cartilage damage.   
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A number of strengths of the current study are worth noting. First, the study is unique in 
the examination of metabolic syndrome without severe obesity on the development of OA. 
Previous studies looking at metabolic disease and OA have focused solely on HFD models and 
leptin/leptin receptor deficient models. Second, the current study is the first to demonstrate an 
effect of HFD on OA in an in-vivo loading animal model without surgery or trauma. Third, the 
study examines modifications to the gut microbiota that influence load-induced OA. The reduced 
response to 6 weeks of loading in the TLR5KOΔMicrobiota is interesting and warrants further 
investigation to understand if the gut microbiome influences OA development (282).  
A number of limitations are worth noting. First, the severity of OA cartilage pathology 
was small compared to more severe OA animal models (253,283). The use of a greater load 
magnitude would lead to higher OARSI scores and increased sensitivity to small group 
differences. However, the milder form of OA cartilage pathology here provides insight into the 
earlier stages of OA development and/or OA generated by more common, lower magnitude 
loads. Second, it is not clear in this study if HFD mice had elevated severity or accelerated 
progression of OA cartilage pathology at 6 weeks. HFD models have been shown to develop 
both increased severity (253) and accelerated progression of OA (254). It is possible that if the 
current study extended beyond 6 weeks, OA cartilage pathology in other groups might become 
as severe as in HFD mice. Lastly, the metabolic syndrome phenotype of the TLR5KO mice was 
not completely confirmed as only one direct measure of metabolic syndrome (abdominal 
adiposity) was assessed. However, the other parameters related to metabolic syndrome (body 
mass and serum insulin) are consistent with the previous characterization of the TLR5KO mouse 
(7).  
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 We conclude the following: 1) severe adiposity and systemic inflammation increased 
load-induced cartilage damage after 6 weeks of loading, while milder adiposity and metabolic 
abnormalities in TLR5KO mice did not worsen OA pathology; 2) the effect of systemic factors 
on OA development appeared to be related to the duration of increased mechanical loading; 3) 
changes in the gut microbiota may contribute to the severity of load-induced OA cartilage 
pathology and subchondral bone morphology. 
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Figure 4.6. Control limb Mankin scores from 2 week loaded animals 
	
After 2 weeks of loading, TLR5KOΔMicrobiota mice had increased Mankin scores compared to 
TLR5KO mice . Solid colored lines on dot plots represent mean. Means sharing the same letter 
are not significantly different from each other (p < 0.05). 
 
	
Figure 4.7. Cartilage thickness from 6 week loaded animals 
	
Cartilage thickness measured in loaded and control limbs after six weeks of loading is shown. 
There was no effect of load or group detected on cartilage thickness. Solid colored lines on dot 
plots represent mean. 
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Figure 4.8. Correlation between subchondral bone thickness and loaded limb OARSI score 
	
Control limb subchondral bone thickness measured by micro-computed tomography was 
correlated with loaded limb OARSI score at six weeks (r=0.66, [0.35, 0.84]). A Pearson’s 
product-moment correlation analysis was used to identify relationships between loaded limb 
OARSI scores and control limb subchondral bone thickness. 
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Figure 4.9. Trabecular bone microarchitecture in the proximal tibia epiphysis in 6 week-loaded 
animals 
	
Microcomputed tomography was used to assess the trabecular bone microarchitecture of the 
proximal tibia epiphysis in loaded and control limbs of animals loaded for a duration of 6 weeks. 
There was no effect of load detected on trabecular thickness or separation. TLR5KOΔMicrobiota 
mice had lower trabecular thickness and separation compared to other groups. Solid colored lines 
on dot plots represent mean. 
 
 
 
Figure 4.10. Scatterplot of Correlation Matrix from Table e 
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Figure 4.11. Correlation between fat pad mass and loaded limb OARSI score 
	
Epididymal fat pad mass was correlated with loaded limb OARSI score in animals loaded for six 
weeks (r=0.43, [0.15, 0.65]). A Pearson’s product-moment correlation analysis was used to 
identify relationships between loaded limb OARSI scores and control limb subchondral bone 
thickness. 
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Figure 4.12. Relative abundance of fecal microbiota by phylogenetic class is shown.	
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Figure 4.13. Principle coordinate analysis of fecal samples  
	
Gut microbiota was characterized from fecal samples of animals loaded for a duration of 6 
weeks. Principal coordinate analysis based on the Bray-Curtis dissimilarity was performed. Each 
point represents a single sample and the Bray-Curtis dissimilarity between each point represents 
how compositionally different each sample is from each other. Each group forms its own distinct 
clusters. 
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Table f	The lower limit of detection for the serum markers evaluated are shown.	
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5- Summary and Future Directions 
	
Chapter 5.1 Summary 
	
 The gut microbiome influences host functions that are associated with bone and joint. 
Alterations in the gut microbiome lead to diseases and conditions that put an individual at 
increased risk of developing bone and joint diseases such as osteoporosis and osteoarthritis. 
Therefore, the objective of this research was to establish an initial understanding of how the gut 
microbiome can influence both bone and joint. Specifically, we use genetic manipulation, 
chronic antibiotic treatment, and diet to disrupt the composition and functions of the gut 
microbiome. We then used mechanical testing methods, Raman spectroscopy, and in-vivo cyclic 
compressive loading to understand how the alterations in the gut microbiome influence bone 
mechanical performance, bone tissue composition, and osteoarthritis pathology.  
 Few studies have examined the role of the gut microbiome in bone and joint. Prior work 
in the bone field has demonstrated that the disruption or absence of the gut microbiome can 
influence bone mass and structure. However, the studies are limited by experimental 
Serum Marker 
Mean Lower 
Limit of Detection 
(pg/ml) 
Leptin 11.7 
Insulin 43.1 
IL-1β 0.149 
IL-6 1.08 
KC 0.447 
IL-10 0.609 
IL-12p70 16.3 
TNF-α 0.126 
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methodology (age of animals, imaging techniques) and have conflicting findings. None of the 
previous studies examined the effect of alterations in the gut microbiome on bone mechanical 
performance or bone tissue composition and material properties. Prior work connecting the gut 
microbiome to joint disease is limited as well. Initial studies have investigated how systemic 
inflammation and obesity may contribute to increased risk and increased severity of 
osteoarthritis. However, the majority of the existing studies are limited by not evaluating the 
composition or functions of the gut microbiome and related pathways, or by the use of extreme 
animal models (high fat diet fed mice, leptin deficient mice) and injury models (intra-articular 
fracture, destabilization of the medial meniscus). Further investigation of each suspected 
pathway connecting the composition and function of the gut microbiome to bone and joint is 
required to begin translating the knowledge to therapeutics. Additionally, by exploring milder 
forms of obesity, non-traumatic injury models, and novel gut microbiome manipulation 
techniques, we can help fill current gaps of knowledge in the field. The work presented in this 
thesis seeks to address these current limitations and gaps in knowledge. 
 
Chapter 5.1.1 Aim 1 
 
 In this aim, we characterized how alterations in the gut microbiome influence bone 
phenotype and mechanical performance at skeletal maturity. We examined alterations in the gut 
microbiome due to both genotypic alterations and chronic treatment with antibiotics. TLR5KO 
mice had larger cross-sectional area and moment of inertia compared to WT mice, but similar 
peak bending moment. Accounting for differences in cross-sectional femoral geometry 
demonstrated that TLR5KO mice had lower whole bone bending strength. Disruption of the gut 
microbiota with chronic antibiotics in WT mice did not result in changes in total area or moment 
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of inertia, but led to decreased cortical area and thickness. Disruption of the gut microbiota with 
chronic antibiotics in TLR5KO mice resulted in decreased cortical area, marrow area, cortical 
thickness, and moment of inertia. Long-term disruption of the gut microbiota in both genotypes 
led to reductions in whole bone bending strength beyond what could be explained by changes in 
cross-sectional femoral geometry. Trabecular bone microarchitecture was not influenced by the 
disruption of the gut microbiota or by genotype. Dramatic changes in the composition of the gut 
microbiota were detected with antibiotic treatment. The composition of the gut microbiome was 
dominated by the phylum Bacteroidetes in untreated animals, but the composition of the gut 
microbiome was dominated by the phylum Proteobacteria in animals treated with antibiotics. 
The changes in B and T cells detected in TLR5KO and antibiotic treated mice are one potential 
route the gut microbiome could influence bone. The results from this Aim together suggest that 
disruption of the gut microbiota can influence bone tissue material properties and composition.  
Chapter 5.1.2 Aim 2 
 
In this aim, we characterized the effects of disrupting the gut microbiome on bone tissue 
composition and the functional profile of the gut microbiome. We examined alterations in the gut 
microbiome due to genotypic alterations and chronic treatment with antibiotics.  High-density 
spatial mapping of the posterior region of the tibial diaphysis revealed increased crystallinity in 
TLR5KO mice with a disrupted gut microbiome compared to untreated TLR5KO mice. Cross-
sectional analysis confirmed the changes in TLR5KO ΔMicrobiome mice in crystallinity and 
measured decreased carbonate substitution as well. Cross-sectional analysis also revealed 
decreased crystallinity and increased carbonate substitution in WT ΔMicrobiome mice compared 
to untreated WT mice. Bone mineral crystallinity was less in TLR5KO mice compared to WT 
mice. Similar tissue modulus and hardness were measured among groups using nano-indentation, 
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suggesting other tissue-scale mechanical properties may be responsible for the impaired 
mechanical performance measured in whole bone testing. The functional capacity of the gut 
microbiome was uniquely different as a result of both antibiotic treatment and genotype. 
Disruption of the gut microbiota with oral antibiotics led to differential changes in microbial 
gene pathways involved in vitamin synthesis, short chain fatty acid fermentation, and bacterial 
cell wall components. Vitamin K is suspected to play a role in the observed changes in bone 
tissue composition. Microbial gene pathways relating to vitamin K synthesis were disrupted in 
mice receiving oral antibiotics.  Furthermore, the resulting vitamin K levels measured in the 
cecum, liver, and kidney were altered in ΔMicrobiome mice. The results from this Aim suggest 
that the gut microbiome has the potential to influence bone tissue composition through changes 
in a variety of microbial gene pathways. As multiple pathways were effected by the antibiotic 
treatment, further study is required to test how each pathway can lead to changes in bone matrix. 
Chapter 5.1.3 Aim 3 
 
In this aim, we investigated the influence of the composition of the gut microbiome, gut 
microbiome-derived inflammation and metabolic syndrome on the development of osteoarthritis. 
We used a model of metabolic syndrome dependent on the gut microbiome, diet induced obesity, 
and an in-vivo tibial cyclic compressive loading model to induce modest osteoarthritis pathology 
in mice. We found that varying levels of obesity, the composition of the gut microbiome, and 
systemic inflammation can influence load-induced cartilage damage, though the effect of each 
condition takes sufficient time to manifest. We see greater levels of load-induced cartilage 
damage in severely obese mice after 6 weeks of loading, but not after 2 weeks of loading. The 
increased cartilage damage in high fat diet mice are likely a result of the systemic inflammation 
and severe adiposity levels in this group.  The systemic levels of bacterial lipopolysaccharide are 
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elevated in high fat diet mice and are correlated with loaded-limb OARSI score, suggesting that 
lipopolysaccharide may have a direct effect on cartilage health or initiate an inflammatory 
cascade. We determined that the effect of a metabolic syndrome phenotype without severe 
obesity did not increase load-induced cartilage damage after 2 or 6 weeks of loading. We 
demonstrated that disruption of the gut microbiome and the subsequent prevention of the 
metabolic syndrome in TLR5KO mice did not influence cartilage damage after two weeks of 
loading but led to less load-induced cartilage damage after 6 weeks of loading.  The 
TLR5KOΔMicrobiota mice had reduced subchondral bone plate tissue mineral density and 
thickness, as well as increased control limb Mankin scores, suggesting that the measured 
osteoarthritis pathology may be a combination of effects on bone and cartilage. The results from 
Aim 3 suggest that the gut microbiome has the potential to influence the severity of load-induced 
osteoarthritis, either through a direct influence on bone or cartilage health, or through indirect 
pathways that involve the systemic state of the animal.  
Chapter 5.1.4 Synthesis 
 
 The studies contained within this thesis are some of the first findings to demonstrate an 
effect of the gut microbiome on bone and joint. The results of Aim 1 demonstrate that not only 
can the gut microbiome modify bone mass and architecture at skeletal maturity, but that 
alterations to the composition of the gut microbiome also can impair whole bone mechanical 
performance. The findings from the first study suggest that bone tissue material properties and 
bone tissue composition can be regulated by the gut microbiome. Aim 2 then evaluates how 
alterations in the gut microbiome influence bone tissue composition by using Raman 
spectroscopy. This aim examines the functional capacity of the gut microbiome to understand 
potential pathways for the changes in bone tissue composition. The results of the second study 
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demonstrate that disruption of the gut microbiome in mice leads to altered bone mineral 
crystallinity and carbonate substitution. Microbial gene pathways relating to vitamin synthesis, 
bacterial cell wall components, and short-chain fatty acid fermentation are disrupted and may 
each play a role in the changes in bone tissue composition. The role of gut microbiome-derived 
vitamin K in bone mineral crystallinity is a promising area that requires further investigation. 
Osteoarthritis is the degenerative disease that involves both changes to subchondral bone and 
cartilage.  In the third study, we evaluate how alterations in the gut microbiome may influence 
the development of load-induced osteoarthritis pathology. The results of the third study 
demonstrate that severe obesity and systemic inflammation are able to increase cartilage damage, 
while mild obesity and moderate metabolic disturbances are not sufficient to increase 
osteoarthritis pathology. Our findings suggest that the gut microbiome may modulate the 
development of OA in both beneficial and detrimental ways. The mechanism behind the changes 
in OA pathology may involve the effects of the microbiome on bone. Together, the results 
suggest that the composition and functional capacity of the gut microbiome play a key role in 
both bone and joint.          
 We see that disruption of the gut microbiome in the TLR5KO mice has a distinct effect in 
both bone and joint throughout the thesis. In Aims 1 and 2, we see that disruption of the gut 
microbiome in TLR5KO leads to an altered gut microbiome and impaired bone strength, as well 
as increased crystallinity. In Aim 3, we see that disruption of the gut microbiome in TLR5KO 
mice, led to less load-induced cartilage damage. It is intriguing how disruption of the gut 
microbiome can have a detrimental effect on bone strength, however, when evaluating the joint 
we find a protective effect. A few explanations may explain the discrepant results: 1) A different 
gut microbiome dependent mechanism is involved in the changes in bone compared to the 
132	
	
changes in the joint. For example, an LPS dependent mechanism may be more relevant for a 
connecting the gut microbiome to joint health, whereas a vitamin-K dependent mechanism may 
have larger detectable effects on bone; 2) The changes observed in bone in Aims 1 and 2, may 
influence the effect of joint loading and cartilage damage. Previous studies have demonstrated 
that differences in bone properties, can lead to different levels of load-induced cartilage damage 
(281). As the TLR5KO mice with a disrupted gut microbiome have impaired tissue material 
properties and increased mineral crystal size, it is possible the bone would behave differently 
under the applied loading in Aim 3. We clearly do see an effect in the bone of TLR5KO mice 
with a disrupted gut microbiome in Aim 3 consistent with Aim 1. In Aim 1 we see that TLR5KO 
mice treated with antibiotics have decreased tissue mineral density in cortical bone of the tibial 
metaphyseal shell, consistent with findings in Aim 3 that show reduced tissue mineral density in 
the subchondral bone plate.; 3) Vitamin K has been connected to both bone and joint disease  
(220,223,284), and also can impact the immune system. We see increased levels of vitamin K in 
TLR5KO mice with a disrupted gut microbiome in Aim 2. It is possible that altering the levels of 
vitamin K has one effect on bone phenotype and then a completely different effect on joint 
health.  
 Throughout the thesis it is clear that the TLR5KO genotype plays a role in the results in 
each Aim. In Aim 1 we see that TLR5KO mice have impaired bone tissue material properties. 
Then in Aim 3, we see that the TLR5KO mice do not have increased load-induced cartilage, 
despite the excess adiposity and metabolic status. It is possible that the TLR5KO do not show 
increased load-induced cartilage damage as was expected, as these mice have impaired bone 
tissue material properties, suggesting they would behave differently when subjected to cyclic 
compressive loading. We also see a different effect of disrupting the gut microbiome depending 
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on genotype in both Aim 1 and 2. It is clear disrupting the gut microbiome in the TLR5KO 
genotype leads to different changes in the composition and function of the gut microbiome than 
compared to the WT mice. This suggests that if WT mice with a disrupted gut microbiome were 
subjected to cyclic-compressive loading as were mice in Aim 3, that a different effect on 
cartilage damage may be observed. Further study can be devoted towards understanding the 
genotypic differences, and how those stemming in the gut microbiome lead to other downstream 
effects. It is possible that the impaired immune status in TLR5KO mice, or the increased 
adiposity are primary contributors to the genotypic differences. Even the divergent effects of 
antibiotic treatment on the metagenomic profiles of the gut microbiome may in turn be a 
downstream effect of an impaired immune system. It may be beneficial to further investigate 
which microbe populations are responsible for which functions both before and after antibiotic 
treatment, and then to see how it differs between the genotypes. Further investigation to connect 
the differing shifts in abundance of microbe populations to the shifts in the functional profile, 
will allow for a deeper understanding of which microbiota are responsible for which pathways.  
We demonstrate that the metagenomic profile is greatly disrupted in animals treated with 
antibiotics, and that tissue vitamin K levels are impacted as well in Aim 2. It is worth 
considering how the metagenomic profile may connect to the findings in Aim 3. Vitamin K has 
been linked to osteoarthritis incidence previously. However, as the overall functional pathways 
are severely disrupted in mice treated with antibiotics, there are many downstream pathways and 
products of the microbiome that can influence the results. Pathways for bacterial cell wall and 
capsule components are disrupted in mice treated with antibiotics. These products have the 
potential to cause an inflammatory response in the body or joint, and in fact have been connected 
to inflammatory arthritis models in mice (285). Additionally, high fat diet fed mice may also see 
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large changes in functional profile as a results of the long-term diet changes. Applying the 
metagenomic analysis performed in Aim 2 on high fat diet fed mice, can allow us to further 
investigate microbiome related mechanisms for the increased load induced cartilage.  
Chapter 5.1.5 Strengths 
 
 The primary strength of the first two Aims in the thesis are the novelty of characterizing 
bone mechanical performance and tissue composition for the first time in relation to the the gut 
microbiome. The investigation of bone mechanical performance in relation to the gut 
microbiome is the first of its kind and demonstrated that bone tissue composition and mechanical 
performance can be influenced by changes in the gut microbiome. Previous studies have focused 
solely on bone microarchitecture and bone mass, neglecting to investigate if whole bone 
mechanical performance is influenced by the gut microbiome. The second study further 
evaluates the impaired bone mechanical performance, and is the first study to investigate how 
alterations in the gut microbiome can influence bone tissue composition. Another key strength 
and novelty of the second study, is the investigation of gut microbiome functional pathways and 
the potential effect of the pathways on bone composition. Previous studies have solely evaluated 
the composition of the gut microbiota in relation to bone phenotype. The primary strength of the 
third study is the use of a novel gut-microbiome derived animal model of metabolic syndrome. 
Prior studies focused on high fat diet induced models that are extreme in the presentation of 
obesity and metabolic syndrome. Furthermore, the study uses a novel in-vivo loading model that 
allows for: 1) the generation of a more modest, non-traumatic form of osteoarthritis, compared to 
the post-traumatic injury models; 2) the evaluation of how duration of loading and time exposed 
to systemic factors can influence osteoarthritis pathology. 
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Chapter 5.1.6 Limitations 
	
	
Despite the novelty of the studies, several limitations must be considered when interpreting 
the results. First, the use of chronic, long-term antibiotics to generate consistent changes in the 
gut microbiome does not simulate treatment in humans. More commonly used antibiotic 
treatment regimens of 1-2 weeks were not used in the studies, as shorter term treatments with 
antibiotics generate only a transient change in the gut microbiome, rather than a sustained 
alteration in the gut microbiome.  Though the use of antibiotics in this study does not mimic 
common clinical treatment, the resulting, sustained change in the gut microbiome can be 
compared to sustained changes in the gut microbiome that are a result of diet, disease, or other 
lifestyle factors. Another major limitation of the two studies focused on bone is that bone 
turnover was not assessed. Assessment of bone turnover using dynamic histomorphometry can 
help to understand the mechanism behind the changes in bone mechanical performance and 
tissue composition in mice with an altered gut microbiome. Prior work has found that 
colonization of germ-free mice with microbiota increased bone formation rate and mineral 
apposition rate (198). As we did not observe changes in cancellous bone volume fraction and 
preliminary studies in the cortex suggest no differences in bone formation at skeletal maturity, 
measures of bone remodeling are unlikely to provide further insight into the observed bone 
phenotypes. However, performing dynamic histomorphometry can determine if bone turnover 
played a role in the current thesis and provide further insight into a gut microbiome dependent 
mechanism. Another limitation of the work is that only two methods of manipulating the gut 
microbiome were used. The gut microbiome is an incredibly complex ecosystem with trillions of 
bacteria. Modifications to the gut microbiome that involve different genotypic alterations, 
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different antibiotic regimens and types, different diets, or gut microbiota transplantation will 
each have a unique impact on the gut microbiome, and thus potentially on bone and joint as well. 
Future work will have to work towards more clearly understanding the gut microbiome as a 
network, as well as the mechanisms driving differences to be able to apply the findings in this 
thesis towards clinical applications.  
	
Chapter 5.2 Future Work 
	
	 The results of the current thesis lay the ground work for several interesting future areas of 
study regarding the influence of the gut microbiome on bone and joint. Understanding the key 
mechanisms connecting alterations in the gut microbiome to the impairment of bone mechanical 
performance and the severity of load-induced cartilage remain to be explored. The most 
attractive future lines of investigation involve isolating the mechanisms responsible for the 
relationships between the microbiome and bone and joint. Future work will be directed towards 
testing each pathway suspected (immune system, nutrient absorption and vitamin synthesis, and 
bacterial translocation), and testing how these pathways may interact. Many of the pathways can 
have effects on one another, and so unraveling the complex system will take multiple 
approaches.	
Chapter 5.2.1 Continued Research Avenues 
	
Chapter 5.2.1.1 Determining the Role of Vitamin K and Non-Collagenous Proteins in Gut 
Microbiome Related Bone Tissue Changes  
	
Based on the results from Chapter 3, vitamin-K dependent pathways are suspected to play 
a role in the changes in bone tissue composition and mechanical performance observed in Aim 1 
and Aim 2. Vitamin-K synthesized by the gut microbiome is responsible for the carboxylation of 
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several non-collagenous proteins present in bone (286). Non-collagenous proteins account for 
about 5% of the organic content of bone and can influence bone mineral crystal nucleation and 
growth. Non-collagenous proteins such as osteocalcin and matrix Gla protein require vitamin-K 
to carboxylate the protein into its active form. Osteocalcin and other non-collagenous proteins 
have been implicated as factors influencing bone quality.  Mice deficient in osteocalcin and 
matrix Gla protein have altered bone mineral crystallinity (287). Therefore, a line of investigation 
that evaluates the role of vitamin K and non-collagenous proteins in gut microbiome related 
changes in bone tissue is required. Experiments that utilize warfarin to block vitamin K can be 
useful to isolate the effects of vitamin K. Determining if the effects of using warfarin are present 
in mice both with a normal and disrupted gut microbiome will be an important study to conduct. 
Disruption of the synthesis of vitamin-K can also be achieved through modification of the gut 
microbiome. Different antibiotic cocktails and diets can be used to help target which microbes 
are primarily responsible for the vitamin-K synthesis. Through the use of osteocalcin-deficient 
mice, matrix Gla protein deficient mice, and administration of antibiotics to disrupt the ability of 
the gut microbiome to synthesize vitamin-K, we can determine if the gut microbiome related 
bone tissue changes are dependent on vitamin-K carboxylation of osteocalcin or matrix Gla 
protein. The influence of genotype on vitamin-K dependent changes in bone composition is 
another area for investigation, as we found in Aim 2 that disruption of the gut microbiome had 
differential effects on the gut metagenome and vitamin K levels in the TLR5KO mice. 
Additional areas for investigation of vitamin-K dependent changes in bone tissue composition 
are when the changes to bone tissue occur (at initial disruption of the gut microbiome or during 
the entire growth period), if the changes in bone tissue composition are permanent, and if the 
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changes to bone tissue properties can be recovered (perhaps through modifications to the gut 
microbiome). 
Lastly, gut microbiome mediated changes in vitamin-k content may influence bone tissue 
through modification of the immune system or by regulation of 
osteoblastogenesis/osteoclastogenesis. Vitamin-K has been associated with inflammatory 
cytokine concentrations (286,288), as well as in the regulation of B-cell development and antibody 
production (289). Vitamin K has recently been shown to regulate osteoblastogenesis and 
osteoclastogenesis, suggesting another route vitamin K may influence bone (290).  
Chapter 5.2.1.2 Understanding How the Gut Microbiome Can Be Used to Improve the 
Systemic Obesity State and Osteoarthritis Pathology  
	
As obesity is a widespread epidemic in the United States, and clinical/experimental data 
suggest increased incidence of OA in obese populations. As we may not be able to stop the 
obesity epidemic, it is important to understand how we can combat the negative effects of 
obesity on OA development. Based on the results from Aim 3, we have demonstrated that severe 
obesity in the high fat diet mouse is sufficient to increase load-induced cartilage damage. The 
results suggest that systemic inflammation and severe obesity contributed to the OA severity. 
The severity of load-induced cartilage damage was also correlated with serum levels of bacterial 
lipopolysaccharide (LPS). Additionally we found there are large changes in the composition of 
the microbiome associated with high fat diet feeding.  Therefore, an interesting and impactful 
line of investigation would be to further investigate the mechanism behind the increase load-
induced cartilage damage in mice fed a high fat diet, with a focus on understanding how the gut 
microbiome may be implicated and can be used to improve or prevent OA pathology. Evidence 
has shown that high fat diet feeding leads to increased levels of LPS in the intestine, leading to 
gut inflammation via TLR-4, leading to increased intestinal permeability, and then increased 
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serum LPS levels that cause systemic inflammation and can accelerate obesity (270). Experiments 
should evaluate different methods of modifying the gut microbiome (antibiotics, diets, prebiotics, 
genotype) to prevent OA pathology in high fat diet fed mice. For example, prebiotics can be used 
to promote commensal bacteria that reduce inflammatory levels and was recently demonstrated 
to improve OA pathology in a post-traumatic OA mouse model (282). Alternative diets, such as a 
Mediterranean diet, as well as varying degrees of fat % in the high fat diet can be investigated. 
Modifying the gut microbiome through chronic antibiotic treatment is another promising 
potential route to combat increased cartilage damage associated with obesity. In Aim 3 we 
demonstrated that alterations to the gut microbiome induced by chronic antibiotic treatment led 
to reduced load-induced cartilage damage. Previous literature shows that modulation of the gut 
microbiota of high fat diet fed mice with oral antibiotics is able to improve insulin signaling and 
glucose tolerance by reducing circulating LPS levels and inflammatory cytokines such as IL-6 
and TNF-α (291,292). Mice treated with a cocktail of ampicillin, neomycin, and metrodinozole 
have a commensal flora dominated by phylum Proteobacteria (291), similar to the results presented 
in this thesis. The results from Aim 3 and prior work suggest that altering the gut microbiome 
with antibiotics in mice fed a high fat diet may be sufficient to mitigate systemic inflammation 
and metabolic disturbances, and prevent the increased severity of load-induced cartilage damage. 
Alternative antibiotic cocktails can be used to explore the effects of different microbiota 
populations on load-induced cartilage damage, with a hope to understand which microbiota 
populations are responsible. LPS, may be one of several MAMP’s that are elevated and involved 
in the increased systemic inflammation and cartilage damage in high fat diet mice. Mice on a 
high fat diet have increased intestinal permeability leading to increased leakage of bacteria 
and/or bacterial products such as lipopolysaccharide (293). Systemic profiling of other potential 
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MAMPs such as peptidoglycan, flagellin, and cell free DNA should be conducted (98), as it is not 
clear if LPS is the only elevated MAMP in high fat diet mice. The use of bacterial LPS binding 
molecules can be used to block any potential effects of LPS and determine if systemic LPS plays 
a role in the inflammation and cartilage pathology (294). Gut microbiome compositional and 
metagenomic profiling can be used to evaluate if the gene pathways related to the production of 
any of these MAMPs is functionally altered. Additionally, the use of various toll-like receptor 
deficient mice can be used to further test the effects of certain MAMPs, as each TLR has specific 
bacterial products/components they detect. The TLR4-deficient mouse may be an interesting 
study group to include for example, as TLR4 is the toll-like receptor responsible for detecting 
lipopolysaccharide. High fat diet feeding does not increase pro-inflammatory cytokine levels in 
TLR4-deficient mice (270). TLR-4 deficient mice have also previously been shown to be protected 
from collagen-induced arthritis, supporting a potential role for TLR4 signaling in arthritis disease 
progression (285).  
Chapter 5.2.1.3 Understanding The Role of TGF-β and the Immune System in Changes in 
Bone Tissue Composition 
	
 The gut microbiome has a large impact on both the development and function of the 
immune system. Therefore, it is important to further understand the role of the immune system in 
gut microbiome related changes in bone tissue. One route the gut microbiome may influence the 
immune system and subsequent bone matrix properties, is through regulation or modification of 
protein- and mineral-rich extracellular material produced by osteoblasts and osteocytes. One key 
example, is the highly conserved anti-inflammatory cytokine, TGF-β. TGF-β has been shown to 
be a key modulator of the gut microbiome and immune cells. TGF-β has also been shown to 
influence the mechanical properties and composition of bone matrix (295). TGF-β can regulate the 
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expression of osteocalcin, osteopontin, osteonectin, type I collagen, and matrix 
metalloproteinases, and thus has the ability to influence bone matrix properties and composition 
(296-298). Knockout-mice used to target signaling pathways related to TGF-β demonstrated that 
growth factor signaling can regulate the mechanical properties of bone matrix independently of 
changes in bone mass and architecture (295), similar to what was found in mice with an altered gut 
microbiome in the current thesis. TGF-β is mainly activated and produced by intestinal epithelial 
cells after stimulation by short chain fatty acids, or by dendritic cells after direct contact with gut 
microbiota (299). TGF-β is also a major factor driving the development and functioning of 
lymphocytes that help maintain the gut barrier (299). A recent study also demonstrated that short 
chain fatty acids (butyrate) produced by commensal gut bacteria activates  TGF-β expression in 
intestinal epithelial cells (300). Additionally, Toll-like receptor deficiency can decrease TGF-β 
induced extracellular matrix protein deposition (301), further supporting a link between the gut 
microbiome and TGF-β induced changes in bone matrix. Therefore, it is possible that altered 
interactions between the immune system and the gut microbiome lead to changes in TGF-β 
activation/expression, resulting in altered expression of proteins in bone. A line of investigation 
evaluating the potential role of TGF-β in the changes in bone found in mice with an altered gut 
microbiome is an interesting and exciting future area of work. To test the role of TGF-β, 1D11 
antibody treatment can be used to inhibit TGF-β signaling (302), as well as other novel TGF-Beta 
inhibitors (303). There are transgenic mouse models that manipulate the TGF-β that can be used as 
well. For example, Smad 3 deficient mice can be used as Smad 3 is an important molecule in the 
TGF-β signaling pathway that leads to changes in bone. Investigating which gut microbiota 
populations are most closely associated with TGF-β  levels will be important, as certain 
microbiota members such as Clostridiales provide a transforming growth factor rich environment 
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that promotes Treg cell populations in the gut (300). Additional assays to understand the changes 
in the immune system would be necessary and would potentially include: flow cytometry to 
investigate the specific immune cell populations (Treg cell), as well as analysis of growth factors 
and cytokines in the serum and small intestine. Furthermore, there are many links between TGF-
β and osteoarthritis (304,305) that may also be worth investigating, given the evidence connecting 
TGF-β and the gut microbiome.  
Chapter 5.2.2 New Research Avenues 
	
Chapter 5.2.2.1 Influence of the Maternal Mouse Gut Microbiome and the Gut 
Microbiome Early in Life on Bone Phenotype 
 
In the studies presented in this thesis, alterations to the gut microbiome through antibiotic 
treatment have begun at 4 weeks of age. However, a critical development window for bone (306) 
and the immune system (307) occurs in-utero and during the initial 4 weeks of life . The femoral 
cortical area of C57BL/6J mice nearly quadruples between embryonic day 18.5 and 28 days 
post-birth, achieving 48% of the cortical area the mouse will reach by 1 year of age (191). Poor 
bone development early in life can lead to reductions in peak bone mass, and thus a higher risk 
of osteoporotic fracture in adulthood. The maternal microbiome is transferred to offspring during 
birth and is then shaped by subsequent nutrient intake from mother’s breast milk (3). The 
maternal microbiome can have serious consequences on the health of offspring. Maternal 
antibiotic treatment used to target gram-negative bacteria was able to prevent the development of 
diabetes in offspring of mice genetically pre-disposed to diabetes (308). Additionally, changes in 
the maternal microbiome after antibiotic treatment has been shown to influence susceptibility to 
inflammatory bowel disease, as well as the resulting composition of the gut microbiome in 
offspring until 21 weeks of age or longer (309). The clear effect of the maternal gut microbiome on 
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offspring health and disease susceptibility suggests that disruption of the maternal gut 
microbiome may influence bone phenotype in offspring. Additionally, as the gut microbiome 
during the first 4 weeks of life is crucial for the development and education of the immune 
system (310), it important to understand how changes in this time window may impact adult bone 
phenotype. A line of investigation that evaluates how changes in the maternal gut microbiome 
and the gut microbiome in early life (birth-4 weeks of age) can influence the bone phenotype of 
offspring can be very informative for clinical management of mother’s during pregnancy. If 
treatment of the maternal gut microbiome during pregnancy can improve bone mass and quality 
in the offspring, then fracture risk in adult age can be reduced. Determining the effect of the 
disruption of the maternal gut microbiome on the bone phenotype of offspring can have clinical 
relevance, as the use or disuse of antibiotics during pregnancy may have implications on bone 
health and disease for the mother and child. Studies should evaluate when changes in bone 
composition initially occur in offspring, if the changes are reversible post-birth, and what 
modifications to the maternal gut microbiome are beneficial or detrimental. It will be interesting 
to evaluate the effects of disrupting the gut microbiome at different ages in the offspring (starting 
at birth) to better understand how and when the changes in bone occur.  
	
Chapter 5.2.2.2 Influence of Natural Mouse Gut Microbiome on Bone Phenotype  
	
	 The results from this thesis and prior work clearly demonstrate that the gut microbiome 
has important consequences on health and disease. However, the majority of our current 
understanding of the gut microbiome are based on research performed on mice raised in tightly 
controlled laboratory conditions. Recently it has been demonstrated that the gut microbiome of 
mice raised in a tightly controlled laboratory environment is dramatically different than the gut 
microbiome of their genetic counterparts living in the wild  (311). Furthermore, the differences in 
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the gut microbiome between lab mice and mice with a “natural gut microbiome” led to 
detectable effects in overall animal health and immune system function. The natural gut 
microbiome beneficially modulated host responses to inflammatory stimuli, improved overall 
host fitness, and improved resistance to infection and tumorogenesis. The findings are not 
surprising as the natural gut microbiome have evolved and adapted over time to increase animal 
survival, while the gut microbiome of laboratory mice has been heavily modified based on 
controlled environment and genetics. Therefore, the natural mouse gut microbiome provides a 
useful model to further our understanding of how the gut microbiome can influence bone 
phenotype.  Additionally, by understanding how the natural gut microbiome may have positive 
or negative effects on bone health, we can evaluate the composition, function, and products of 
the natural gut microbiome to further evaluate potential mechanisms. Investigating the effects of 
the natural mouse gut microbiome on bone phenotype can provide key insights into how immune 
changes stemming from the gut microbiome can influence bone. Monitoring immune cell 
changes and the systemic inflammatory environment resulting from the natural gut microbiome 
can be informative as beneficial changes in the immune system occur in mice with a natural gut 
microbiome. Studies that use gut microbiome transplantation can be conducted where germ-free 
mice are gavaged with either natural mouse gut microbiome or WT mouse gut microbiome and 
the subsequent changes in bone phenotype are monitored over time.  
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